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Infectious diseases are the result of a tight interplay between microbial character-
istics and host response. Whether this interaction results in microbial clearance, 
colonization or disease, defined as host damage, depends on both the virulence 
treats of the pathogen and the capacity of the host to respond in an appropriate 
manner (1).  The filamentous fungus Aspergillus rarely causes disease in healthy 
immune competent hosts. The host defense against Aspergillus relies on the ability 
of the immune system to restrict spore germination and to prevent invasive hyphal 
growth, thereby limiting fungus-induced and/or inflammation-induced damage 
in infected tissues. 
 Consequently, the development of invasive disease caused by Aspergillus species 
points out a specific defect in the host defense. These specific defects can be caused 
either by an inherited inborn error of immunity (primary immunodeficiency) or 
by an external predisposing factor interfering with a normal function of the 
immune system (secondary immunodeficiency).  Chronic granulomatous disease 
(CGD) is a primary immunodeficiency of the phagocytic cell characterized by the 
highest lifetime incidence of invasive aspergillosis among all cases of immuno-
compromised patients (2).  Chronic granulomatous disease is a well-described 
disease in terms of the functional immune defect as well as the underlying gene 
mutations. In its response, the CGD host offers a genuine ‘experiment of nature’, 
highlighting the importance of a specific component of the immune system in 
human antifungal immunity.  
CHRONIC GRANULOMATOUS DISEASE
Chronic granulomatous disease is a genetically heterogeneous disease caused by a 
defect in any of the five structural components of the NADPH-oxidase complex 
including the granule or plasma membrane-bound glycoprotein gp91phox (phagocyte 
oxidase) and p22phox, and the cytoplasmatic components p47phox, p67phox and p40phox 
(3). Up to now, 5 genes are responsible for all known cases of CGD: the X-linked 
inherited CYBB, and the autosomal recessive CYBA, NCF1, NCF2 and NCF4, 
respectively (4). Birth prevalence ranges from 1/450.000 in Sweden up to 1/120.000 
in the United Kingdom and Ireland (5-7). Most of the patients are diagnosed in 
early childhood; however, some patients remain undiagnosed until adolescence. 
The presenting symptom of the underlying primary immunodeficiency is often a 
localized invasive infection caused either by a relatively narrow spectrum of 
bacteria (e.g. Staphylococcus aureus, Burkholderia cepacia, Serracia marcescens, Salmonella 
species) or by fungi (Aspergillus species and other molds). In addition to the recurrent 
life-threatening bacterial and fungal infections, patients suffering from CGD are 
characterized by abnormal exuberant inflammatory responses leading to colitis 
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patients with fungal osteomyelitis, A. nidulans has been isolated in up to 50% of the 
cases (14, 15). In an extensive review of all PubMed database notated papers from 
1970 to 2010 relating to invasive fungal infections in patients suffering from CGD, 
A. nidulans was the second most encountered species (23 cases out of the 116; 18%) 
only preceded by A. fumigatus (44 cases, 35%) (16). Aspergillus nidulans seems to have a 
remarkable unique interaction with CGD patients, as it remains a rare pathogen 
among other risk groups. In the Transplant-Associated Infections Surveillance 
Network (TRANSNET) report, A. fumigatus was isolated in 187 (44%) of the 425 cases of 
IA. No notification of A. nidulans was made (17). In a cohort of 139 cases of pediatric 
IA, including seven CGD patients, A. fumigatus was isolated in 67 cases (52.8%) 
compared to A. nidulans in only 1 patient (0.8%) (18).
 Those clinical observations and the published epidemiological data suggest 
that CGD patients are at greater risk to develop A. nidulans infection than other 
immunocompromised patient populations and that A. nidulans is more virulent 
than A. fumigatus based on mortality rates and propensity to spread (15). As disease 
pathology and progression are the results of the complex interaction between the 
pathogen and the host, this striking observation of the unique epidemiology and 
clinical features in CGD patients was the starting point of the research presented 
in this thesis.
Aspergillus nidulans
Microscopically, Aspergillus spp. are characterized by the presence of a narrow, 
dichotomously branched septated hyphae and a conidiophore composed of a foot 
and granuloma formation in liver, spleen, lung and lymph nodes (6)(9). These 
clinical manifestations are either a direct or indirect consequence of the defect in 
the NADPH-oxidase complex in phagocytes (12). Activation of the phagocytic 
NADPH-oxidase complex results in the production of the reactive oxidant 
superoxide anion and the downstream reactive oxygen species (ROS) hydrogen 
peroxide (H2O2), hydroxyl anion (HO-) and hypochlorous acid (HOCl). The NADPH 
oxidase complex mediates host defense via direct antimicrobial activity of the 
ROS, but is also coupled to intracellular and extracellular release of a variety of 
antimicrobial proteases. The lack of ROS leads to an impaired alkalization of the 
phagolysosomes and interferes with the release and activation of granule-derived 
enzymes within the phagosome impairing microbial killing (8). Neutrophil 
NADPH oxidase activation is furthermore linked to the formation of neutrophil 
extracellular traps (NETs) able to target and kill bacteria and fungi (9, 10). 
 In addition to the anti-microbial effects, NADPH-oxidase has shown to be 
essential in dampening the inflammation. Its absence leads to both an increased 
neutrophil influx at sites of infection driven by increased IL-8 production, and a 
diminished apoptosis and clearance of those neutrophils resulting in uncontrolled 
inflammation (11, 12). In addition, NADPH-oxidase is involved in the modulation 
of redox-sensitive transcription factors such as NF-κB, and leads to a dysregulated 
pro-inflammatory cytokine profile when absent.  
 Overall, the NADPH-oxidase complex is a critical regulator in the innate 
immunity and acts as anti-microbial effector complex as well as an important 
regulator of inflammation (Figure 1). 
INVASIVE ASPERGILLOSIS 
Aspergillus spp. are known to cause invasive diseases primarily in immunocompromised 
patients with quantitative or qualitative neutrophil defects. The Aspergilli are a 
ubiquitous group of over 185 filamentous fungi belonging to the Phylum Ascomycota. 
Aspergillus spp. are saprophytic fungi abundantly present in soil and decaying plant 
material. Their conidia are widely dispersed in the air and inhalation is the first 
event in establishing invasive disease by immunocompromised patients. One of the 
most common etiological agents in human invasive aspergillosis is Aspergillus 
fumigatus, being responsible for approximately 90% of all human filamentous fungal 
infections (2, 13), followed by A. flavus, A. terreus and A. niger. Much less attention had 
been given to A. nidulans as an opportunistic pathogen in humans until recent years, 
when it was recognized especially in patients with CGD. Scrutinizing the micro - 
biology database of CGD at the National Institutes of Health (NIH; Bethesda, MD) 
revealed six A. nidulans infections compared to seventeen caused by A. fumigatus. In 
Figure 1   NADPH-oxidase and its main 3 effector mechanisms. 
(Figure adapted from T. Kuijpers 2011)
Anti-microbial eector
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NADPH-oxidase complex as direct and indirect anti-fungal effector complex 
against A. nidulans and A. fumigatus. We aim to identify the role of the dysregulated 
inflammation in the pathogenesis of invasive Aspergillus infections in the CGD host 
and question whether this inflammatory response is Aspergillus-species dependent. 
And ultimately, we investigate to which extent an improved insight in the 
molecular interaction between Aspergillus species and the CGD host may result in 
the design of new management strategies.
OUTLINE OF THIS THESIS
In chapter 2 a comprehensive overview of all published invasive fungal infections 
in patients suffering from chronic granulomatous disease is presented. 
 To investigate whether the current concepts of the increased susceptibility to 
A. nidulans infections are related to the direct antimicrobial effect of the 
NADPH-oxidase complex, which is defective in CGD patients, we investigate the 
susceptibility of A. nidulans and A. fumigatus to ROS, the ability of those two species 
to activate the production of ROS in phagocytes, and we determine antifungal 
killing by various, both human and murine, CGD cell populations. The results of 
these studies are described in chapter 3.  
 In chapter 4 the function of the NADPH-oxidase and its role in intracellular 
pathways is investigated with respect to the tryptophan metabolism by which 
tryptophan is converted to L-kynurenine and its relationship to the Th17 response. 
The results of the studies presented in chapters 3 and 4 support the hypothesis 
that the occurrence of A. nidulans infections in the CGD host is possibly more 
related to the dysregulated inflammation causing damage to the host, than to an 
intrinsic impaired fungal killing ability of the CGD phagocyte. NADPH-oxidase is 
cell ending into a vesicle. Identification of the different Aspergillus spp. is based 
predominantly upon the morphology of these conidiophores with differences in 
conidial heads, phialides, colour, shape and morphology of the conidia (Figure 2). 
Aspergillus nidulans is characterized by a very evident foot cell with short conidial 
heads. The conidiogenous cells are biseriate, with metulae and phialides covering 
the upper half of the vesicle. The conidia are spherical, green in mass and 3-4 µm 
in diameter. Colonies are often brown due to the conidiophores and the presence 
of cleistothecia and Hulle cells. In contrast, Aspergillus fumigatus has short hyaline 
or green conidiophores with a pear- or club-shaped vesicle. The conidiophore is 
uniseriate, with often green phialides, originating directly on the upper half of 
the vesicle. The conidial heads have a columnar disposition. The conidia are globose 
(2-3.5 µm), green, and can be either smooth or rough or echinulate, produced in 
long, basipetal chains. 
 Unfortunately, this morphology-based identification of clinically relevant 
aspergilli has often lead to misidentification. In an era of increasing antifungal 
resistance and multiple classes of antifungal agents, it is crucial to correctly 
identify the causative fungi to species level as it is of utmost importance to tailor 
therapy appropriately. Use of comparative sequence-based methods in conjunction 
with the traditional phenotype-based methods will offer increased resolution in 
identification of these Aspergillus species. Recently, the taxonomy of Aspergillus spp. 
has been revised by incorporating sequence-based information. Following the 
 recommendations of the international group of experts gathered for a workshop 
“Aspergillus Systematics in the Genomic Era”, sequence analyses of the internal 
transcribed spacer (ITS) region appears to be appropriate for identification of 
Aspergillus isolates to the subgenus/section level. The Partial β-tubulin or calmodulin 
are the most promising loci for Aspergillus identification to the species level (19). 
The use of molecular techniques for species identification has already impacted on 
the epidemiology of fungal diseases in CGD patients (20), and will definitely 
increase our insight into specific pathogens and host-pathogen interactions in the 
near future.
RESEARCH QUESTIONS
The aim of the studies presented in this thesis is to explore in depth the 
host-pathogen interaction between A. nidulans and patients suffering from CGD. 
We question whether the higher incidence of A. nidulans infections in the CGD 
patients may be explained by the presence of specific defects in the innate immune 
system, having more consequences for an efficient host defense against A. nidulans 
compared to A. fumigatus. We want to get more insight in the role of the deficient 
Figure 2  A. fumigatus (A) and A. nidulans (B). Lactophenol cotton blue, 400 x.
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well known to play a key role in modulating inflammation that is distinct from its 
antimicrobial function. Chapter 5 summarizes our current insights with respect 
to the interaction of A. nidulans and the CGD host, leading to a new hypothesis 
concerning the pathophysiology of invasive A. nidulans infections in the CGD patient.
 In chapter 6 the results are described of the studies performed to assess if 
specific A. nidulans fungal cell wall components might be responsible for the extent 
of inflammation, playing a differential role in the observed clinical pathogenesis 
of A. nidulans infections in the CGD patient.
 In the search for new management strategies to improve the outcome of 
invasive A. nidulans infections in the CGD patient, we hypothesize that an adjunctive 
therapeutic agent should target both functions of the NADPH-oxidase. The ideal 
agent should be characterized by having both an antifungal and an immuno-
modulatory effect, and by being active in the CGD phagolysosome known to 
display an abnormal pH regulation. Based on this consideration, we explore in 
chapter 6 a new application of the ‘old drug’ chloroquine.
 Finally, all the studies presented in this thesis are discussed and framed into 
future perspectives in chapter 7.
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ABSTRACT
Invasive fungal infections are a major threat for chronic granulomatous disease 
(CGD) patients. The present study provides a comprehensive overview of published 
invasive fungal infections in the CGD host through an extensive review of epide-
miological, clinical, diagnostic and therapeutic data. In addition to the often mild 
clinical presentation, the currently used diagnostics of invasive aspergillosis have 
low sensitivity in CGD patients and cannot be easily translated to this non-neutro-
penic host. Aspergillus fumigatus and A. nidulans are the most commonly isolated 
species. A. nidulans infections are seldom reported in other immunocompromised 
patients, indicating a unique interaction between this fungus and the CGD host. 
The occurrence of mucormycosis is mainly noted in the setting of treatment of 
inflammatory complications with immunosuppressive drugs. Candida infections 
are infrequently seen and do not cause mucocutaneous disease but do show an 
age-dependent clinical presentation. The CGD patient is susceptible to a wide 
range of fungal pathogens, indicating the need to determine the causative fungus, 
often by invasive diagnostics, to guide optimal and rational treatment. This review 
summarizes current understanding of invasive fungal infections in patients with 
CGD and will serve as a starting point to guide optimal treatment strategies and 
to direct further research aimed at improving outcomes.
INTRODUCTION
Patients suffering from chronic granulomatous disease (CGD) are well known to 
be prone to invasive fungal infection, thereby providing a unique opportunity to 
examine host susceptibility to fungal invasion within the framework of a well 
defined immune defect. CGD is a rare inherited disorder of the NADPH oxidase in 
which phagocytes fail to generate the microbicidal reactive oxidant superoxide 
anion and its metabolites, hydrogen peroxide, hydroxyl anion, and hypohalous 
acid. Clinically, as a result of the defect in this key innate host defense pathway, 
CGD patients suffer from recurrent life-threatening bacterial and fungal infections 
and inflammatory sequelae. The molecular basis of CGD is well understood: CGD 
is a genetically heterogenous disease caused by mutations in any of the five 
structural components of NADPH oxidase, including the membrane-bound 
glycoprotein p91phox (phagocyte oxidase) and p22phox and the cytoplasmatic components 
p40phox, p47phox and p67phox. Birth prevalence ranges from 1/450,000 in Sweden, 
1/250,000 in the United States and Japan, up to 1/120,000 in the United Kingdom 
and Ireland (1-4). Although the majority of CGD patients are diagnosed in early 
infancy, fungal infection as presenting symptom in adult patients has been 
reported (5-9). The suspicion of the presence of CGD as an underlying condition 
should arise whenever the diagnosis of invasive aspergillosis (IA) is made in the 
absence of another known risk factor.
 Aspergillus is one of the most important encountered pathogens (10, 11), and 
the life-time incidence of IA in children with CGD before the advent of specific 
antifungal prophylaxis varied between 25 % and 40 % (11, 12); although since the 
introduction of azole prophylaxis the incidence seems to decrease (13). In comparison, 
the incidence of aspergillosis in children undergoing allogeneic haematopoietic 
stem cell transplantation (HSCT) or who were treated for hematological malignancy, 
who typically have a very limited period of susceptibility, lies between 2 % and 
6.8% (13-17). 
 In more detailed information extracted from the published data of CGD 
patient registries, the percentage of patients who had at least one infectious 
episode caused by Aspergillus spp. ranges from 26 % in Europe (18) up to 46 % in 
Japan (19). More importantly, independent of the epidemiology of fungal infections 
in the published data, in the cases of pulmonary infection, brain abscesses and 
osteomyelitis, Aspergillus spp. have been the most commonly isolated organisms 
(1, 4, 18, 20) (Table 1). 
 The most common Aspergillus spp. affecting CGD patients is A. fumigatus (10, 21, 
22) followed by A. nidulans (23).  Much less attention has been paid to A. nidulans as 
an opportunistic pathogen in humans until recent years, when it was recognized 
especially in patients with CGD or with histories suggestive of CGD. White et al. 
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(24) suggested in 1988 that CGD patients were at greater risk for A. nidulans than 
other immunocompromised patient populations. Scrutiny of the microbiology 
database of CGD patients at the National Institute of Health (NIH, Bethesda, MD) 
over a 10-year-period revealed six cases of A. nidulans, compared to 17 cases of A. 
fumigatus (23). In cases of osteomyelitis, A. nidulans was isolated in up to 50 % of the 
cases (23, 25). Although A. nidulans behaves more virulently in CGD patients than 
A. fumigatus, solid information on the relative frequency of IA due to A. nidulans in 
CGD patients is lacking. Candida is a less frequently encountered pathogen in CGD 
and is reported as being responsible for invasive fungal infection in 6 % of all 
isolated microorganisms among CGD patients registered in the European database, in 
10 % in a Swedish CGD population, and up to 14 % in the Italian CGD study (3, 18, 20).  
 Invasive mucormycosis has not been recognized in patients with CGD as 
frequently as IA (26, 27). A review of 929 pediatric and adult cases of mucormycosis 
revealed 81 % of the individuals having an impaired immune status, but none of 
these were associated with CGD (28). In a systematic review of 157 cases of 
mucormycosis in children, 86 % were associated with risk factors as neutropenia, 
prematurity, diabetes mellitus and ketoacidosis; but no underlying primary 
 immunodeficiency was noted (29). However, when CGD patients are subjected 
to further immune compromising conditions affecting T cell function, such as 
methotrexate or steroids, typically in the setting of management of their 
inflammatory complications, mucormycosis has been encountered (30).
 Globally, specific data regarding the epidemiology of non-Aspergillus, non-Candida 
IFD in CGD patients are scarce or described as “Fungi: not identified”. Little detailed 
information is given on the identification of the causative fungus, and available 
data are almost exclusively found as individual case reports, making it difficult to 
assess any epidemiological burden of those fungi within the CGD population. 
 As a cause of death, fungal infections caused by Aspergillus spp. have been 
responsible for one-third to half of all deaths in CGD patients (2, 4, 20). Mortality rates 
due to IFD caused by other fungi are unknown but, since case reports are more 
common with severe infections, may be overestimated from their true incidence.
 Overall, as disease pathology and progression are the results of the complex 
interaction between the fungal pathogen and the host defense, exploring these 
host-fungus interfaces of the different fungal pathogens in relation to the host, 
gives us insight and detailed understanding of this challenging frontline, in order 
to optimize diagnostic and therapeutic tools. 
 We reviewed the literature of invasive fungal infections in CGD through topics 
such as epidemiological data, mycological characterization and identification, 
clinical manifestations, diagnostic features and in vitro susceptibility data in 
order to assess these findings within a framework of our current understanding of 
IFD in CGD.Ta
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in CGD patients with a positive culture from a specimen obtained by an invasive 
procedure showing histological evidence of growing fungi. Cases were considered 
probable if radiological features were considered to be consistent with fungal 
infection by the radiologist and mycological evidence was obtained, including a 
positive culture or detection of circulating galactomannan or 1,3-beta D glucan. 
Cases without mycological evidence were not included in this review. In case of a 
negative culture during the patient’s lifetime, inclusion required the demonstration 
of infection at autopsy by culture of the causative agent from the affected organs.
Localisation of infection
Documentation of the primary site of the infection was required. The definitions 
used were the following. (i) Localized infections were defined by isolation of the 
fungus from a clinically infected site without positive blood cultures or evidence 
of dissemination to distant organs; (ii) Disseminated infections were defined by 
the isolation of the fungal isolate from two or more noncontiguous sites showing 
clinical or histological evidence of infection, and/or positive blood cultures; (iii) 
Infections with contiguous spread were defined by the isolation of the fungal 
isolate from at least one contiguous site showing clinical or histological evidence 
of infection; (iv) Fungemia indicated the presence of the fungus in the blood.
RESULTS
We identified 116 reported cases fulfilling the inclusion criteria of invasive fungal 
infections in CGD patients between 1970 and 2010. The demographic and clinical 
characteristics are summarized in Table 2. 
One hundred twenty-seven fungal species were isolated: 44 (35 %) A. fumigatus, 23 
(18 %) A. nidulans, 5 (4 %) A. niger, 1 A. flavus, 11 (9 %)  species belonging to the phylum 
Zygomycota (mainly Rhizopus spp.), 10 (8 %) Candida spp., 8 (6 %) Trichosporon spp., 6 (5 
%) Paecilomyces spp., 5 (4 %) Scedosporium spp., 4 (3 %) Penicillium spp., 2 Acremonium 
spp., 2 Alternaria spp., 1 Inonotus spp., 1 Exophiala, 1 Chrysosporium spp., 1 Fusarium 
spp., 1 Microascus spp. and 1 Hansela spp. (Figure 1). No reports of endemic mycoses 
in patients suffering from CGD were found following the above described search 
strategies.
METHODS
Search strategy
A PubMed database search of the English-, French-, and Dutch language literature 
from 1970 - 2010 was performed using keywords “chronic granulomatous disease” 
and “fungal”, “mycoses”, “aspergillosis”, “aspergillus”, “candidiosis”, “candida”, 
“zygomycosis”, “dermatophytosis”, “scedosporium”, “trichosporon”, “paecilomyces” 
and “endemic mycoses”. In addition, published data concerning diagnostic features 
and susceptibility testing were reviewed. All the articles found by this means were 
systematically reviewed and the references cited in the articles were screened for 
additional information and cases, or for any duplicate reports of the same patient. 
Criteria for inclusion of case reports
Criteria for diagnosis of chronic granulomatous disease
The phagocytes of CGD patients lack the ability to generate superoxide and its 
metabolites due to a defect in the NADPH oxidase complex. As a diagnostic tool 
multiple tests have been validated in literature: the semi-quantitative nitro 
blue- tetrazolium test (NBT) (31); the cytochrome c test - a quantitative test based 
on the reduction of c ferricytochrome - and assays using probes of which the 
chemilu minescent or fluorescent properties are altered by their reaction with 
reactive oxidants. More recently, a fluorescence assay has been introduced, which 
uses the conversion of dihydrorhodamine 123 (DHR) to rhodamine 123, in the 
presence of hydrogen peroxide, being detected by flow cytometry (32, 33). In the 
past, patients were diagnosed as having CGD by the occurrence of an appropriate 
clinicopathologic syndrome as described by Berendes et al. (34) and by the 
investigation of neutrophil killing defects. The vast majority of the included cases of 
CGD are confirmed by use of either the NBT test, chemoluminescence, cytochrome c 
reductase or DHR 123 test. If the patient died before proper diagnostic tests had 
been performed, inclusion was accepted when the autopsy and histology reports 
were suggestive of CGD in association with a positive genetic test of a sibling or a 
first-degree relative. A highly suggestive postmortem analysis in the absence of 
any genetic argument was not included in this review.
Documentation of infection
As there are no definitions to categorize invasive fungal infection in patients with 
CGD, the principles of the EORTC/MSG criteria for invasive fungal infections (35), 
which apply to patients with cancer, were followed. Host factors, clinical symptoms 
and mycological evidence were used to categorize cases as probable or proven 
invasive fungal infection. Obviously, CGD was the host factor associated with an 
increase risk for fungal infection. Invasive fungal infection was considered proven 
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 Seventy-two percent of the reported fungal infections in CGD had lung- 
involvement. Some species were more prone to cause pulmonary infection, e.g. 
Zygomycetes (91 %), A. nidulans (78 %), followed by A. fumigatus (72 %). The majority 
of the trichosporiosis patients suffered from lung infections as did half of the 
patients infected with Paecilomyces spp. Among the patients with candidiasis, only 
two out of ten mentioned pulmonary involvement, which can be explained by the 
route of infection being the result of disruption of skin or mucosal membrane 
(endogenous) instead of inhalation of spores (exogenous).
 Symptoms include cough, usually non-productive, fever, chest discomfort and 
progressive dyspnea. However, some species have the propensity to be quite 
indolent, e.g. the clinical onset of A. nidulans infections was, compared to A. 
fumigatus, often very mild with nonspecific symptoms. Trichosporon inkin infections 
have also been described with an asymptomatic or mild presentation. However, 
the masking of the symptoms in those cases might have been at least partially 
explained by concomitant immunosuppressive drug use. Hemoptysis, a relatively 
common symptom of angioinvasive aspergillosis or mucormycosis in the immuno-
compromised host, has not been reported in CGD patients. In line with this, the 
typical lung lesions observed in neutropenic patients, i.e., the air crescent and 
FUNGAL INFECTIONS IN CGD: BY CLINICAL MANIFESTATION
Pneumonia
Fungal involvement of the lung can result in 2 major clinical manifestations: the 
first is the result of direct infection of the pulmonary tissue or the infection of 
lung cavities, the second is the ability to trigger an immunological reaction when 
the fungus is inhaled. The CGD patient can suffer from both clinical identities. 
However, the clinical course and diagnostic signs and symptoms of invasive fungal 
pulmonary involvement differ remarkably from the classical clinical spectrum 
derived from cancer patients.
Table 2   Characteristics of invasive fungal infections in 116 CGD patients
Variable Cases, n (%) Mortality, n (%)
Median age in years (range) 10 (0-69)
Male/Female/unknown 103/10/3 24/4/2
X-linked 65 (56) 16 (25)
AR 22 (19) 6 (27)
p47phox 10 2
p67phox 2 1
p22phox 2 0
AR, no details 8 3
Genetics unknown 29 (25) 8 (28)
Mono-fungal infections 108 26 (24)
Mixed-fungal infections 8 4 (50)
Antifungal prophylactic treatment 22
INF-γ prophylactic treatment 28
Lung involvement 83 25 (30)
Bone involvement 47 10 (21)
Infecting organism (n=127)   
A. fumigatus 44 13 (30)
A. nidulans 23 6 (27)
Other Aspergillus spp. 6 3 (50)
Zygomycetes 11 6 (55)
Paecilomyces spp. 6 0
Scedosporium spp. 5 0
Trichosporon spp. 8 2 (25)
Candida spp. 10 4 (40)
Miscellaneous group 14 3 (21)
Figure 1  Distribution (%) of 127 fungal isolates out of 116 cases of invasive fungal 
disease in CGD reported between 1970-2010.
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designation of A. fumigatus in most clinical laboratories is insentitive to subtle 
distinctions between A. fumigatus sensu strictu and organisms that have roughly 
similar growth and color characteristics but different clinical features, such as A. 
viridinutans (42).
 As previously described by Sponseller et al. (43), fungal osteomyelitis is often 
the result of direct spread from a pulmonary focus towards adjacent chest-wall 
structures (64 %). Localized bone infection, without other organ involvement, was 
seen in only 4 subjects. Of these, A. fumigatus was isolated twice: a localized 
osteomyelitis of the midfoot (44) and an osteomyelitis of the patella and arthritis 
with positive culture of both tissue and the synovial fluid (45). A. nidulans, later 
identified as E. rugulosa, was responsible for a femoral osteomyelitis (46) and the 
basiomycetous mold Inonotus tropicalis for a destructive sacral bone osteomyelitis 
with soft tissue abscesses (47). None of these infections were preceded by trauma or 
apparent direct inoculation. The mortality rate was 21 %. Surgery was the cornerstone 
of treatment (72 %) and in combination with antifungal therapy the cure rate was 
62 %. However, more prospective research is needed to define optimal treatment 
strategies.
 Few data are available about the clinical, histopathology and radiologic 
 characteristics of fungal bone infections in CGD patients. In a brief report published 
by Galluzzo et al. (48), 14 CGD patients were compared with control subjects to 
determine osteomyelitis-related markers suggestive of CGD. Generally, multifocal 
osteomyelitis and/or simultaneous other organ involvement were the most relevant 
and statistically significant clinical findings suggesting CGD as an underlying disease. 
Histopathologic findings of chronic inflammation plus granulomata, multinucleated 
giant cells, histiocytes, or necrosis were significantly over-represented among 
CGD patients. In contrast, acute or chronic inflammation plus granulation tissue, 
remodeled bone, or lymphocytes were significantly under-represented and 
infrequently found in CGD patients. The presence of extensive destruction in 
association with minimum sclerosis on the X-ray, almost invariably noted at the 
time of diagnosis, was also described previously by Wolfson et al. (49). Whether the 
particular histopathologic and radiologic patterns described in osteomyelitis 
occurring in CGD patients are fungus dependent or CGD host dependent is unclear. 
Overall, the lack of early clinical signs of osteomyelitis in association with advanced 
destructive lesions - often multi-focal – and the isolation of a likely opportunistic 
pathogen, is highly suggestive for the presence of CGD as an underlying condition, 
especially if the osteomyelitis is associated with other organ involvement, or if 
there are histopathologic signs of chronic inflammation and granulomata-related 
features.
halo signs, have never been reported in CGD cases. Nevertheless, A. fumigatus can 
hematogenously disseminate to liver, skin, brain. In contrast, A. nidulans tends to 
spread by contiguity. 
 A distinct pulmonary fungal infection syndrome in CGD is acute fulminant 
fungal pneumonia, “mulch pneumonitis”, a medical emergency highly associated 
with and probably pathognomonic for CGD. High-level exposure to aerosolized 
fungi, such as that which occurs during spreading of mulch, lawn care, gardening, 
haying or digging in soil, leads to rather stereotypical signs and symptoms of 
pneumonia with hypoxia and diffuse infiltrates on chest radiographs. This 
condition can deteriorate rapidly leading to acute hypoxemic respiratory failure, 
mechanical ventilation, and death. Since the first report in 1986 (36), 11 cases have 
been described (36-40). Mean age was 23 years, ranging from 7 - 64 years, 4 out of 
11 patients were previously well and mulch pneumonitis was the initial 
presentation leading to the diagnosis of CGD. In more than half of these cases 
multiple organisms were isolated, including Aspergillus spp. in association with 
members of the phylum Zygomyceta and/or Penicillium spp.. A. fumigatus and A. 
nidulans were the only causative agents isolated in all cases of mulch pneumonitis. 
The mortality rate was high (8/11, 73%) despite aggressive antifungal treatment, 
mechanical ventilation, extra-corporal membrane oxygenation and pulse cortico-
steroids (82 %) for the acute respiratory distress syndrome. However, it is obvious 
that with early recognition and prompt institution of antifungals to control the 
infection and steroids to regulate inflammation that response rates will improve. 
More recently developed immune regulatory agents might be of interest to further 
improve outcome. The pathological role of the agents of mucormycosis in this 
syndrome is unclear, and treatment directed at the Aspergillus component alone is 
probably adequate.
 Aspergilloma and chronic necrotizing pulmonary aspergillosis have not been 
reported in CGD patients. Allergic bronchopulmonary aspergillosis (ABPA) in the 
CGD patient is rare, but has been reported (41). However, it seems much more likely 
that what was described as ABPA in a CGD patient, acute respiratory failure after 
heavily mulching, should be more appropriately classified as “mulch pneumonitis”. 
Osteomyelitis
Bone-involvement was reported in almost half of the cases (41 %) of IFD in CGD, 
being the second most commonly encountered organ. A. fumigatus and A. nidulans 
were almost equally frequent (Table 3). However, in case of an A. nidulans IFD, 
osteomyelitis occurred in 74 % (n=17/23), whereas A. fumigatus had a lower 
propensity to spread to the bone (n=18/44, 41 %). It is very important to recognize 
that speciation of Aspergillus is an evolving field that has been transformed by 
molecular biological approaches, just as the other fields in microbiology has. The 
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malaise and fever. The responsible pathogens are listed in Table 3. One case of linear 
IgA dermatosis has been described during IFD caused by Paecilomyces spp. (50).
 Half of fungal skin lesions were preceded by a superficial abrasion of the skin 
or a minor trauma. The extremities were the most common locations. Primary 
cutaneous fungal infections can be the first manifestation of CGD. Mansoory et al. 
(9) described a chronic cutaneous Fusarium infection in a 54-year-old women with 
undiagnosed CGD. In such patients, milder CGD phenotypes likely due to residual 
levels of superoxide production are considered to be the reason for the unusually 
late manifestation (51). Secondary cutaneous fungal infection, defined as the skin 
being an end-organ of hematogenous dissemination, is a much more aggressive 
clinical feature, resulting in massive dissemination and a very high case-fatality 
rate.
 Fungal invasive gastrointestinal (GI) involvement in CGD is very rare, especially 
when compared to the extensive granulomatous involvement of the GI tract (52). 
Etiologic agents are listed in Table 3. The clinical picture is that of hematogenous 
dissemination with abscess formation in liver, spleen and kidney, with exception 
of one isolated case of gastrointestinal mucormycosis that presented with an 
abdominal mass in a 10-month-old prematurely born infant (53). In this boy, the 
diagnosis of gastrointestinal zygomycosis served as the presenting symptom of the 
underlying CGD.
 Lymphadenitis, one of the classical presenting signs of CGD, has been rarely 
attributed to infection by fungi. Nevertheless, Candida lymphadenitis in the infant 
is very suspicious for CGD (54-56). In case of Aspergillus infections, the lymph nodes 
involved are often those draining the site of infection.
 Infection of the central nervous system was mainly observed as the consequence of 
a spread by contiguity from a primary pulmonary focus to the spinal cord. 
Localized brain abscesses are extremely rare but have been reported caused by A. 
fumigatus, S. prolificans and Alternaria infectoria (7, 57-59). Candida spp. were responsible 
as causative agents in meningitis or ventriculitis (60, 61).
FUNGAL INFECTIONS IN CGD: BY ORGANISM
Aspergillus fumigatus
Forty-four invasive A. fumigatus infections in CGD patients were reviewed. 
According to our criteria, 40 cases were proven IA and four were categorized as 
probable. Three out of the four patients with a probable IA presented with signs of 
symptoms of a mulch pneumonitis (37). The majority of infections (37/44), were 
caused by a single fungus. In mixed fungal infections, the associated organisms 
were, Rhizopus spp., A. niger, Penicillium spp., Absidia corymbifera and C. dubliniensis (37, 
Other organ involvement
The skin is less commonly infected by fungal than bacterial pathogens. The 
pathology is diverse, ranging from erythematous plaques, crusted, papulous, 
pustulous to purulent ulcers in the absence or presence of generalized symptoms as 
Table 3   Fungal species distribution and localization of invasive infections in  
CGD patients
Organ  
involvement
 Cases 
(%)
Species involved
Lung 83(72) A. fumigatus (n=31)
  A. nidulans (n=25)
  Zygomycetes (n=9)
  Trichosporon spp. (n=7)
  Scedosporium spp., Aspergillus other (n=4)
  Paecilomyces spp. (n=3)
  Penicillium spp., Candida spp., Acremonium spp. (n=2)
  Exophilia dermatitis, Chrysosporium zonatum, Hansenula  
polymorpha (n=1)
Bone 47(41) A. nidulans (n=17)
  A. fumigatus (n=18)
  Scedosporium spp. (n=3)
  A. niger, Trichosporon spp. (n=2)
  Paecilomyces spp., Penicillium spp., Crysosporium zoantum,  
Inonotus tropicalis, Exophilia dermatitis (n=1)
Brain 17(15) A. fumigatus (n=9)
  A. nidulans (n=2 )
  Zygomycosis (n=3)
  Scedosporium prolificans, Exophilia dermatitidis,  
Alternaria infectoria (n=1)
Skin 11(10) A. fumigatus, Paecilomyces spp. (n=3)
  Fusarium solani, Microascus cinerius, Alternaria alternate,  
A. nidulans and T. pullulans (n=1)
Gastro-intestinal 11(10) Rhizopus spp. (n=4)
  A. fumigatus, C. glabrata (n=3)
  Paecilomyces (n=1)
Lymphadenitis 11(10) A. fumigatus (n=4)
  C. lusitaniae (n=2)
  A. flavus, A. nidulans, T. glabarata, C. albicans, H. polymorphae (n=1)
Meningitis 1 C. lusitaniae (n=1)
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Aspergillus nidulans
Twenty-three cases of invasive fungal infections due to A. nidulans in CGD patients 
were previously reported and fulfilled the inclusion criteria of proven infection 
(n=22) or probable infection (n=1). In one patient, A. nidulans, A. fumigatus and A. 
restrictus were detected in sputum. However, no histological confirmation of 
multiple fungal infections was obtained (85).
 The major clinical features of invasive A. nidulans infections in CGD patients 
are summarized in Table 5. Twenty-two patients were male, and the median age of 
the population was 8 years (range 3-21 years). Interestingly, of those patients whose 
genetic pattern was reported (n=19), 90 % were X-linked gp91phox, compared to 75 
% in all documented cases and 74 % in those caused by A. fumigatus. One boy had a 
defect in p22phox and one girl had a defect in the cytoplasmic factor p67phox. Four 
patients had suffered from previous fungal infections by the time the invasive A. 
nidulans infection occurred.
 The most common localization (74 %) of the reported A. nidulans infections in 
CGD patient was the lung, with direct spread to adjacent chest-wall structures 
(Figure 2). 
 In contrast to IFD caused by A. fumigatus, the presenting signs and symptoms 
were often mild with low grade fever, local pain or swelling, malaise and cough, 
but could even be completely asymptomatic, with undetected lung infiltrates. 
Vertebrae, mostly thoracic, were the most frequent sites of bone involvement (47 % 
of cases), while the ribs and skull were involved in 39 % and 9 % of the cases, 
respectively. Invasion of the vertebrae was accompanied in 45 % by clinical signs 
and symptoms of spinal cord invasion. Two more exclusive cases were noted: 
Casson et al. (86) reported an A. nidulans endocarditis in a three-year-old girl with 
CGD who also had an atrial septal defect. Extensive prior investigation by local 
biopsy and repeated fungal antibody titers were negative and diagnosis was made 
on a second culture in which the organism grew from a mass obtained in the right 
atrium. Subsequently, A. nidulans was grown from embolic skin lesions and the site 
of the sternotomy. Despite extensive surgery and antifungal treatment, blood 
cultures grew A. nidulans and she died 24 days post-surgery. In 2003, an unusual 
mild and localized course of the disease was described in a 16-year-old male with 
CGD presenting with femoral osteomyelitis, without pulmonary involvement (46). 
No blunt or penetrating trauma was noted. Treatment with liposomal amphotericin 
B and granulocyte colony-stimulating factor as well as extensive surgical 
debridement, followed by prolonged treatment with itraconazole resulted in an 
excellent clinical response. Microscopic characteristics include very short 
conidiophores and the presence of ascospores with two equatorial crests. However, 
after molecular typing in 2008, this showed to be caused by A. rugulosa, originally 
identified as A. nidulans based on microscopic features (87). 
38, 40, 62, 63). Interestingly, in five out of the seven multiple-fungal infections a 
clear temporal relationship between massive exposure to molds, especially mulch, 
and the clinical presentation of pneumonia, was found (37, 38, 40). The age, sex 
distribution and genetic profile did not differ from the overall demographic char-
acteristics. Interferon-γ had been administered prophylactically to one third of the 
patients. However, prophylactic use of itraconazole was documented in only two 
cases. All of the invasive fungal infections caused by A. fumigatus were symptomatic, 
and accompanied by fever in 61 %. Detailed information on the individual clinical 
pictures is illustrated in Table 4. 
 Almost three-quarters had a history suggestive for primary lung invasion 
(30/44). Of these, half remained localized in the lungs (22, 36-38, 63-66) and more 
than one-third were disseminated, causing metastatic foci in bone, skin and/or the 
central nervous system (22, 67-74). In 14 % of the A. fumigatus infections, the fungus 
had spread by contiguity from the lung to adjacent chest-wall structures (22, 70, 
75-77).
 The brain and the skin were the most common extra-pulmonary sites affected 
by A. fumigatus. Primary cutaneous aspergillosis due to A. fumigatus occurred in 
three cases, all of them in relation to direct inoculation of disrupted skin (78-80). 
In four patients A. fumigatus caused isolated brain abscesses (7, 22, 57, 73). It should 
be emphasized that the symptoms can be very indolent ranging from mild fever 
and headache in the absence of any localizing neurologic signs (57), up to isolated 
seizures mimicking intracranial tumor (58).  Isolated osteomyelitis without 
evidence for pulmonary involvement was reported twice (44, 45).
 Susceptibility data were rarely provided. An elevated MIC for amphotericin B 
of 1.2 mg/l was found in an A. fumigatus isolate causing pneumonia and secondary 
osteomyelitis of the foot (69) and a MIC of 1.5 mg/l in a dual pulmonary infection 
with A. fumigatus and C. dubliensis (63). A multi-azole resistant A. fumigatus isolate 
(MIC itraconazole > 16 mg/l, voriconazole > 16 mg/l, posaconazole 0.25 mg/l) 
causing osteomyelitis of the midfoot of a patient who received itraconazole 
prophylaxis, was treated successfully with extensive surgery and long-term oral 
posaconazole (44). Patients with CGD may be at risk for azole-resistant fungi as 
they usually receive life-long azole antifungal prophylaxis (81-84)  Amphotericin B 
was the most commonly used first line treatment, followed by voriconazole. Half 
of the cases also underwent surgical interventions. If mentioned, adjuvant immu-
nomodulatory therapy, in the form of INF-γ and/or granulocyte transfusion was 
given in 27 %. The overall mortality rate was 30 %, mulch pneumonitis being 
responsible for more than half of the case-fatalities. However, as A. fumigatus has 
been the most commonly encountered fungal pathogen in CGD, it might be that 
less severe cases are not published, leading to overrepresentation of severe cases.
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Table 4   The major clinical features of A. fumigatus infections in CGD
Case 
(Ref.)
Sex Genetic Type Age 
(years)
Site of Disease Prophylaxis Treatment Surgery Outcome
1 (22) NM AR 8 Lung, chest wall TMP-SMX, INF-γ AMB Yes Survived
2 (22) NM AR 6 Lung, liver, brain, ribs TMP-SMX, INF-γ AMB No Died
3 (22) M X-CGD 2 Brain TMP-SMX, INF-γ AMB, 5-FC Yes Survived
4 (22) M X-CGD 5 Hepatic abscess, chest wall, rib osteomyelitis TMP-SMX, INF-γ AMB, ITC Yes Died
5 (22) NM AR 4,5 Lung TMP-SMX, INF-γ AMB, ITC Yes Died
6 (62) M NA 5 Chest-wall, thoracic vertebrae, spinal cord NM AMB NA Survived
7 (62) M NA 5 Lung, chest wall, thoracic vertebrae No AMB, 5-FC, MIC No Survived
8 (36) M X-CGD suspected FA 20 Mulch pneumonitis No AMB, 5-FC No Died
9 (67) M X-CGD suspected FA 10 Lung, lymphadenitis, femoral osteomyelitis TMP-SMX AMB, ITC No Survived
10 (68) M X-CGD 11 Lung, brain, bone (mastoid) TMP, rifampicin AMB, 5-FC, ITC, gran Tx Yes Survived
11 (126) M NA 18 Anterior chest wall, sternum osteomyelitis, 
 mediastinum, extensive vascular invasement with 
mycotic pseudoaneurysm
NM NM Yes Survived
12 (69) M X-CGD suspected FA 7 Lung, osteomyelitis foot, lymphadenitis draining Lnn Ampicilline AMB Yes Survived
13 (70) M X-CGD 18 Lung, ribs, humerus, chest wall TMP-SMX AMB, 5-FC, ITC Yes Survived
14 (71) M NA 15 Lung, humerus No AMB, 5-FC, ITC, gran Tx Yes Survived
15 (75) M X-CGD 10 Lung, rib, vertebrae, epidural soft tissue TMP-SMX, INF-γ AMB, ABLC,5-FC, ITC, gran Tx Yes Survived
16 (64) M X-CGD 30 Lung TMP-SMX, INF-γ VOR No Survived
17 (65) M X-CGD 0 Lung No AMB No Survived
18(57) M X-CGD 11 Brain abscess TMP-SMX AMB, ITC Yes Survived
19 (44) M X-CGD 18 Osteomyelitis midfoot TMP-SMX, INF-γ VOR, CAS, POS Yes Survived
20 (76) F AR 14 Lung, pericard, myocard, endocard No AMBL, VOR, CAS, gran Tx Yes Died
21 (166) M X-CGD 3 Soft-tissue skull, parietal bone, brain parenchym No NM Yes NA
22(80) M X-CGD suspected FA 3 Skin “sporotrichoid Aspergillosis”, lung No AMB, VOR, ITC Yes Still not under control 
23 (79) M X-CGD 13 Skin TMP-SMX, INF-γ AMB, ITC Yes Survived
24 (72) M NA 7 Lung, skin NM AMB NA Died
25 (78) M X-CGD 19 Skin TMP-SMX ITC No Survived
26 (37, 
38, 40)
M p47phox 14 Mulch pneumonitis No VOR, gran Tx No Died
27 (38) M X-CGD 7 Mulch pneumonitis No AML, VOR, CAS No Died
28 (37) F p47phox 23 Mulch pneumonitis No VOR, CAS No Survived
29 (37) M X-CGD 20 Mulch pneumonitis TMP-SMX AMB No Died
30 (37) M X-CGD 23 Mulch pneumonitis TMP-SMX, ITC AMBL No Died
31 (37) M p47phox 64 Mulch pneumonitis TMP-SMX, INF-γ, ITC AMB No Died
32 (37) M X-CGD 10 Mulch pneumonitis TMP-SMX, INF-γ AMB No Died
33 (66) M NA 3 Lung NA AMB No Survived
CHAPTER 2 FUNGAL INFECTIONS IN CGD
34 35
2
 A. nidulans has a unique predeliction for CGD. It remains a rare pathogen 
among all other immunosuppressed patients at high risk for IA  (88,89,90).
Other Aspergillus species
A. fumigatus is the primary agent of invasive human fungal infections, followed by 
A. flavus, A. terreus, and A. niger (12, 91-93). In contrast, among CGD patients, A. 
fumigatus and A. nidulans are by far the most commonly isolated Aspergillus spp., 
followed by A. niger (n=5) and A. flavus (n=1) (22, 37, 62, 94). 
 Most of the non-fumigatus non-nidulans Aspergillus spp. were isolated in mixed 
fungal infections, and associated to A. fumigatus or Rhizopus spp. (37, 62). The clinical 
picture related to multiple fungal species was that of mulch pneumonitis in half 
of the cases. 
 Kaltenis et al. (94) described  a ten-year old child suffering from disseminated 
aspergillosis associated with systemic amyloidosis. The causative agent was A. 
niger. Despite aggressive treatment with amphotericin B and surgical drainage, 
intravenous leukocyte transfusions, INF-γ and immunoglobulin infusions, the 
Table 4   Continued
Case 
(Ref.)
Sex Genetic Type Age 
(years)
Site of Disease Prophylaxis Treatment Surgery Outcome
34 (66) M NA 8 Lung NA AMB No Survived
35 (66) M NA 9 Lung NA AMB No Survived
36 (39) M X-CGD suspected FA 32 Mulch pneumonitis NA gran Tx No Died
37 (167) M AR suspected, sister 
AR CGD
17 Vertebrae, ribs, cervical sinus, spinal cord No AMB, AMBL, ITC, CAS, ABLC, 
VOR
Drainage 
abscess, 
vertebral 
surgery 
not 
 possible
Survived
38 (58) M p47phox 16 Brain abscess No AMBL, VOR Yes Survived
39 (7) M X-CGD 8 Brain abscesses, multiple No AMB, AMBL, VOR No Survived
40 (73) M X-CGD 20 Lung, osteomyelitis skull and subcutaneous abscess TMP-SMX AMB, gran Tx Yes Survived
41 (74) M X-CGD 4 Lung, osteomyeltis skull, epidural and intracerebral 
abscesses
No AMB, 5-FC Yes Survived
42 (45) M NA 17 Arthritis, osteomyelitis patella No AMB, ITC No Survived
43 (63) F NA 6 Lung No AMB,VOR No Survived
44 (77) M X-CGD 4 Lung, rib, subphrenic abscess NA AMB, ITR NA Survived
AMB, amphotericin B deoxycholate; AMBL, amphotericin B liposomal; ABLC, amphotericin B lipid 
complex; ITC, itraconazole; VOR, voriconazole; POS, posaconazole; KTC, ketoconazole; MIC, miconazole; 
CAS, caspofungin; 5-FC, 5-flucytosine; NA, not available
Figure 2  Computed tomography scan of A. nidulans infection in a patient with chronic 
granulomatous disease. (The extensive chest wall invasion and subcutaneous 
infiltration (arrow)).
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Table 5   The major clinical features of A. nidulans infections in CGD
Case 
(Ref.)
Sex Genetic Type Age  
(years)
Site of Disease Prophylaxis Treatment Surgery Outcome
1 (46) M NA 16 Osteomyelitis, long bone INF-γ ABLC, AMBL, ITC Yes Survived
2 (168) M NA 6 Lung, chest wall, vertebrae TMP-SMX AMB, ABLC, ITC Yes Died
3 (135) M X-CGD 20 Lung, 3th rib, femur, skull NA AMB, ITC, 5-FC Yes Survived
4 (43) M X-CGD 4 Lung, 8th-9th ribs, T6-L1 vertebrae NA AMB, AMBL, gran Tx Yes Died
5 (43) M X-CGD 9 Lung, 4th rib NA AMB Yes Survived
6 (43) M X-CGD 13 Progression of 4th rib lesion, T3-T4 with paraparesis NA AMB Yes Survived
7 (23) M X-CGD 6 Lung, pleura no  INF-γ AMB, ITC, gran Tx Yes Survived
8 (23) M X-CGD 19 Lung, pleura, chest wall, vertebrae, skin, skull, brain No AMB, ABLC, ITC, 5-FC, gran Tx Yes Died
9 (23) M X-CGD 16 Lung, pleura, vertebrae, chest wall KTC AMB, ABLC, ITC, gran Tx Yes Survived
10 (23) M X-CGD 7 Lung, pleura, vertebrae, chest wall, sinuses, brain NA AMB, ABLC, gran Tx Yes Died
11 (23) M X-CGD 4 Lung INF-γ until 1 mo before  
A. nidulans infection
AMB, ITC Yes Survived
12 (169) M X-CGD 8 Lung, rib Clindamycin AMB, gran Tx No Survived
13 (170) M NA 10 Lung, pleura, axillay abces, 2nd-3th ribs, vertebrae No AMB Yes Survived
14 (86) F p67phox 3 Endocarditis, skin lesions, blood TMP AMB Yes Died
15 (128) M X-CGD 21 Lung, chest wall, spinal cord, T5-T7 vertebrae, 
 popliteal abscess
TMP-SMX, ITC, INF-γ AMB, AMBL, VOR, CAS, gran Tx Yes Died
16 (129) M X-CGD 4 Lung, T2-T5 vertebrae, spinal cord TMP-SMX, ITC AMB, AMBL, VOR, POS, CAS, 
gran Tx
Yes Survived  
(ex-vivo gene therapy) 
17 (85) M X-CGD 13 Lung TMP-SMX, ITC but  diarrhea 
and serum levels (-)
AMBL, VOR, CAS No Survived
18 (130) M p22phox 5 Lung, chest wall cutaneous abscess NA AMB, VOR, ITC, gran Tx Yes Survived
19 (149) M X-CGD 8 Lung, 6th rib, chest wall fistula over the rib, psoas 
abcess
TMP-SMX, ITC stopped  
4 wk prior to A. nidulans 
AMB, AMBL, gran Tx Yes Survived (BM Tx) 
20 (24) M X-CGD 4 Lung, chest wall, T8-T11 vertebrae, 7th rib NA AMB, 5-FC, ITC gran Tx Yes Survived
21 (171) M NA 5 Lung, chest wall, vertebrae, spinal cord syringomyelia NA VOR Yes Survived
22 (37) M X-CGD 16 lung, MULCH pneumonitis TMP-SMX, INF-γ AMB, ITC No Survived
23 (150) M X-CGD 18 lung, osteomyelitis rib, vertebra TMP-SMX, ITC AMBL, VOR, CAS Yes Survived (BM Tx) 
AMB, amphotericin B deoxycholate; AMBL, amphotericin B liposomal; ABLC, amphotericin B lipid complex; 
ITC, itraconazole; VOR, voriconazole; POS, posaconazole; KTC, ketoconazole; CAS, caspofungin;  5-FC, 
5-flucytosine; NA, not available; gran Tx, granulocyte transfusion; BM Tx, bone marrow transplantation
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 A particular case of localized gastrointestinal mucormycosis in an eight-
month-old infant was reported by Dekkers et al. (53). The patient presented with 
an abdominal tumor associated with fever and diarrhea and Rhizopus microsporus 
var. rhizopodiformis was cultured within 24h from tissue specimens taken during 
laparotomy. Analysis of his neutrophil function confirmed CGD. The use of 
antacids might have contributed to the development of invasive mucormycosis by 
increasing the pH in the stomach (53). Voriconazole and itraconazole are not 
effective treatment options for mucormycosis. The first line treatment was 
amphotericin B in most of the cases. However, in two patients with mulch 
pneumonitis, voriconazole was used together with caspofungin, without coverage 
for zygomycetes. Overall mortality was high (54 %) compared to mortality 
associated with IA in CGD, likely due to delays in diagnosis and delayed and 
inadequate use of steroids to down-modulate the acute inflammatory aspects of 
mulch pneumonitis.
Candida species
The clinical spectrum of Candida infections in the immunocompromised host 
ranges from mucocutaneous disease to systemic life-threatening infections. 
Mucocutaneous involvement is remarkably rare in CGD. One report mentions an 
achalasia-like esophageal motility disorder as a result of a previously experienced 
Candida esophagitis (97), although this has not been observed in other diseases. 
Overall, in the CGD patient, Candida was the most common cause of meningitis, 
fungemia and lymphadenitis (54-56, 61, 98), but is not a causative agent of 
pneumonia, keratitis, hepatic abscesses and disseminated disease (10, 60, 63, 99, 
100). 
 Young children appear more prone to develop Candida lymphangitis, blood 
streem infections and meningitis than older patients. Among the proven cases of 
reported meningitis, candidemia and lymphadenitis with or without 
dissemination, the age ranged from 8 weeks to 4 months. Clinical signs were those 
of a septic infant, febrile, irritable, sometimes associated with local signs of organ 
involvement like lymphadenopathy, hepatosplenomegaly or signs of CNS 
involvement. The isolation of Candida spp. in an “otherwise healthy infant” was 
often the clue to diagnosis of a primary immunodeficiency defect. A possible 
explanation might be the immature mucosal immunity of the infant in the 
absence of a well-established tolerance for the Candida pathogen superposed to a 
defect in the phagocytic defense mechanisms.
  The second risk group includes older children and adults in whom the “classic” 
risk factors, such as prolonged broad spectrum antimicrobial drug use (3/5 for 
having bacterial co-infection), use of intravascular catheters and prolonged 
intensive care stay or hospitalization, may be present. 
patient died of multiple organ failure. A. flavus was the only causative agent in a 
seven-year old boy suffering from pulmonary aspergillosis associated with 
lymphadenitis; infection was controlled by surgical resection, amphotericin B and 
itraconazole (22). In vitro susceptibility data concerning these Aspergillus spp. were 
not reported. 
 Attention has to be drawn to the occurrence of fumigati-mimetic molds in 
unusual, chronic or refractory IA. Neosartorya udagawae and A. viridinutans have 
been reported in CGD patients. Phenotypical they resemble A. fumigatus, but the 
course of the disease is distinctive from typical aspergillosis, being chronic and 
spreading in a contiguous manner across anatomical planes, and relative 
refractoriness to antimycotic drugs.  Although encountered in the CGD patient, 
fumigati-mimetic molds are not confined to CGD; unlike A. nidulans that is essentially 
restricted to this host. Correct genotypic-based identification of fumigati- mimetic fungi 
may have implications for clinical course and management (42, 95).
Non-Aspergillus species
Zygomycetes
Mucormycosis refers to a group of opportunistic invasive fungal infections caused 
by fungi of the order Mucorales, predominantly of the genus Rhizopus, Mucor and 
Absidia. 
 Eleven cases of mucormycosis in CGD patients have been reported. Among 
them, nine Rhizopus isolates were identified (30, 37, 53), one A. corymbifera (40), and 
in one report, published in 1976, the clinical manifestation was described as 
“Phycomycosis”, indicating the causative species as belonging to the phylum 
Zygomycota (96). 
 Two major clinical identities were noted: “mulch pneumonitis” (n=5) (37, 38, 
40) and “invasive pulmonary mucormycosis” (n=5) (30, 96). Dissemination occurred 
in three patients. Mucorales are the second most commonly occurring species 
found in mulch pneumonitis, mostly in association with Aspergillus spp. The 
association of mucorales and mulch pneumonitis in CGD seems to be related to the 
fact that both mucorales and aspergilli are found in the same demographic or 
environmental niche. 
 Invasive pulmonary mucormycosis can progress to thoracic wall abscess or 
nodular infiltrates of lung, spleen and brain. Attention has to be drawn to the use 
of prolonged steroid-based intense immunosuppressive regimes prior to the onset 
of mucormycosis. Median age was high, 18 years, which might well be explained 
by the fact that the inflammatory sequelae needing anti-inflammatory therapy 
develop with age in CGD. The prescription and prolonged use of steroid-based 
intense immunosuppressive regimes seems to predispose those CGD patients to 
“less typical” fungal infections, such as mucormycosis. 
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in CGD are often aggressive, refractory to medical treatment and associated with 
a high fatality rate.
Scedosporium species
S. apiospermum (previously known as Pseudoallescheria boydii) and S. prolificans 
represent important multidrug-resistant opportunistic pathogens. Both pathogens 
have been described in CGD patients as breakthrough infections during treatment 
with amphotericin B and voriconazole, or after long-term treatment for Aspergillus 
infections (107, 108). 
 In these patients, S. apiospermum caused pulmonary infections with both 
contiguous spread to adjacent bone and central nervous system, and/or hematogenous 
dissemination. Outcome was favorable after extensive surgery of the infected tissues 
and antifungal therapy including azole derivatives, itraconazole and voriconazole, 
and INF-γ. S. apiospermum is generally considered resistant to amphotericin B, 
while extended-spectrum triazoles are active in vitro and voriconazole as well 
as posaconazole have been used successfully for the treatment of CNS abscesses 
(109-111).
 Bhat et al. (107) described the development of a S. prolificans brain abscess in a 
23-year-old CGD patient with a history of recurrent pulmonary aspergillosis who 
was on maintenance voriconazole and interferon-γ. MRI revealed a right frontal 
lobe lesion and CT-guided biopsy yielded non-specific yeast forms without hyphal 
elements. Cultures identified S. prolificans. This pathogen is considered resistant to 
virtually all antifungal agents, including the extended-spectrum triazoles and the 
echinocandins (109). The isolate showed high MICs for amphotericin B (>16 mg/l) 
and 5-FC (>16 mg/l). Although terbinafine does not appear to be active alone (112), 
the combination of voriconazole and terbinafine appeared synergistic and was 
used to treat the case, resulting in complete resolution of the brain abscess (107).
Trichosporon species
The eight cases of Trichosporon infection described in patients suffering from CGD 
include three due to T. pullulans, although one isolate was subsequently identified 
as Cryptococcus albinus, a likely contaminant (113, 114). T. pullullans has been reported 
as being a human pathogen, but controversy exists regarding whether T. pullulans 
causes invasive infection in patients with CGD (114). It is unlikely that T. pullulans 
causes invasive disease in patients with CGD, nor is it a significant invasive 
infectious agent in other immune compromised humans. 
 The case described by Lestini et al. (115), highlighted how difficult it may be 
to treat CGD colitis with a high dose of immunosuppressive drugs, including 
prednisone and infliximab: opportunistic organisms with high mortality and 
morbidity soon occur in such patients. 
 Detailed information on Candida spp. distribution in CGD patients is not 
available. According to the individual reports, C. glabrata and C. lusitaniae were each 
isolated three times (10, 54, 55, 61, 98, 100), C. albicans was suspected twice 
according to microscopic features or positivity of antigen testing and the 
occurrence of antibodies (56, 99); in one case no species identification was given 
(60). Susceptibility testing was rarely performed. Species identification is important 
with respect to the intrinsic resistance profiles of various Candida spp., most 
notably the non-albicans Candida spp. Amphotericin B resistance has been reported 
in cases of C. lusitaniae infections. Four of the 11 CGD patients with invasive Candida 
infections died, three of them in the neonatal period due to a severely disseminated 
disease.
Paecilomyces species
In CGD patients, Paecilomyces spp. have been reported as the third most common 
cause of osteomyelitis after Serratia spp. and Aspergillus spp. (4). Cultured-proven 
infections caused by Paecilomyces  spp. in CGD have been nicely reviewed by Wang 
et al. (8) in 2005. One additional probable pulmonary infection was described in a 
12-year old boy receiving cyclosporine treatment for severe colitis and peri-rectal 
disease (101). In total six cases have been reported of which four showed primary 
extrapulmonary disease. One of the extra-pulmonary cases was related to 
traumatic inoculation through a minor trauma. All of them were symptomatic 
and the clinical picture did not differ from those reported in the non-CGD host.
 P. variotii has been shown to be the causative agent in four cases: two cases of 
soft-tissue infection of which one was associated with multifocal osteomyelitis 
(102, 103), one case developed isolated splenic abscess (8) and one pneumonia (101). 
P. lilacinus was reported only once in a soft-tissue infection of the abdominal wall 
(104). Sillevis Smitt (50) implicated a Paecilomyces spp. in a pulmonary infection of a 
CGD patient also suffering from bullous Ig-A dermatosis.
 Differentiation between the two species is extremely important, since P. 
lilacinus and P. variotii seem to present marked differences in their in vitro suscepti-
bilities. Amphotericin B, itraconazole, and echinocandins showed poor activity 
against P. lilacinus, while the new triazoles, voriconazole and posaconazole show in 
vitro activity. In contrast, P. variotii was susceptible to most antifungal agents apart 
from voriconazole and ravuconazole (105). All of the patients recovered; however, 
two were still under treatment by the time their report was published and one 
patient died after four months due to an Aspergillus pneumonia.
 De Ravin et al. (106) raise the possibility that some of the Paecilomyces infection 
in CGD patients in previously published reports may have been caused by the 
emerging pathogen Geosmithia argillacea. When P. variotii is identified phenotypically, 
molecular approaches should be used to exclude G. argillacea, as infections observed 
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DIAGNOSIS
Culture and biopsy of clinical specimens
One hundred and eight of the 116 patients (93 %) reviewed in this study fulfilled 
our criteria for proven IFD and 8 patients for probable IFD. The proportion of 
proven cases was much higher than observed in other risk groups, such as patients 
with hematological malignancy. The tendency to prefer proven cases for 
publication might cause a bias leading to a high proportion of proven cases. 
Invasive procedures may be higher in CGD patients compared to other patient 
groups because they are relatively in a better clinical condition and rarely have 
thrombocytopenia. 
 Recovery of fungi by culture of sterile material in association with consistent 
radiologic or clinical infectious disease process made the diagnosis in 101/108 
cases. Blood cultures were positive in one mycotic pseudoaneurysm due to A. 
fumigatus (126), one A. nidulans endocarditis (86), fungemia due to C. lusitaniae (54) 
and T. pullulans (115). Histopathologic and direct microscopic examination of a 
biopsy taken during open surgery was conclusive in the 7 additional proven cases 
(39, 59, 60, 85, 96, 108, 113). Percutaneous fine needle biopsy was performed in 16 % 
(n = 19), including 11 fine needle lung biopsies. Of these lung biopsies, all were 
conclusive, either on microscopic examination or culture. Molecular studies were 
helpful in diagnosing Inonotus tropicalis osteomyelitis of the sacrum using 
ultrasound guided bone biopsy (47).
 In an era of multiple classes of antifungal agents, it is crucial to identify 
causative fungi to tailor therapy appropriately. Since 1970 numerous changes in 
the taxonomy of fungi have been implemented, especially through the use of 
molecular sequence information. Multilocus sequence-based phylogenetic 
analyses have emerged as the primary tool for inferring phylogenetic species 
boundaries and relationships within subgenera and sections. Recently, an 
international group of experts gathered for a workshop entitled “Aspergillus 
Systematics in the Genomic Era” and reviewed research data presented from 
research groups worldwide on recent genomic investigations, secondary metabolite 
analyses, multi locus phylogenetic analyses of the genus Aspergillus, and sequence 
based identification schemes for previously recognized human pathogens within 
the genus (127). 
 Sequence analyses of the ITS region appear to be appropriate for identification 
of Aspergillus isolates to the subgenus/section level (127). Use of the ITS sequence 
will not provide sufficient sensitivity to discriminate among individual species 
within the section. At present partial β-tubulin or calmodulin are the most 
promising loci for Aspergillus identification to the species level. For the section 
Nidulanti the identification of clinical isolates by use of β-tubulin sequencing 
 The four remaining Trichosporon spp. were identified as T. inkin, based on 
microscopic characteristics and inoculation on commercially available yeast 
identification systems. Clinically, T. inkin infection presented with pulmonary 
infiltrates. In three cases, the individuals were asymptomatic; the pulmonary 
infiltrates were found on routine chest radiographs. In one case, the lung lesions 
spread directly to adjacent ribs and penetrated the chest wall. Variable susceptibility 
to amphotericin B has described, and in general this agent lacks fungicidal activity 
against Trichosporon. The outcomes with voriconazole have been curative (S. M. 
Holland, unpublished). 
Miscellaneous
A few other species of fungi have also been reported to cause invasive infections in 
CGD patients. Among these species, Penicillium spp. have been reported most 
commonly (n=4) (37, 116, 117) However, it is now clear that many if not most of the 
isolates identified as invasive Penicillium in CGD are in fact due to the morphologically 
similar but treatment resistant Geosmithia argillacea (106) Acremonium spp. (n=2) (118, 
119) and Alternaria spp. (n=2) (59, 120) cause occasional infections as well. Inonotus, 
Chrysosporium, Exophiala, Fusarium, Microascus and Hansenula spp. have been reported 
once (9, 47, 121-125). All of these cases fulfilled the criteria of a proven IFD, with the 
exception of one mulch pneumonitis, in which a bronchoscopic specimen grew 
A. fumigatus, A. niger and Penicillium spp. (37). 
 The majority of patients presented with localized infections, two of them with 
spread to adjacent structures. The lung was the most commonly involved organ, 
skin and soft-tissue infections were observed in three cases, osteomyelitis and 
cerebral abscess were each reported once. With exception of a 4-month-old infant 
who suffered from a localized pneumonia caused by Acremonium kiliense (119), 
the age at onset was quite high. Half of the patients were adults (median 18, range 
0 – 69). Seven patients had X-linked CGD, four were diagnosed with autosomal 
recessive CGD and in three patients the genetic mutation was not reported. Five 
patients each had received itraconazole prophylaxis and interferon-gamma 
prophylaxis. Amphotericin B was used in 12/14 cases as first line treatment, two of 
them also received miconazole or voriconazole combination therapy. One patient 
received itraconazole. The mortality rate was 21 %. Two patients died of multiple 
organ failure related to mulch pneumonitis and one patient succumbed to cerebral 
alternariosis (59).
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Furthermore, since galactomannan is an immunogenic molecule, it could be 
rapidly removed from the circulation in the non-neutropenic host. 
 In our review of IFD in CGD, information on diagnostic PCR was retrieved in 
six proven cases (46, 47, 59, 77, 85, 129). Nucleic acid amplification of plasma and 
cerebrospinal fluid samples were all negative. In contrast, PCR performed on 
material obtained by biopsy of a brain lesion (59) and in the case of an osteomyelitis 
(47) revealed the etiological fungus.  
 Six cases mentioned strongly positive anti-Aspergillus antibodies (24, 64, 69, 77, 
128, 135), even while circulating galactomannan was undetectable in repeated 
serum samples (128). Except for the latter, no information was given about the 
assays used or about the epitopes recognized by these antibodies or corresponding 
antigen testing. In addition, antibody detection against Scedosporium spp. was 
helpful in two diagnoses (108), and once in a C. albicans sepsis (99). Antibody 
responses to Aspergillus spp. may result from environmental exposure in the 
absence of disease, occur in the course of either aspergilloma or invasive disease, 
or be detected as part of a hypersensitivity syndrome. Secreted, cell wall and 
cytosolic fractions of A. fumigatus hyphae have been reported as potent B cell 
antigens (136). Furthermore, work using the recombinant antigen mitogillin 
(Aspergillus protein toxin) suggests that specific antibody may be more prevalent in 
severely immunocompromised patients than has been described previously (137). 
However at the moment, antibody detection is not considered useful for the 
diagnosis of IFD. Combined detection of Candida mannanaemia and anti-mannan 
antibodies may substantially contribute to the early diagnosis of candidosis in 
high-risk patients (138). Nevertheless, little is known about the sensitivity of 
diagnostic modalities for IFD within specific immunocompromised patient groups 
as CGD. More work is required to define which diagnostic methods – or combination 
of methods – confer optimal predictive values in diagnosing IFD at an early stage 
in the CGD patient.
Radiologic findings
Although pulmonary involvement was present in 72 % of the reported cases, 
beyond the description of “pulmonary consolidation” and “lung infiltrates”, no 
specific signs as nodules, air crescent formation, halo signs, necrosis or cavitations 
were described or could be detected in the published images. Computed tomography 
and magnetic resonance scanning established extra-pulmonary extension to soft 
tissues, spinal cord injury and the extension of the osteolytic lesions. Local 
extension of disease from lung parenchyma to adjacent structures and osteomyelitis 
of the thoracic cage have been found particularly associated with underlying CGD. 
Unfortunately, not a single feature was pathogen-specific (139). The absence of the 
characteristic diagnostic radiologic findings of IA in pediatric patients has been 
revealed that clinical isolates were commonly misidentified when solely relied on 
morphologic characteristics (87). Differences in drug activity against the different 
species of the section Nidulanti was shown, underscoring the need for identification 
to the species level (87). In addition to Aspergillus spp. the taxonomy of many other 
genera involved in fungal diseases in CGD has changed including Candida, 
Paecilomyces, Scedosporium, and Trichosporon. These changes will have impact on the 
epidemiology of fungal diseases in CGD patients, and the use of molecular 
techniques for fungal strain identification will increase our insight into specific 
pathogens and their susceptibilities in the near future.
Nucleic acid amplification, antigens and serology
In seven of the reported CGD cases, information about circulating Aspergillus 
antigen galactomannan could be extracted (46, 65, 77, 99, 128-130). In 5 of 7 
patients (71 %) circulating galactomannan could not be detected despite extensive 
invasive infection (46, 65, 77, 128, 129). Interestingly, Verweij et al. (77) reported a 
CGD patient who developed invasive pulmonary aspergillosis and a subphrenic 
abscess. Fine needle aspiration of the subphrenic abscess recovered A. fumigatus as 
the etiologic agent. During treatment, high levels of Aspergillus antigen were 
detected in the abscess, but circulating antigen and Aspergillus DNA were 
undetectable in the serum.
 van ‘t Hek et al. (130) described circulating galactomannan in a five-year-old 
boy with X-linked CGD suffering from invasive A. nidulans infection and chest-wall 
invasion in whom treatment with amphotericin B failed. The galactomannan ratio 
in serum remained high during amphotericin B treatment but started to decline 
six weeks after therapy with voriconazole was initiated and finally became 
negative after four months of treatment.
 There has been a progressive increase in the understanding of the diagnostic 
utility of galactomannan which has enabled its incorporation into the EORTC/
MSG consensus definitions and the ECIL guidelines (35). Excellent performance 
characteristics in patients with hematological malignancies have been reported, 
with sensitivity up to 92.6 % and specificity of 95.4 % when serial monitoring of 
galactomannan was performed (131, 132), but the kinetics and predictive values of 
the antigen as a diagnostic marker in non-neutropenic hosts have not yet been 
defined (133). The performance of galactomannan detection is the highest in the 
neutropenic host, while in non-neutropenic patients circulating galactomannan 
is detected in only a quarter of patients (134). Possibly the rapid angio-invasive 
growth of Aspergillus in neutropenic patients facilitates the release of galactomannan 
into the blood. The poor performance of galactomannan detection in patients 
with CGD may be due to the fact that they are not neutropenic and the well-formed 
abscesses may preclude the release of the antigen into the blood (46, 77). 
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which might contribute to the high rate of treatment failure of these IFD in the era 
before azole antifungals (143). In a clinical CGD study, the total dose of amphotericin 
B used in patients with A. nidulans infections was not only higher than for those 
with A. fumigatus infections (231 mg versus 56 mg, respectively), but also the 
duration of amphotericin B therapy was substantially longer, 220 days for A. 
nidulans infections compared to 65 days for A. fumigatus infections (23). 
 Voriconazole has recently been introduced as drug of choice of invasive 
aspergillosis in children and has been shown as successful salvage therapy in 
patients with CGD (144). Among the described cases, use of voriconazole was first 
reported in 1998 and prescribed in 23 % of the cases. In comparison, 86 % of the 
cases received amphotericin B.
 In an open-label trial of oral posaconazole, Segal et al. evaluated the effect in 
eight CGD patients suffering from refractory invasive mold infection including P. 
variotii, S. apiospermum and A. fumigatus infections. Posaconazole led to complete 
response in seven of the eight infections. In addition, Notheis et al. (129) described 
the beneficial effect in a deteriorating A. nidulans infection refractory to 
voriconazole and caspofungin treatment. Posaconazole shows promising results as 
safe and effective salvage therapy in CGD patients (145, 146).
 Granulocyte transfusions were prescribed in 22 % of our cases, and/or 28 % 
received INF-γ. The use of granulocyte transfusions in CGD is supported by the 
observation that in vitro a small number of normal phagocytes may complement 
the oxidative defect and restore the killing ability towards A. fumigatus hyphae 
(147). However, the efficacy of granulocyte transfusions is poorly documented and 
limited to case reports. The use of INF-γ as adjunctive therapy of IFD in CGD 
patients has not been investigated by controlled studies and remains controversial 
(148). Three uncontrolled A. nidulans invasive fungal infections were cured either 
by ex-vivo gene therapy (129) or by BMT (149, 150).
 The utility of in vitro susceptibility testing for filamentous fungi is poorly 
defined, as acquired resistance was uncommon and species identification was 
sufficient to guide antifungal therapy. However, both CLSI and EUCAST are 
developing and validating reference methods for in vitro susceptibility testing of 
Aspergillus and other conidium-forming fungi (151). For A. fumigatus breakpoints 
have been proposed, while awaiting the recommendations by CLSI and EUCAST 
(152) .With the emergence of acquired resistance in A. fumigatus the need to 
determine the susceptibility in order to guide antifungal therapy has increased. 
In general, voriconazole is appropriate first line therapy for most IFD in CGD, with 
the important exception of mucormycosis, for which lipid formulations of 
amphotericin are first line and posaconazole a possible oral substitute.
 In 104 of the 116 cases information on prophylactic treatment was retrieved. 
Itraconazole or ketoconazole was prophylactically prescribed in 19 cases (18 %). In 
previously described by Burgos (93) in a multicentre retrospective analysis of 139 
children with malignancy with or without hematopoietic stem cell transplantation. 
Thomas (139) performed a retrospective review of imaging performed in 27 
consecutive patients with documented invasive aspergillosis, 12 of whom had 
primary immunodeficiency syndromes (including six CGD patients). Different 
pathophysiology in children compared to adults or, the exuberant granuloma 
formation in CGD in response to infection might explain the observed radiographic 
differences (64). 
 Pulmonary involvement is a common clinical feature of invasive fungal 
infections. This highlights the importance of identifying early, host-specific 
radiologic features on CT scan early in the course of disease. In the case of new or 
rapidly changing lesions, it is usually necessary and highly desirable to move to 
invasive diagnostic methods to identify the causative organisms. 
TREATMENT
Overall, the combination of antifungal treatment and extensive and early surgical 
debridement was used in most patients. Almost all of the patients received 
presumptive initial treatment with amphotericin B (86 %). However, it is important 
to keep in mind that this series is accumulated from the era well before the advent 
of azole antifungals, and therefore is heavily weighted to amphotericin as the sole 
antifungal agent available. In general, the treatment guidelines for patients with 
aspergillosis and candidiosis can be followed in patients with CGD (140, 141) 
keeping in mind that non-fumigatus Aspergillus species, in particular A. nidulans, 
may require a different antifungal treatment. Furthermore, the use of adjunctive 
immunomodulatory treatment options as INF-γ and granulocyte transfusions, 
while conceptually robust in CGD is unproven and remains quite anecdotal. 
 Amphotericin B is active against the majority of clinically relevant yeasts and 
moulds isolated in the CGD patient, including Candida spp., Aspergillus spp. and 
Zygomycetes. However, the susceptibility of Trichosporon spp. to amphotericin B is 
variable and Scedosporium  spp. are generally considered resistant (109). 
 Acquired and intrinsic resistance of Aspergillus spp. has been documented. 
Acquired azole-resistance is an emerging problem in A. fumigatus and may develop 
during azole therapy. This observation is of particular interest for CGD patients, as 
they should receive life-long itraconazole prophylaxis (82-84). Development of 
resistance in A. fumigatus during azole therapy has recently been described in a 
patient suffering from CGD (81).  Non-fumigatus Aspergillus species, especially A. 
terreus and A. nidulans, may be intrinsically resistant to specific classes of antifungal 
agents (142). Of particular interest is the resistance of A. nidulans to amphotericin B 
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CLINICAL OUTCOME
Unambiguous data on clinical outcome in accordance to the definition of complete 
response (defined as resolution of all clinical signs and symptoms attributable to 
IFD and complete or nearly complete radiological resolution) or a partial response 
(improvement or resolution of all clinical signs and symptoms attributable to IFD 
and ≥50 % improvement in radiological findings) were lacking and follow-up 
ranged from “still under treatment” to nine years after treatment. At the time 
cases were published, the mortality rate related to the fungal infection was 26 % 
(Table 1). Mixed fungal infections (50 %) and mucormycosis (55 %) seem to be 
responsible for the highest mortality rates, followed by Candida spp. (40 %), A. 
fumigatus (30 %) and A. nidulans (27 %). However, the reported small numbers of the 
individual groups, the occurrence of particular species like A. nidulans, or severe 
clinical presentations of the more commonly encountered A. fumigatus may 
substantially influence these mortality rates. This underscores again the need of 
more prospective surveillance cohort studies of invasive fungal infections in this 
unique host.
CONCLUSIONS
To summarize our current understanding of fungal epidemiology and clinical 
management of invasive fungal disease in CGD patients we have to conclude that 
there is a paucity of data. Consequently, current management strategies may not be 
optimal to protect CGC patients from these life-threatening infectious complications. 
 Host defense mechanisms influence the manifestations and severity of 
infections; the clinical presentation of fungal disease depends on the patient’s 
immune response. As a result, there are important clinical and diagnostic 
differences between IFD in CGD patients compared to patients with other immu-
nocompromised conditions. 
 First of all, the CGD patient is a non-neutropenic host suffering from impaired 
phagocytic killing and a dysregulated inflammatory response. As a result, IFD can 
present with a huge variety of often non-specific symptoms, ranging from indolent 
and asymptomatic up to acute onset of hypoxia and respiratory failure, or isolated 
symptoms of specific organ involvement. Timely diagnosis of IFD in CGD requires 
a high degree of suspicion. This is in contrast to the neutropenic host, in whom the 
risk depends mainly on the duration of the neutropenia and in whom persistent 
febrile neutropenia is one of the early signs of a possible invasive fungal infection. 
 Secondly, invasive mould infections in neutropenic patients are characterized 
by hyphal angioinvasion, necrosis and paucity of inflammatory cells. In contrast, 
addition, three patients were still under antifungal treatment at the onset of a 
new IFD: two developed a Scedosporium breakthrough infection (S. prolificans during 
voriconazole and S. apiospermum during amphotericin B treatment) (107, 108) and 
one Trichosporon sp. was cultured during amphotericin B, caspofungin, and 
voriconazole treatment for active A. nidulans infection (113). Twenty-eight patients 
received INF-γ (27 %), in almost half in combination with antifungal prophylaxis.
 Interferon-gamma (INF-γ) is a macrophage-activating cytokine produced by T 
cells and natural killer cells and has a key role in the innate and adaptive host 
response against fungi (153). A subgroup of variant X-linked CGD patients (i.e., 
with very low, but detectable, baseline superoxide-generating activity), who have 
splice site mutations, has been shown to be responsive to INF-γ (154, 155). Treatment 
resulted in improved splicing efficiency and an increase in cytrochrome b 
expression, allowing near normal levels of superoxide production and bactericidal 
activity of neutrophils and monocytes (156-158). However, subsequent reports have 
not confirmed the enhancement of superoxide production as the principal 
mechanism of INF-γ activity in CGD individuals (159-161). To date placebo-con-
trolled studies are still limited and controversy remains about the routine 
prophylactic administration in CGD patients. INF-γ prophylaxis is offered only in 
selected CGD cases by most European physicians, while it is more universally 
prescribed in the USA and Japan (162, 163). In contrast to the multiple studies 
confirming value for the use of INF-γ prophylaxis to reduce infections in CGD, 
there are no prospective data to show any benefit of INF-γ treatment during acute 
infection.
 One of the cornerstones of clinical care for CGD patients is the lifelong 
prophylactic treatment with intracellular active microbicidal agents. After the 
introduction of antibacterial prophylaxis, fungal infections persisted with an 
incidence of 0.15 episodes per patient year (4). In a prospective, open-label study 
with 30 patients, administration of itraconazole reduced the rate of Aspergillus 
infections to one-third in comparison with historical controls (164). Gallin et al. 
(165) performed a randomized, double-blind, placebo-controlled crossover study 
in 39 CGD patients, finding only one serious fungal infection in the itraconazole 
group compared to seven cases in the placebo arm. Serious fungal infections 
developing during long-term itraconazole prophylaxis may well be due to molds 
that are resistant to itraconazole. Further studies are warranted to evaluate 
potential alternatives to the currently used antifungal prophylactic strategies. 
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directed antifungal therapy will improve outcome without the need for aggressive 
surgery. Adjunctive immunomodulatory therapy was used in about 25 % of the 
patients. The role for immunomodulatory agents in addition to antifungal therapy 
is not well studied. Due to lack of a profound understanding of the pathogenesis of 
invasive fungal infections in the CGD host, it is currently hard to define to what 
extent specific immunomodulatory therapies will be of benefit for this specific 
patient population. 
 Antifungal prophylaxis is not universally prescribed and has been associated 
with invasive infections caused by intrinsically or acquired resistant fungal 
organisms. However, since the introduction of azole prophylaxis the incidence of 
invasive aspergillosis seems to have decreased. 
 An infection-related mortality of 26 % was noted, but underestimation cannot 
be ruled out because of the huge variability in follow-up. Furthermore, large 
variability in the mortality was noted based on the clinical presentation and the 
causative fungus. 
 Management and outcome data should be gathered to guide optimal treatment 
decisions for future patients. At present, international and national databases are 
used to collect clinical data prospectively in children suffering from invasive 
fungal infections. Although not specifically designed for patients with CGD, it will 
be a first step to improve our knowledge about these devastating infections.
angioinvasion is not a feature of invasive mould infections in CGD. As a consequence, 
the characteristic radiologic halo-signs, air-crescents and cavities within areas 
of consolidation (one of the EORTC/MSG diagnostic criteria of invasive fungal 
infections) are typically lacking in CGD infections. 
 Furthermore, indirect laboratory markers of IFD, like the detection of 
Aspergillus antigen (galactomannan) in serum, have a low sensitivity in this patient 
group. Molecular diagnostic modalities, like the Aspergillus PCR, either have not yet 
been standardized or their sensitivity and specificity in CGD patients have not 
been studied. As a result, the recognition and diagnosis of IFD in CGD patients is 
distinct from that in cancer and transplant patients.
 Due to the rather long and obscure list of unusual invasive fungal infections 
in CGD patients, it is of the utmost importance to identify the causative fungus in 
a particular patient. In general, the clinical condition of CGD patients often can 
tolerate invasive diagnostic procedures and they should be performed to isolate 
the causative species, subsequently followed by targeted antifungal therapy. On 
the other hand, it is critical to keep in mind that the identification of an invasive 
infection in a previously healthy host is highly suggestive of CGD as the underlying 
disease. 
 IA caused by A. nidulans is virtually unique to CGD patients and needs more 
aggressive antifungal therapy than the more commonly encountered A. fumigatus. 
Invasive infections by A. nidulans are very seldomly reported in other immunocom-
promised patients and indicate a unique interaction between this fungus and 
the CGD host. The clinical entity of “mulch pneumonitis” is a characteristic 
presentation of fungal pneumonia in the CGD patient in which multiple causative 
fungi may be recovered. The occurrence of infectious complications by Zygomycetes 
is mainly noted in the setting of inflammatory complications being treated with 
immunosuppressive drugs. Candida infections are less frequently seen but show an 
age-dependent clinical presentation; meningitis, fungemia and lymphadenitis 
with or without dissemination, were reported in neonates and young infants, and 
were not observed in older patients.
 Details regarding strain identification and in vitro susceptibility testing are 
scarce in CGD patients. Accurate identification of the causative fungus to species 
level, due to a species dependent susceptibility to the currently used antifungal 
drugs for treatment and prophylaxis will definitely affect patient management. In 
vitro susceptibility testing may also have a role, but is as yet undefined. 
 Extensive and early surgery has been the cornerstone of treatment and 
amphotericin B was mostly used as the first-line drug. Since the introduction of 
the new triazoles, the occurrence of invasive fungal infections as a cause of death 
seems to decrease dramatically. It remains to be seen if the combination of an early 
diagnosis with an accurate specification of the causative fungus and subsequently 
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ABSTRACT
Invasive aspergillosis is a major threat for patients suffering from chronic 
granulomatous disease (CGD). Although Aspergillus fumigatus is the most commonly 
encountered Aspergillus species, the presence of A. nidulans appears to be dispropor-
tionately high in CGD patients. The purpose of this study was to investigate the 
involvement of the NADPH-oxidase and the resulting reactive oxygen species (ROS) 
in host defense against fungi and to clarify their relationship towards A. nidulans. 
 Murine CGD alveolar macrophages (AM) and polymorphonuclear leucocytes 
(PMNs) and peripheral blood mononuclear cells (PBMCs) from healthy controls and 
CGD patients were challenged with either A. fumigatus or A. nidulans. Analysis of the 
antifungal effects of ROS revealed that A. nidulans, in contrast to A. fumigatus, is not 
susceptible to ROS. In addition, infection with live A. nidulans did not result in any 
measurable ROS release. Remarkably, human CGD PMNs and PBMCs and murine 
CGD AM were at least equipotent at arresting conidial germination compared to 
healthy controls. Blocking of the NADPH-oxidase resulted in  significantly reduced 
damage of A. fumigatus but did not affect A. nidulans hyphae. Furthermore, the 
microbicidal activity of CGD PMNs was maintained towards A. nidulans but not A. 
fumigatus. In summary, antifungal resistance to A. nidulans is not directly ROS 
related. The etiology of A. nidulans infections in CGD cannot be explained by the 
simple absence of the direct microbicidal effect of ROS. In vivo, the NADPH-oxidase 
is a critical regulator of innate immunity whose unraveling will improve our 
understanding of fungal pathogenesis in CGD.
INTRODUCTION
Chronic granulomatous disease (CGD) is a rare (prevalence, 1/250,000 individuals) 
inherited immunodeficiency disorder of the NADPH-oxidase in which phagocytes 
fail to generate the microbicidal reactive oxidant superoxide anion and its 
metabolites, due to a mutation in any of the five structural components of the 
NADPH-oxidase complex. As a result, CGD patients are characterized by recurrent 
life-threatening bacterial and fungal infections as well as chronic inflammatory 
diseases due to dysregulated inflammatory pathways. The lifetime incidence of 
invasive aspergillosis (IA) in children with CGD varies between 25 % and 40 % and 
IA has been the main cause of death (35 %) (7,24). 
 The etiology of IA differs remarkably between patients with CGD and those 
with other underlying immunodeficiencies. Although Aspergillus fumigatus is by far 
the most frequently encountered pathogen, A. nidulans causes up to 50 % of cases of 
osteomyelitis and is overrepresented in cases of invasive aspergillosis in CGD 
patients, with a five- to tenfold higher mortality rate (8,22). Differences in either 
fungal virulence factors or antifungal mechanisms mounted by the host to kill 
these pathogens could explain why A. nidulans causes such a disproportionately 
high infection rate in CGD patients versus other immunocompromised patients 
(1,2,5,14,31). 
 Most studies focusing on innate immune responses against Aspergillus spp. 
have used A. fumigatus; knowledge of the host response against other Aspergillus 
species is scarce, in particular with respect to A. nidulans. The almost exclusive 
contribution of NADPH-oxidase to microbial killing has been debated, with studies 
showing contradictory results. On the one hand, the absence of NADPH-oxidase in 
CGD cells indicates its essential role in effective microbial killing. Investigators 
have focused attention on the products of the oxidase themselves as the 
microbicidal agents. In addition, clinical epidemiological data for infections 
occurring in CGD patients suggest a direct link between catalase-positive 
microorganisms as causative organisms and the absence of reactive oxigen species 
(ROS) in CGD patients. Species such as Staphylococcus aureus, Burkholderia cepacia, 
Serratia marcescens, Aspergillus species, and Nocardia species are able to destroy their 
own hydrogen peroxide radicals. This makes microbe-produced H2O2 unavailable 
to the phagocytic cells for conversion into more potent and potentially toxic 
microbicidal reactive oxygen intermediates. Several in vitro studies have proposed 
a direct link between an increased oxidative response and enhanced fungal 
damage (19,20).
 On the other hand, in vivo and in vitro studies have reported unaltered virulence 
of catalase-deficient A. nidulans and S. aureus in the CGD host (5,16), and experimental 
studies with alveolar macrophages (AM) from C57BL/6 and gp91phox-deficient mice 
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lysis buffer was added and an extra washing step was performed. The AM were 
resuspended in warm RPMI plus 10 % fetal bovine serum (FBS) in a total volume of 
1 ml. The cells were counted with the use of a Bürkerchamber and adjusted to a 
concentration of 5 x 105/ml. Cellviability was checked by trypan blue exclusion. 
Aliquots of 100 µl/well (5 x 104 AM) were added to 96-well plate and incubated 
overnight at 37°C. After 18h, the nonadherent cells were washed away and the 
medium (RPMI plus 10 % FBS) was refreshed.
Fungal strains
In all experiments, we used fully molecularly characterized A. nidulans and A. 
fumigatus strains originally isolated from patients with CGD who were suffering 
from invasive aspergillosis. The cell-free assay and the assays for the assessment of 
the interaction with human PMNs and PBMCs were performed with A. fumigatus 
strain V45-07 and A. nidulans strain V44-46. A. fumigatus strain B5233 and the A. 
nidulans strain RYCB were used for the animal experiments. The growth and 
killing assays of the Aspergillus isolates were prepared in a lipopoly-saccharide 
(LPS)-free fashion. A.  fumigatus strains were grown on Sabouraud glucose agar 
supplemented with chloramphenicol for 4 to 7 days at 37°C. Abundant conidia 
were produced under these conditions. Conidia were harvested by gently scraping 
the surfaces of agar slants and suspending the conidia in PBS with 0.05 % Tween 
80. To remove hyphal debris, the conidial suspension was filtered twice through 
five layers of sterile gauze. Conidia were washed twice in PBS, resuspended in HBSS 
without phenol red, calcium, or magnesium [HBSS(-)] , and stored in individual 
aliquots of 1 x 108/ml at -80°C. Due to the tendency of A. nidulans strains to produce 
cleistothecia in their sexual cycle, the growth conditions used for A. fumigatus had 
to be modified.  After growth on Sabouraud glucose agar, conidia were plated on 
water-agar for 3 days, followed by incubation on malt extract agar for an additional 
3 days. Under these conditions, pure asexual growth was obtained. The harvest 
protocol was identical to that described for A. fumigatus.
 To collect hyphal fragments, conidia were added to 5 ml of yeast nitrogen base 
medium (YNB) (Difco) at a final concentration of 1 x 106/ml. After 18 h of incubation 
at 37°C, the cultures were centrifuged at 3,000xg for 15 min, and the pellet, 
containing almost exclusively mycelia, was washed twice in PBS and resuspended 
in 1 ml of HBSS(-). 
 Aliquots of the conidial suspension were heat killed for 15 min at 121°C. 
Nonviable conidia were centrifuged at 3,000xg for 15 min, resuspended, and 
vortexed vigorously. Finally, the suspension was washed three times with HBSS(-) to 
remove released Aspergillus components and then kept frozen at –80°C until they 
were used. The viability of the fungi was checked by culture at 37°C on Sabouraud 
glucose agar. No growth was observed following heat treatment. 
showed that conidial germination was equally inhibited in vitro. These results 
suggest that NADPH-oxidase independent mechanisms in murine alveolar 
macrophages contribute to the inhibition of conidial germination (6). 
 In order to unravel the unique interaction of the CGD host and A. nidulans and 
to evaluate the role of the NADPH-oxidase complex and ROS in resistance to Aspergillus 
spp., we investigated the ability of the various phagocytic cells to generate ROS in 
response to fungal invasion. This was carried out with the CGD-specific pathogen 
A. nidulans and compared to the more general pathogen A. fumigatus. 
MATERIALS AND METHODS
Human PBMCs and PMNs
Venous blood was drawn from healthy volunteers and two gp91 phox-deficient CGD 
patients after informed consent. Periferal blood mononuclear cells (PBMCs) and 
polymorphonuclear leucocytes (PMNs) were isolated from peripheral blood by use 
of Lymphoprep (Axis-Shield) and density gradient centrifugation. Briefly, blood 
was anticoagulated by use of lithium heparin (BD Vacutainer) and then diluted 
with an equal volume of phosphate-buffered saline (PBS). The diluted blood was 
carefully added to the top of the Lymphoprep and centrifuged at 800xg to separate 
the plasma from the PBMCs fraction and the PMNs. PBMCs were harvested, washed 
twice in PBS, and counted by use of a hemocytometer. To remove the erythrocytes 
from the PMNs, the pellet was shocked at least twice with an ice-cold lysing reagent 
(NH4Cl, Na2EDTA, KHCO3). Subsequently cells were washed and resuspended in 
PBS. When the experiment required cells in ‘Hanks’ buffered salt solution (HBSS; 
Invitrogen Life Technologies) or culture medium (CM), the last step was adjusted 
with the corresponding medium. RPMI 1640 GlutaMAX-I medium (Invitrogen Life 
Technologies) plus 10 % heat inactivated fetal calf serum (FCS) was used as CM for 
all cell experiments. 
Animal handling and AM sample collection
Wild-type 8- to 16-weeks-old male and female C57BL/6 mice and CYBB/C57BL/6 
mice, which have a homozygous mutation in the CYBB gene, were used. The 
animals were maintained in sterilized microisolator cages in a pathogen-free 
environment at the animal facility of the National Institute of Allergy and 
Infectious Diseases, Bethesda, MD. Alveolar macrophages were isolated from bron-
choalveolar lavage fluid (17). Lavage was performed by using 0.75 ml warm PBS 
(37°C) plus 3 mM EDTA. In total, 10 lavages were done four each mouse to increase 
the yield of AM. The bronchoalveolar lavage fluid was spun down at 400xg for 12 
min and washed once with warm PBS. If many red blood cells were observed, a 
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XTT assay
The XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)2H-tetrazolium-5-carboxanilide 
sodium salt] assay of fungal viability described by Meletiadis et al. (15) was modified 
as follows. Each well of a 96-well plate was filled with 100 µl of live resting conidia 
of A. nidulans or A. fumigatus at 1 x 106/ml CM. Hyphae were obtained directly in the 
test well by overnight incubation (13h) of the conidia (1 x 106 /ml) at 37°C. 
Subsequently, CM was refreshed, and 100 µl of isolated PMNs or PBMCs was added 
at a concentration of 5 x 106/ml. Conidial viability was assayed after 18h of 
incubation at 37°C in 5 % CO2, while  hyphal viability was assayed after 90 min of 
incubation to avoid overgrowth of hyphae. At the indicated times, the plates were 
centrifuged at 3,000xg for 10 min and the supernatant was removed. Cells were 
lysed by addition of ice-cold MilliQ with 0.025 % Triton for 5 to 10 min on ice, after 
which each well was washed to remove cell debris. One hundred microliters of PBS 
and 100 µl of XTT-menadione solution was added to each well in order to obtain a 
final concentration of 200 µg/ml XTT (Sigma-Aldrich) and 25 µM (4.3 µg/ml) 
menadione (Sigma-Aldrich). Incubation was continued at 37°C for at least 2 h in 
the dark to allow conversion of XTT to its formazan derivative. Control wells 
containing PBMCs, PMNs, or AM alone were used as negative controls, while wells 
containing conidia or hyphae alone were used as positive controls. Plates were 
centrifuged, and the absorbance of the supernatant was read at 450 nm in a spec-
trophotometer. Fungal damage was defined as the percent reduction in metabolic 
activity compared to that of  controls and was calculated as follows: [1 – (X/C)] x 
100, where X is the mean absorbance in the test wells and C is the mean absorbance 
in the control wells. In addition, the potential enhancement of the antifungal 
effect by INF- γ was tested in 2 different concentrations: 100 U and 500 U of INF- γ/
ml. This process was followed as indicated above. Ninety-six-well clear-bottom 
plates were used for the killing experiments with healthy host cells. To minimize 
loss of fungi, the killing experiments with and without DPI and the comparison 
between healthy and CGD cells were performed with a 96-well 0.45-µm-filter-bot-
tom plate (Millipore Multiscreen-HV).
Statistical analysis
Each experiment was performed with the cells of one particular donor and by 
their use in triplicate (growthrate), quadruplicate (XTT assay) or quintuplicate 
(chemiluminescence) wells. The mean value of these replicate wells was taken as the 
value for the particular donor and/or experiment. All cell-mediated experiments 
were performed in quadruplicate unless otherwise indicated. The means were 
then used in the data analysis to calculate the means ± standard errors of the 
means (SEM) for all the experiments under the same conditions. Comparisons 
between two means were tested by t tests, calculated using GraphPad Prism 4.0 
Cell-free effect of reactive oxygen species
The antifungal activity of ROS was evaluated by the growth rate and the amount 
of cell-free hydrogen peroxide-induced damage. Resting conidia, swollen conidia, 
or hyphae (1 x 106 /ml) were incubated at 37°C in the presence of hydrogen peroxide 
at three different concentrations, namely 10-1 M, 10-3 M, and 10-5 M H2O2. Swollen 
conidia were obtained by incubation in YNB at a density of 1x106 conidia/ml. 
Growth was measured for 48h by spectrophotometry (optical desity at 450 nm 
[OD450]) and compared to that of the negative control. The cultures were observed 
under a microscope during the first 5h. All experiments were performed in 
triplicate under the same condition and were repeated twice.
Measurement of superoxide production/reactive oxygen 
intermediates
Oxygen radical production was evaluated by luminol-enhanced chemilumines-
cence, as measured in an automated LB96V Microlumat Plus luminometer (EG & G 
Berthold, Bad Wildberg, Germany). Luminol (Sigma-Aldric) is an organic dye which 
reacts with both extracellular and intracellular oxygen species. As a result, the 
luminol molecule is excited and when the luminol returns from the excited state 
to the steady state, the energy is released in the form of light, which can be detected 
by the luminometer. Briefly, 100 µl of PBMCs or PMNs suspension (2 x 106 cells/ml) 
in HBSS(-) was added to a 96-well nontransparent white microtiter plate. The cells 
were then challenged with 0.5 µg/ml phorbol 12-myristate 13-acetate (PMA; 
Sigma-Aldric), 1 mg/ml opsonised zymosan (Sigma-Aldric), or fungal cells. Either 
resting or heat-killed conidia of A. nidulans or A. fumigatus were tested at a cell-to- 
conidium ratio of 1:20 (100µl of 4 x107 cells/ml per well). Control wells received 
100 µl of medium. Luminol (10-2M [1.77 mg/ml]) in dimethylsulfoxide [DMSO]) was 
diluted 10-fold in HBSS-0.5 % bovine serum albumin (BSA) prior to use. The reaction 
was started by the addition of 20 µl of luminol solution. Each measurement was 
performed in quintuplicate. Chemiluminescence was measured using a 1-s 
integration time at intervals of 228 s over a 3-hour incubation period at 37°C and 
a 0.5-s integration time over a 10-hour incubation. Luminescence was expressed as 
relative light units per second (RLU/s). The area under the concentration-time 
curve (AUC), representing the overall oxygen radical production during incubation, 
was calculated. To evaluate the effect of gamma interferon (INF-γ), conidia were 
added with or without 100 U or 500 U of commercially available human INF-γ /ml 
(Immukine; Boehringer Ingelheim BV). Blocking of the NADPH-complex was 
performed by use of diphenyleneiodonium chloride (DPI; Sigma-Aldrich).
CHAPTER 3 ROS-INDEPENDENT KILLING OF ASPERGILLUS NIDULANS
70 71
3
Live and heat killed A. nidulans conidia are poor stimulators of ROS
Since phagocytosis is associated with the activation of NADPH-oxidase, resulting 
in the release of ROS, the release of ROS was assessed in real time and during the 
whole process of phagocytosis by use of luminol-enhanced chemiluminescence. 
Human polymorphonuclear cells and PBMCs produced ROS in response to live 
resting A. fumigatus conidia. In contrast, no significant NADPH-oxidase activity 
could be measured in response to live resting A. nidulans conidia, either by PBMCs 
or in PMNs. Furthermore, the global respiratory burst activities of the PBMCs and 
PMNs during stimulation with live A. nidulans conidia  (5,161 ± 547 RLU/sec and 
4,512 ± 227 RLU/s, respectively), were similar to that of unstimulated cells (4,224 ± 
428 RLU/s and 4,129 ± 225 RLU/s, respectively) (Figure 2).
 To determine whether the lack of ROS production after A. nidulans conidial 
stimulation was dependent on the metabolic activity of the fungus, we exposed 
the PMNs and PBMCs to swollen conidia (4 h of incubation prior to stimulation). 
However, no additional germination-induced ROS production was observed (data 
not shown). Increasing the time of measurement up to 10 h, thereby covering the 
entire process of germination, from resting conidia to swollen conidia and then to 
hyphae, confirmed that infection with live A. nidulans did not result in any 
significant increase of ROS production by phagocytic cells. In contrast, live A. 
(GraphPad Software, San Diego, CA). P values of  < 0.05 were considered statistically 
significant. Comparisons between more than two means were analyzed by analysis 
of variance (ANOVA), using the statistical software SPSS 16.0. When the ANOVA 
result was significant, pairwise comparisons were performed using a Bonferroni 
adjusted level of significance.
RESULTS
Swollen A. nidulans conidia are resistant to H2O2 
We initially investigated the link between the products of the NADPH-oxidase 
themselves and the death of the microbe by assessing the direct antifungal effect 
of ROS. Therefore, growth characteristics of resting conidia, swollen conidia, and 
hyphae were evaluated in the presence of H2O2 at three different concentrations, 
namely 10-1M, 10
-3M, and 10-5M H2O2. There was a direct correlation in the 
dose-response relationship between H2O2 and growth inhibition of both species of 
Aspergillus. The 10-3M H2O2-induced damage to swollen A. fumigatus conidia was 
significantly greater than to A. nidulans conidia and was sustained for up to 18 h of 
incubation (P<0.01). Growthcurves for A. nidulans at 10-3M H2O2 were similar to 
those for their negative controls, suggesting resistance of swollen A. nidulans 
swollen to H2O2 (Figure 1). No differences in growth inhibition were found between 
resting conidia or hyphae of both species at either 10-3M H2O2 or 10
-1M H2O2 
(complete inhibition) or at 10-5M H2O2 (no inhibition).
Figure 1  Cell-free damage of H2O2 on swollen conidia. Growth-curves of A. nidulans 
at 10-3M H2O2 (dashed line) were similar to the negative controls (solid line), 
reflecting a complete H2O2 resistance of A. nidulans swollen conidia.
Figure 2  Live resting A. nidulans conidia are extremely poor stimulators of ROS. 
Data represent mean relative light units (RLU) per second as measured by 
luminescence. Bar heights indicate the mean area under the curve (AUC) performed 
in 5 healthy donors. Error bars are the SEM of the 5 results. *, P < 0.05; **, P < 0.01.
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 Since both species have a slightly different green color, it is possible that 
differences in light absorption between the species could interfere with chemilu-
minescence. Therefore, live and heat killed A. nidulans or A. fumigatus were incubated 
in a cell-free ROS generation system, ammonium persulfate (APS) (Bio-Rad) and 
light emission was measured by luminol-enhanced luminescence. Only live A. 
fumigatus conidia absorbed light significantly more than their negative controls 
(40 % ± 3 %), further accentuating the observed differences between live A. nidulans 
and A. fumigatus.
Live A. nidulans hyphae are extremely poor stimulators of ROS
Whether ROS are important for conidial host defense is somewhat controversial, 
but it is widely accepted that once the conidia germinate into hyphae, degranulation 
of PMNs and release of ROS induce hyphal damage. Interestingly, after incubation 
of A. nidulans hyphae with healthy PMNs, no significant amount of ROS could be 
measured compared to that in unstimulated cells (9,922 ± 1,131 RLU/s versus 
20,100 ± 8,616 RLU/s). In contrast, A. fumigatus hyphae induced a rapid and robust 
response (51,360 ± 6083 RLU/s), with a peak at approximately 20 min and completion 
within 1 h. PBMCs were also able to mount a significant respiratory burst in 
response to A. fumigatus hyphae. Interestingly, although the reaction was much less 
fumigatus conidia were able to generate a secondary peak during germination, but 
this was observed only for PBMCs (Figure 3). The fungal morphology was checked 
microscopically, and the viability of PMNs and PBMCs was tested by trypan blue 
exclusion at the 10 h time point. Both celltypes reached similar levels of viability.
 To determine whether the lack of ROS production in response to live A. nidulans 
was due to active processes suppressing the respiratory burst or, alternatively, to a 
failure to stimulate the phagocytic cells, we exposed PMNs and PBMCs to heat-killed 
A. fumigatus and A. nidulans conidia. No significant difference in ROS induction was 
observed for either cell type between heat killed and live A. fumigatus stimulation 
(7,338 ± 452 RLU/s and 6,914 ± 590 RLU/s, respectively, for PMNs; and 15,477 ± 2,869 
RLU/s and 12,632 ± 2869 RLU/s, respectively, for PBMCs). Although PMNs were 
unable to respond to live A. nidulans, they did respond to heat- killed A. nidulans 
conidia (P < 0.05), suggesting some active response to the killed conidia (4,512 ± 
227 RLU/s versus 6,558 ± 463 RLU/sec). The cells were still able to mount an ROS 
reaction in response to PMA or zymosan after incubation with the conidia, 
indicating maintained cellviability and NADPH activity.  
Figure 3  Germinated A. nidulans conidia do not stimulate the respiratory burst. 
Data from a representative experiment with each cell type are shown. ROS produced 
by unstimulated cells and resting or swollen A. nidulans- or A. fumigatus-stimulated 
PBMC (A) and PMN (B) were measured by luminol-enhanced chemiluminescence 
for 10h.
Figure 4  Oxidative burst activity in phagocytes. (A) Data for one representative 
experiment with PMNs. (B) Overall ROS production. Data represent mean relative 
light units (RLU) per second, as measured by luminescence. Bar heights indicate 
the mean AUC (n=4). **, P < 0.01; ***, P < 0.001.
A B
A B
CHAPTER 3 ROS-INDEPENDENT KILLING OF ASPERGILLUS NIDULANS
74 75
3
Blocking of the NADPH-oxidase does not affect germination and 
hyphal damage of  A. nidulans
To further investigate the antifungal effect of the NADPH- oxidase on A. fumigatus 
and A. nidulans, we assessed the fungal damage to A. nidulans induced by PMNs and 
PBMCs in the presence of the NADPH-oxidase inhibitor DPI (10µM). Inhibition of 
NADPH-oxidase activity was controlled by serum-opsonized zymosan stimulation 
of the phagocytic cells after 1 h of DPI preincubation. NADPH-oxidase blocking by 
DPI resulted in a 98 % reduction of superoxide production by granulocytes as 
measured by chemiluminescence.  Since DPI has an inhibitory effect on fungal 
germination, PMNs and PBMCs were preincubated with DPI for 1 h at 37oC prior to 
addition of fungi. Cells were washed, resuspended in fresh CM, and incubated 
with the hyphae. No differences were found in the inhibition of germination, 
either towards A. nidulans, or towards A. fumigatus. Accordingly, A. nidulans hyphae 
were equally damaged by PMNs in the absence and presence of the NADPH-oxidase 
blocker DPI (96 % ± 1 % versus  95 % ± 1 %). However, in contrast to the case for A. 
nidulans, the hyphal damage of A. fumigatus was significantly (P < 0.01) lower after 
blocking of NADPH-oxidase (85 % ± 5 % versus 59 % ± 5 %) (Figure 6).
pronounced than that observed in PMNs, it lasted longer (180 min). As seen with 
the PMNs, ROS were not detected after stimulation of PBMCs with A. nidulans 
hyphae. For both celltypes, the differences between A. fumigatus and A. nidulans 
were significant (P < 0.01 and P < 0.001 for PMNs and PBMCs, respectively) (Figure 4). 
Germination of  A. nidulans is reduced significantly compared to  
that of  A. fumigatus 
In order to assess the relationship between the NADPH-oxidase activity and the 
antifungal activity of the cell, the capacity of healthy PMNs and PBMCs to arrest 
conidial growth was assessed by XTT assay. Interestingly, the degree of PMN-induced 
fungal damage, defined as the percent reduction in metabolic activity compared 
to that of the negative controls, was significantly higher for  A. nidulans (63 % ± 2 %) 
than for A. fumigatus (30 % ± 4 %) ( P < 0.001). Also, the PBMC-induced antifungal 
activity to A. nidulans was higher than to A. fumigatus (74 % ± 9 % versus 52 % ± 16 %), but 
it did not achieve significance.
PBMCs and PMNs cause more damage to A. nidulans hyphae than to 
A. fumigatus hyphae
Hyphae were obtained directly in the test well by overnight incubation of resting 
conidia. Subsequently, CM was refreshed and cells were added at a 5:1 cell-to-conidium 
ratio. After 90 min of incubation with PMNs, hyphal damage towards A. nidulans 
reached 67 % (± 2 %) compared to 21 % (± 7 %) for A. fumigatus (P < 0.001). PBMC- 
mediated hyphal damage was found to be 50 % (± 3 %) for A. nidulans, compared to 
32 % (± 6 %) for A. fumigatus (P < 0.05).
Murine gp91phox-deficient AM inhibit germination of  A. nidulans 
more efficiently than do control AM
Since Aspergillus species are airborne, the most common route of infection is the 
lung. As a consequence, the first line of defense consists of resident alveolar 
macrophages, the main phagocytic cells of the lung. Establishment of invasive 
aspergillosis occurs in immunocompromised patients as the fungus escapes from 
AM control and invades the tissue. We investigated the ability of AM from 
 gp91phox-deficient  mice (CYBB/C57BL/6mice) to inhibit germination of A. nidulans and 
A. fumigatus and compared it to that for AM of healthy mice (C57BL/6 mice). 
A cell-to-conidium ratio of 1:5 was used. Interestingly, the growth inhibition of 
A. nidulans and A. fumigatus by murine gp91phox-deficient AM (35 % ± 4 % and 26 % ± 4 %, 
respectively) was higher than that by healthy AM (11 % ± 4 % and 17 % ± 8 %, 
respectively) (P < 0.05) (Figure 5). 
Figure 5  Alveolar macrophage-mediated antifungal activity assessed by XTT-assay. 
X-CGD murine AM induce fungal damage toward A. fumigatus and A. nidulans 
compared to the wild-type AM. Data are derived from four separate experiments. 
X-CGD murine AM inhibit A. nidulans conidia significantly better than wild-type 
AM did (*, P < 0.05).
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Antifungal activity of gp91phox-deficient PMNs towards A. nidulans 
hyphae is maintained
Having characterized ROS release after stimulation of phagocytic cells with either 
A. fumigatus or A. nidulans hyphae as well as the antifungal activity after blocking 
of the NADPH-oxidase by DPI, we tested the extent to which PMNs of a gp91phox-de-
ficient patient were able to damage either A. nidulans or A. fumigatus. Interestingly, 
in line with previous results obtained after blocking the NADPH- complex with 
DPI, in vitro X-CGD cells are perfectly able to damage A. nidulans hyphae (97 % versus 
95 % ± 1 % for CGD and NADPH blocking respectively). In contrast, the ability of the 
gp91phox-deficient PMNs to induce hyphal damage to A. fumigatus was between that 
of healthy controls and that after NADPH blocking (Figure 6).
DISCUSSION
We have investigated the effect of the NADPH-oxidase and its products on fungal 
host defense. Specifically, we attempted to clarify the host resistance of the unique 
CGD fungal pathogen A. nidulans. We observed striking differences between 
reactivities toward A. nidulans and A. fumigatus. Unexpectedly, we conclude that 
human phagocytes appear to kill A. nidulans by NADPH-independent mechanisms. 
This surprising conclusion is based on the following observations: (i) A. nidulans is 
not susceptible to the direct effect of ROS, (ii) A. nidulans does not induce a 
measurably different ROS release by PMNs or PBMCs of healthy donors, (iii) human 
gp91phox-deficient PMNs and PBMCs and murine gp91phox-deficient AM inhibit 
conidial germination as efficiently as healthy cells do, (iv) blocking of the NADPH- 
oxidase complex results in a significantly reduced ability to damage A. fumigatus 
but does not affect the damage to of A. nidulans hyphae, and (v) the antifungal 
activity of human gp91phox-deficient PMNs toward A. nidulans hyphae is maintained. 
 Roilides et al. (19,20) showed that superoxide is important for efficient host 
defense and is produced through NADPH-dependent mechanisms. Stimulation of 
PMNs and PBMCs with either conidia or hyphae of A. fumigatus resulted in increased 
ROS production, leading to inhibition of germination and to fungicidal activity. 
However, we found A. nidulans to be a weak inducer of ROS in both cell types. 
Surprisingly, even in the absence of any NADPH activity, as in CGD cells, A. nidulans 
growth was inhibited just as in normal cells, indicating that mechanisms other 
than ROS must be responsible for the predilection of CGD patients for A. nidulans 
infection. Since CGD phagocytes lack the ability to produce ROS, recent studies 
have focused on the role of ROS-independent factors in arresting the growth of 
Aspergillus conidia (9,27,32). Zarember et al. demonstrated that neutrophils from 
healthy as well as CGD donors were able to arrest conidial growth with equal 
efficiencies and that lactoferrin, a major protein of neutrophil granules, contributes 
gp91phox-deficient PMNs and PBMCs inhibit conidial germination as 
efficiently as control cells do
CGD patients having a defect in the gp91phox component of the NADPH-complex 
are unable to produce microbicidal superoxide anions and its metabolites. In order 
to test the hypothesis that CGD patients suffer from invasive aspergillosis due to 
the absence of microbicidal ROS, we analyzed the antifungal capacity of human 
CGD cells towards A. fumigatus and A. nidulans. PBMCs and PMNs were isolated from 
patients which have a defect in the gp91phox component of the NADPH-complex 
(X-CGD PBMCs and PMNs) and were incubated with either conidia or hyphae. The 
capacity of X-CGD PMNs to inhibit germination of either A. nidulans conidia (72 % ± 
3 % versus 67 % ± 2 %) or A. fumigatus conidia (65 % ± 4 % versus 60 % ± 2 %) did not 
show a significant difference compared to that of healthy control cells. Accordingly, 
no differences were found in the ability of X-CGD and healthy PBMCs to cope with 
either A. nidulans (86 % ± 3 % versus 95 % ± 2 %) or A. fumigatus (74 % ± 9 % versus 73 
% ± 16 %) .
 Furthermore, to test whether INF-γ could affect ROS production or enhance 
antifungal capacity, we added INF-γ (Immukine; Boehringer Ingelheim BV) to 
reaction mixtures to assess both processes. Neither of the tested concentrations 
(100 U/ml and 500 U/ml) enhanced the antifungal effect or the respiratory burst 
activity. 
Figure 6  Percentage hyphal damage of wild type PMNs with (gray bar) and 
without (white bar) NADPH-oxidase blocked by 10µM DPI, and of gp91phox deficient 
PMNs (black bar) to A. nidulans and A. fumigatus hyphae. Bar heights indicate % 
fungal damage. Error bars indicate SEM of 4 healthy controls. **, P < 0.01
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They concluded that non-fumigatus aspergilli are generally more resistant to 
mononuclear and polymorphonuclear phagocytes than A. fumigatus aspergilli. 
These results suggest a direct link between the induced oxidative response and 
hyphal damage. In contrast, we found that nonopsonized hyphae of A. fumigatus, 
being potent ROS inducers, were less damaged than those of A. nidulans, which 
were not able to induce any measurable respiratory burst activity. Akpogheneta et 
al. monitored the ROS at the 1-h time point, and concluded that nonopsonized 
hyphae suppress the oxidative burst compared to that in non-stimulated cells. By 
using luminol-enhanced chemiluminescence, which gave us the ability to follow 
the amount of ROS produced over time, we observed a high peak of ROS, with a 
maximum at 20 min and completion at 60 min. We could indeed confirm that the 
NADPH-oxidase activity at 60 min decreased below the basal activity.
 The unique compositions of the cellwalls of A. fumigatus and A. nidulans might 
be responsible for the observed differences with respect to ROS stimulation and 
fungicidal activity of host immune cells. Melanin is known to be an important 
virulence factor by protecting fungal cells from ROS produced by phagocytic cells 
(13,28) and by modulating the hostimmune response (4). The biosynthesis of 
melanin, and consequently its composition, differs between A. nidulans and A. 
fumigatus (3,29). Furthermore, during germination, the hydrophobic rodlet layer is 
removed and fungal pathogen-associated molecular patterns (PAMP) are exposed, 
mediating the immune response. Girardin et al. (11) found clear physiochemical 
differences in the composition of the cell wall between A. nidulans and A. fumigatus 
after they removed this rodlet layer. Analysis and comparison of the chemical 
characteristics of both species would definitively give new insights into this 
complex interface and are the subjects of future studies.
 The question remains of whether the pathogenicity of aspergillosis in CGD 
patients is due to the loss of a direct antifungal effect of superoxide and its 
metabolites or to loss of more downstream effects of NADPH-activation. We 
attempted to clarify some of these points by examining the opportunistic pathogen 
A. nidulans, which is found almost exclusively in patients suffering from CGD. Our 
findings are robust but unexpected: first, A. nidulans is not susceptible to the direct 
fungicidal effect of ROS; second, gp91phox-deficient AM are able to inhibit A. nidulans 
more efficiently than controls; third, PMNs and PBMCs from healthy donors inhibit 
germination and induce hyphal damage to A. nidulans, even in the absence of 
significant ROS production, distinct from A. fumigatus; fourth, blocking the 
NADPH-oxidase does not affect the ability to kill A. nidulans hyphae, in stark 
contrast to the killing of A. fumigatus; and fifth, gp91phox-deficient neutrophils, 
which have complete NADPH deficiency, A. nidulans kill adequately in vitro, 
suggesting that at least the early antifungal effector activity of the innate response 
is maintained in the absence of a functional NADPH-oxidase. 
to reduced conidial growth (32). These data were subsequently confirmed by tran-
scriptional responses of Aspergillus conidia to healthy and CGD PMNs (27). The role 
of ROS-independent antifungal mechanisms was underscored by Shibuya et al. 
(25). They found that the mycelium of the double cat1 cat2 mutant of A. fumigatus, 
which has no catalase activity at all, has only a slightly increased sensitivity to 
H2O2 and is as sensitive to killing by PMNs as the wild-type strain but shows 
delayed infection in an experimental rat model of invasive aspergillosis. Chang et 
al. (5) showed previously shown that the virulence of catalase-deficient A. nidulans 
was unimpaired in p47phox-/- mice, indicating that the catalase activity of fungi is 
not a virulence factor for CGD pathogenicity.
 Cornish et al. showed that the in vitro inhibition of germination of A. fumigatus 
conidia by C57BL/6 and gp91phox-deficient mouce AM was comparable. Furthermore, 
they could not find evidence of the importance of NADPH-oxidase in AM by using 
transcriptional microarray analysis, luminometry or nitroblue tetrazolium (NBT) 
staining (6). Instead, they found the most strongly upregulated transcripts in vivo 
encoded chemokines and additional factors that play critical roles in neutrophil 
and monocyte recruitment. Indirect evidence of NADPH-independent resistance 
in AM was also found by Shibuya et al., who found that killing of catA conidia by 
AM and conidial virulence in animals were similar to those with wild-type conidia 
(25). In contrast, AM from p47phox-/- mice were unable to kill A. fumigatus conidia in 
vivo as shown by Philippe et al. (18). In addition, inhibitors of NADPH-oxidase that 
decreased the production of reactive oxidant intermediates inhibited the killing 
of A. fumigatus conidia in vitro, suggesting an NADPH-oxidase dependence. However, 
the inoculation time was limited to 6 h, in contrast to the 24 h inoculation time in 
vivo, probably reflecting a more fungistatic effect than a fungicidal effect. Our 
XTT assays with murine AM underlined the ability of conserved primary defense 
mechanisms toward Aspergillus conidia. Even in the absence of a functional 
NADPH-oxidase, germination of  both A. fumigatus and A. nidulans were inhibited, 
with the latter inhibited even better by a gp91phox-deficient AM than by those 
derived from C57BL/6 mice. 
 With respect to the antifungal host defense mechanisms against hyphae, 
several studies have investigated the ability of Aspergillus species to modulate ROS 
in phagocytes relative to their fungicidal activity (1,10). Akpogheneta et al. (1) 
evaluated the activity of human PMNs and mononuclear phagocytes against 
hyphae of non-fumigatus Aspergillus species and compared it to that against A. 
fumigatus hyphae. They concluded that nonopsonized hyphae suppress the 
oxidative burst of PMNs and that these cells respond with a less vigorous oxidative 
burst in the presence of serumopsonized hyphae of non-fumigatus Aspergillus species. 
Similarly, PMNs induced less hyphal damage to non-fumigatus species, particularly 
A. flavus and A. nidulans, than to A. fumigates, as assessed by XTT colorimetric assay. 
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 Despite these robust findings, CGD patients are the most susceptible hosts for 
invasive aspergillosis, in particular that caused by A. nidulans. The central role of 
neutrophils in optimal microbial killing and regulation of tissue damage has been 
discussed extensively by Smith (26). Smith describes the complex function and 
balance of stimulatory and inhibitory pathways in the neutrophil, which are 
regulated by a plethora of local and systemic mediators. Superoxide is an important 
signal transduction intermediate (12). Romani et al. (21) indicated that the absence 
of ROS leads to defective tryptophan catabolism, dominant overproduction of 
interleukin-17 (IL-17), defective regulatory T-cell activity, and excessive inflammation. 
The role of ROS as mediator/regulator in inflammation has also been underscored by 
van de Veerdonk et al. (30). They showed that ROS appear to dampen inflammasome 
activation. As a consequence, the absence of ROS in CGD monocytes may in partly 
explain the inflammatory complications seen in CGD patients. A recent study by 
Segal et al. (23) supports the occurrence of NADPH-oxidase dependent, redox- 
mediated signaling which is critical for termination of lung inflammation. By 
challenging NADPH-oxidase deficient p47phox-/- mice and gp91phox-deficient mice 
with intratracheal zymosan, they showed that NADPH-oxidase limits lung 
inflammation by attenuating the proinflammatory transcription factor NF-κβ and by 
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factor. Results for X-linked CGD patients were consistent with these findings (26). 
It may well be that the increased inflammation in CGD patients leads to the 
observed pathogenicity of Aspergillus spp. instead of being the result of direct 
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 In summary, these in vitro studies do not support a direct role of ROS in the 
antifungal resistance to A. nidulans and  cannot explain the etiology of A. nidulans 
infections in CGD patients by the simple absence of the direct microbicidal reactive 
oxidant superoxide anion and its metabolites. The NADPH-oxidase is a critical 
regulator of certain limbs of innate immunity, and its unraveling will improve 
our understanding of fungal pathogenesis in CGD.
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ABSTRACT
Patients with chronic granulomatous disease (CGD) cannot produce reactive oxygen 
species (ROS) due to a genetic defect in the nicotinamide adenine dinucleotide 
phosphate (NADPH)-oxidase system. Dysregulation of the L-tryptophan metabolism 
in mice with defects in NADPH-oxidase, resulting in overproduction of interleukin 
(IL) -17), has been proposed to link ROS defects with hyperinflammation and 
susceptibility to pulmonary aspergillosis. In this study, we assessed the L-tryptophan 
metabolism and cytokine profiles in response to fungal pathogens in CGD patients.
 Peripheral blood mononuclear cells (PBMCs) from CGD patients showed increased 
production of IL-6, tumor necrosis factor-α and interferon-γ upon stimulation with 
Aspergillus or Candida species, while IL-17A production was strikingly low compared 
with healthy controls. Indoleamine 2,3-dioxygenase expression was similar in 
PBMCs and neutrophils from CGD patients compared with healthy controls. 
Conversion of L-tryptophan to L-kynurenine, as measured by high-performance 
liquid chromatography, did not differ between CGD patients and healthy controls. 
Moreover, adding L-kynurenine to the cell cultures did not suppress fungal-induced 
IL-17A production. Although PBMCs of CGD patients produced more proinflamma-
tory cytokines after stimulation, IL-17A production was strikingly low in response 
to fungal pathogens when compared with healthy controls. In addition, cells from 
CGD patients did not display a defective L-tryptophan metabolism.
INTRODUCTION
Chronic granulomatous disease (CGD) is a rare (incidence 1/250,000 live births) 
inherited immunodeficiency disorder due to a defect in any of the structural 
components of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. 
NADPH-oxidase is a key player in innate host defense, and its activation results in 
production of superoxide anion and downstream reactive oxygen species (ROS). 
Clinically, CGD patients suffer from life-threatening bacterial and fungal infections 
and are characterized by abnormal inflammatory responses leading to granuloma 
formation. The precise “microbial” pathogenesis in CGD patients is unclear.
 While the central role of ROS as direct antimicrobial effectors is still under 
discussion, ROS are also linked to key intracellular signaling events, such as the 
activation of transcription factors (1, 2), among which nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκβ) (3, 4), induction of mitogenesis (5, 6), and 
activation of proteases (7). ROS can also act as a substrate or cofactor for the 
catabolic indoleamine 2,3-dioxygenase enzyme (IDO) (8-11). IDO is the rate-limiting 
enzyme in the tryptophan metabolism (12). Activation of IDO results in decreased 
levels of L-tryptophan, thus actively depriving invading microorganisms of an 
essential amino acid (9, 13, 14). IDO is expressed in several tissues throughout the 
body and in immune cells like dendritic cells (DCs) (15), macrophages (16, 17),  and 
eosinophils (18). IDO expression can be induced by mediators of immunity, such as 
interferon (IFN)-γ (19, 20) and tumor necrosis factor (TNF)-α (21). In addition, 
activation of tryptophan catabolism induces maternal immune tolerance (22), 
indicating that IDO can regulate T-cell responses. IDO can suppress the Th1 
response (23-25), while in DC’s IDO is able to induce a Th2 response (26). In contrast, 
pulmonary IDO decreased Th2-driven experimental asthma (27). The immuno-
modulatory functions of IDO have made it an important target of research in 
many inflammatory conditions.
 The tryptophan metabolism has also been linked to Th17 responses.  In a collagen- 
induced arthritis mice model, L-kynurenine dampened the Th17 response (28). 
Furthermore, in a murine candidiasis model, retinoic acid receptor-related orphan 
receptor C transcription was decreased by the induction of IDO (29). In a recent 
article, Romani and others (30) suggested that p47phox-deficient mice that have a 
phenotype reminiscent of CGD have a defective tryptophan metabolism, leading 
to an increased interleukin (IL)-17 production. It has thus been proposed that the 
activation of IDO and subsequently conversion of L-tryptophan to L-kynurenine 
suppresses the Th17 response.
 A robust Th17 response is necessary for an adequate defense against Candida 
(31). Th17 cells are characterized by the production of IL-17A (32), which is 
important for attracting neutrophils to the tissues (33). The importance of IL-17A 
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in antifungal host defense is reflected by the fact that IL-17A receptor antagonist- 
deficient mice have an increased susceptibility to disseminated candidiasis (31). 
Furthermore, in a murine oropharyngeal candidiasis model, IL-17A- or IL-23p19- 
deficient animals showed increased severity of oropharyngeal candidiasis (34). 
Also humans with chronic mucocutaneous candidiasis (CMC) and hyper-IgE 
syndrome (HIES) have decreased Th17 responses that are believed to be responsible 
for their susceptibility to fungal infections (35-40).
 CGD is the primary immunodeficiency with the highest incidence of invasive 
fungal infections (41), mainly due to Aspergillus spp. (lifetime incidence 25 %-40 %). 
Candida is commonly encountered in cases of fungal meningitis, fungemia and 
lymphadenitis (41-43). It is currently not clear why patients with CGD are specifically 
susceptible to fungal infections, although infections with bacterial pathogens 
such as Staphylococcus aureus are also often encountered. The absence of ROS has 
been shown not to be the direct explanation of the increased susceptibility (44).
 In the present study, the tryptophan metabolism and IL-17A response in human 
CGD patients were investigated. We demonstrate that CGD patients, in contrast to 
the p47phox-deficient mice, are able to convert L-tryptophan to L-kynurenine, and 
that they have a lower IL-17A production in response to stimulation with the 
fungal pathogen Candida albicans, which might explain their incapacity to clear 
fungal infections.
MATERIALS AND METHODS
Patients and healthy volunteers
Blood was collected from healthy volunteers who did not suffer from infectious or 
inflammatory diseases, and from eight CGD patients, harboring homozygous 
mutations in the NCF1 gene (p47-phox) or CYBB gene (p91-phox). After informed 
consent was given, blood was collected by venipuncture into 10 mL ethylenedi-
aminetetraacetic acid tubes (367525; BD). The clinical characteristics of all patients 
are presented in Table 1.
Reagents
The following study materials were used: recombinant IFN-γ  (Boehringer Ingelheim 
BV); L-kynurenine, L-tryptophan, 5-OH-tryptophan, serotonin, melatonin, niacin 
and resveratrol were purchased from Sigma-Aldrich; αCD3αCD28 beads were 
prepared from a T-cell activation/expansion kit (130-091-441, MACS, Miltenyi 
Biotec); lipopolysaccharide (LPS) (Escherichia coli serotype 055:B5) was purchased 
from Sigma and an extra purification step was performed as described previously 
(45). Purified LPS was tested in Toll-like receptor (TLR) 4-/- mice for the presence of Ta
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(Applied Biosystems). The primer sequences for human IDO are as follows: 5-GGT-
CAT-GGA-GAT-GTC-CGT-AA-3 (forward) and 5-ACC-AAT-AGA-GAG-ACC-AGG-AAG-
AA-3 (reverse). β2M was used as a reference gene, for which the primers were 5- 
ATG-AGT-ATG-CCT-GCC-GTG-TG-3 (forward) and 5- CCA-AAT-GCG-GCA-TCT-TCA-
AAC-3 (reverse). PCR conditions were as follows: 2 min at 50°C and 10 min at 95°C, 
followed by 40 cycles of PCR at 95°C for 15 seconds, and 60°C for 1 min. Data are 
expressed as fold increase compared to the unstimulated sample.
High-performance liquid chromatography
To compare the amount of L-tryptophan metabolized and the amount of 
L-kynurenine produced upon stimulation with fungal pathogens between CGD 
patients and healthy controls, cell culture supernatants were subjected to high- 
performance liquid chromatography (HPLC) analysis. HPLC was performed on a 
Spectra-SYSTEM autosampler and pump (Thermo Separation Products). Chromato-
graphic separation was performed using an Inertsil 5 ODS-2 column (100 mm x 3.0 
ID; Varian Inc.). Absorbance was monitored with a diode-array detector (UV6000LP; 
Thermo Separation Products) at wavelength of 280 nm for tryptophan and 360 nm 
for kynurenine (50). The mobile phase for isocratic elution was made by dissolving 
40 mM sodium acetate. The pH of the eluent was adjusted to pH 4.5 with a solution 
of 40 mM citric acid and 2% acetonitrile of the total volume buffer was added. The 
continuous flow rate was 0.3 mL per minute (51). Data are presented as area under 
the curve.
Statistical analysis
Experiments were performed in duplicate, and supernatants were pooled. The 
differences between groups of 3 or more subjects were analyzed using the 
Mann-Whitney U test or the Wilcoxon signed rank test, for unpaired and paired 
data, respectively. The level of significance between groups was set at P < 0.05 (*) 
and P < 0.01 (**). Data are presented as mean ± standard error of the mean.
RESULTS
CGD patients have an increased production of proinflammatory 
cytokines in vitro 
The cytokine profile of CGD patients upon stimulation with several stimuli was 
investigated. PBMCs of CGD patients produced more IL-6 and TNF-α upon 
stimulation with the specific TLR4 ligand LPS (Figure 1). Similarly, heat-killed C. 
albicans induced more IL-6 and TNF-α production in PBMCs isolated from CGD 
patients (Figure 1). In line with this, stimulation with live A. nidulans and A. 
contaminants and did not have any TLR4-independent activity (46). As culture 
medium, RPMI 1640 Dutch modifications (Sigma-Aldrich) was used, supplemented 
with 1% gentamicin, 1% l-glutamine and 1% pyruvate (Life Technologies).
Microorganisms
C. albicans ATCC MYA-3573 (UC 820) (47) was grown overnight in Sabouraud broth 
at 37°C; cells were harvested by centrifugation, washed twice, and resuspended in 
culture medium. C. albicans was heat-killed for 1h at 100°C;  S. aureus (ATCC 25923) 
was heatkilled for 30 min at 100 °C; heat-killed conidia and hyphae of  Aspergillus 
fumigatus (V4507) and Aspergillus nidulans (V44-46) were prepared as described 
previously (44, 48).
Human mononuclear cells and neutrophils
Peripheral blood mononuclear cells (PBMCs) and neutrophils were isolated from 
peripheral blood using density gradient centrifugation (800g) of diluted blood (1 
part blood to 1 part pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech) (49). 
PBMCs were harvested, washed twice in phosphate buffered saline (PBS), and 
suspended in culture medium. To remove the erythrocytes from the neutrophils, 
the pellet was shocked at least twice with an ice-cold lysing reagent (2.75 g NH4Cl 
+ 0.25 g KHCO3) for 15 min. Subsequently, cells were washed in PBS and resuspended 
in culture medium. The PBMCs and neutrophils were counted in a hemocytometer, 
and their concentration was adjusted to 5 x 106 cells/ml.
 About 5x105 PBMCSs or neutrophils in a total volume of 200 µL per well were 
incubated at 37°C in round-bottomed 96-well plates (Greiner) with the different 
stimuli, as indicated in the figure legends. After 24 h, 48 h or seven days of incubation, 
supernatants were collected and stored at –20°C until assayed. When cells were 
cultured for seven days, this was done in the presence of 10% human pooled serum.
Enzyme-linked immunosorbant assay
The concentration of IFN-γ, IL-6, IL-17A, and TNF-α was measured in cell culture 
supernatants using enzyme-linked immunosorbent assay (ELISA) (IL-17A and 
TNF-α: R&D Systems; IFN-γ and IL-6: Sanquin), according to the instructions of the 
manufacturer.
Real-time polymerase chain reaction
One million freshly isolated PBMCs or neutrophils were incubated with the various 
stimuli. After 24 h of incubation at 37°C, total ribonucleic acid (RNA) was extracted 
in 400 µl of TRIzol reagent (Invitrogen). Isolated RNA was being reverse transcribed 
into complementary DNA using oligo(dT) primers and MMLV reverse transcriptase. 
Polymerase chain reaction (PCR) was performed using a 7300 realtime PCR system 
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fumigatus conidia, two commonly encountered species in CGD patients, resulted in 
a higher cytokine production by PBMCs of CGD patients compared with healthy 
controls (Figure 1). Heat-killed Aspergillus conidia and hyphae showed to be poor 
stimulators of the proinflammatory cytokines.
CGD patients have an intact L-tryptophan metabolism 
Romani et al. (30) showed that p47phox-deficient mice have a hyperinflammatory 
phenotype due to a defect in the conversion of L-tryptophan into L-kynurenine. 
Therefore we assessed whether the increased production of proinflammatory 
cytokines in patients with CGD could also be explained by an incapability to 
convert L-tryptophan into L-kynurenine. Cells isolated from CGD patients had a 
higher transcription of IDO upon stimulation with Candida and IFN-γ in both 
PBMCs and neutrophils, compared with healthy controls (Figure 2A). Moreover, 
upon stimulation with Candida, both healthy controls and CGD patients were able 
to convert L-tryptophan into L-kynurenine (Figure 2B). The conversion of 
L-tryptophan to L-kynurenine was independent of which fungal pathogen was 
used for stimulation (data not shown). This indicates that IDO functions normally 
in human CGD patients.
 The tryptophan metabolite L-kynurenine has been suggested to be responsible 
for dampening the proinflammatory cytokine response, and has especially been 
associated with a lowering of IL-17A production by murine cells (28, 52). To 
determine whether L-kynurenine is able to influence the IL-17A response in human 
cells in vitro, we tested Candida-induced IL-17A production in healthy volunteers in 
the absence or presence of tryptophan metabolites. PBMCs from healthy controls 
were also stimulated with Candida in the absence or presence of increasing 
concentrations of L-kynurenine. There was no clear dose-response relationship 
between L-kynurenine and IL-17A (Figure 2C). Furthermore, L-tryptophan 
significantly increased Candida-induced IL-17A production (Figure 2D), while the 
other metabolites (5-OH-tryptophan, serotonin, melatonin and resveratrol) did not 
influence Candida-induced IL-17 production.
CGD patients have a low IL-17A and high IFNγ production upon 
stimulation with fungal pathogens 
To investigate whether IL-17A production is affected in cells from CGD patients, 
PBMCs from CGD patients and healthy controls were stimulated for 7 days with 
αCD3αCD28-coated beads, LPS, different morphotypes of A. nidulans and A. fumigates, 
and heat-killed C. albicans. There was no difference in αCD3αCD28-induced IL-17 
production between CGD patients and healthy controls (Figure 3A). It is well 
established that especially in hyphal antifungal host-defense, rapid and efficient 
recruitment of neutrophils is important (53). Here we found that in response to A. 
Figure 1  CGD patients show increased production of proinflammatory cytokines 
upon fungal stimulation in vitro. PBMCs of healthy controls and CGD patients were 
stimulated for 24 h with Roswell Park Memorial Institute (RPMI) medium, live and 
heat-killed (HK) Aspergillus nidulans (AN) and Aspergillus fumigatus (AF) conidia or 
hyphae, heat-killed Candida albicans (1x106/mL), or LPS (10 ng/mL). IL-6 and TNF-α 
were measured in cell culture supernatants using ELISA. Data represent 5 CGD 
patients and 5 healthy controls from 3 different experiments. Data were analyzed 
using the Mann Whitney U test (** P < 0.01). Bars represent mean + SEM. CGD, 
chronic granulomatous disease; PBMCs, peripheral blood mononuclear cells; LPS, 
lipopolysaccharide; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; ELISA, 
enzyme-linked immunosorbent assay; SEM, standard error of the mean.
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Figure 2  CGD patients do not have a defective L-tryptophan metabolism. (A) PBMCs 
and neutrophils of 2 healthy volunteers and of 3 CGD patients were stimulated for 
48 h with heat-killed C. albicans (1x106/mL) or IFN-γ (50 ng/mL). IDO expression was 
measured using qPCR. Bars represent mean + SEM. (B) PBMCs of healthy volunteers 
and CGD patients were cultured for 48 h in the presence of L-tryptophan (50 µg/
mL), with or without heat-killed C. albicans (1x106/mL). L-Tryptophan (285 nm; black 
lines and arrows) and L-kynurenine (360 nm; grey lines and arrows) were measured 
using HLPC. (C) PBMCs of healthy volunteers were stimulated for 7 days in the 
presence of 10% human pool serum with heat-killed C. albicans yeast (1x106/mL), 
in the absence or presence of L-kynurenine (200 ng/mL, 1 µg/mL or 10 µg/mL). 
IL-17 was measured in cell culture supernatants using ELISA. Experiments were 
performed in duplicate and cell culture supernatants were pooled. Data represent 
at least 7 healthy volunteers from at least 3 different experiments. Data were 
analyzed using the Wilcoxon signed rank test (* P < 0.05). Bars represent mean + SEM. 
(D) PBMCs were stimulated for 7 days in the presence of 10% human pool serum with 
heat-killed C. albicans yeast (1x106/mL), in the absence or presence of L-tryptophan 
(50 µg/mL), 5-OH-tryptophan (200 ng/mL), serotonin (1 µg/mL), melatonin (200 ρg/
mL), or resveratrol (10 µg/mL). IL-17A was measured in cell culture supernatants 
using ELISA. Experiments were performed in duplicate and cell culture 
supernatants were pooled. Data represent at least 5 healthy volunteers from at 
least 2 different experiments. Data were analyzed using the Wilcoxon signed rank 
test (** P < 0.01). Bars represent mean + SEM. IDO, indoleamine 2,3-dioxygenase; 
qPCR, quantitative polymerase chain reaction; HPLC, high-performance liquid 
chromatography.
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Figure 3  CGD patients have a low IL-17A and high IFNγ production upon 
stimulation with fungal pathogens. (A) PBMCs of healthy controls and CGD 
patients were stimulated for 7 days in the presence of 10% serum with RPMI or 
αCD3αCD28-coated beads. IL-17A was measured in cell culture supernatants using 
ELISA. Data represent 4 CGD patients and 5 healthy controls from 3 different 
experiments. (B) PBMCs of healthy controls and CGD patients were stimulated for 
7 days in the presence of 10% serum with RPMI, heat-killed A. nidulans (AN) and A. 
fumigatus (AF) conidia or hyphae, or LPS (10 ng/mL). IL-17A and IFN-γ were measured 
in cell culture supernatants using ELISA. Data represent at least 5 CGD patients 
and 6 healthy controls from 4 different experiments. (C) PBMCs of healthy controls 
and CGD patients were stimulated for 7 days in the presence of 10% serum with 
RPMI or heat-killed C. albicans (1x106/mL). IL-17A was measured in cell culture 
supernatants using ELISA. Data represent 8 CGD patients and 8 healthy controls 
from 7 different experiments. Data were analyzed using the Mann-Whitney U test 
(* P < 0.05). Data are presented separately, and as mean + SEM.
A C
B
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controls, indicating that the decreased IL-17 production observed in CGD patients 
is only present in the presence of a specific pathogen. This might explain why the 
rest of the phenotype of CGD patients is not similar to HIES or CMC. 
 A difference in proportion of γδ T-cells in PBMCs from CGD patients compared 
with healthy controls could be an explanation for the observed differences in 
IL-17A production (61). Therefore we have determined the relative contribution of 
the γδ T-cells to IL-17A production in response to Candida in healthy volunteers. We 
found that a very low amount of γδ T-cells was IL-17 positive compared to CD4-T 
cells (data not shown). These data suggest that the large proportion of IL-17 in 
response to C. albicans is from the CD4-T cell population. Since CD4 lymphopenia is 
not described in CGD patients it is unlikely that differential T-cell counts are 
responsible for the low IL-17A production in CGD patients.
 It is interesting to observe that both p47phox-deficient mice and patients with 
CGD are susceptible to Aspergillus infections, but the underlying mechanisms seem 
to differ. In mice it was suggested that the tryptophan metabolism was defective, 
which led to an increased level of IL-17 production that was detrimental for the 
mice. Here we confirm that in CGD patients the tryptophan metabolism is intact 
(62), and moreover we observed that they had a lower IL-17 production in response 
to fungal stimulation. In addition, L-kynurenine did not decrease IL-17A production 
induced by C. albicans in PBMCs of healthy controls, indicating that in human 
primary cells L-kynurenine does not suppress the Th17 response. However, 
L-tryptophan itself could increase Candida-induced IL-17A production in healthy 
controls. In line with this, Veldhoen and others (63) previously demonstrated that 
L-tryptophan is one of the aryl hydrocarbon receptor (AHR) agonists that can 
increase IL-17A production. The role of the tryptophan/kynurenine metabolism of 
the different human leucocytes was recently evaluated by De Ravin and others 
(62). They compared cultured DC, monocytes and isolated PMNs. In line with our 
data obtained from monocytes, De Ravin and others (62) found that highly purified 
PMN could indeed upregulate IDO expression after INF-γ treatment.
 In contrast to a low IL-17A production, we observed that the cells from CGD 
patients have an increased IFN-γ production compared with healthy controls in 
response to fungal stimuli. IFN-γ stimulates intracellular killing of C. albicans 
conidia by PMN in vitro (64, 65), and in a recent overview it has been reported that 
a large proportion of patients with defects in IL-12Rβ1 experience fungal infections 
(66). However, both IFN-γ and IL-17 are required for an adequate antifungal host 
defense. Although there is no defect in IFN-γ production, the low IL-17A production 
might cause a sensitivity to fungal infections. CGD patients also have an increased 
susceptibility to S. aureus infection. Susceptibility to S. aureus has also been 
associated with a defective IL-17A response (67, 68), which is in line with the data 
presented here.
nidulans hyphae and A. fumigates hyphae, the IL-17A production was relatively low 
in CGD patients although this was not significant (Figure 3B). CGD patients 
produced more IFN-γ in response to all stimuli (Figure 3B). PBMCs of CGD patients 
produced significantly less IL-17A upon stimulation with C. albicans (Figure 3C).
DISCUSSION
In the current study we demonstrate that human CGD patients produce markedly 
lower IL-17A concentrations upon stimulation with the fungal pathogen C. albicans 
compared with healthy controls, despite an overall higher proinflammatory 
cytokine production. CGD patients are able to convert L-tryptophan into 
L-kynurenine, and ROS are not crucial for the IDO activity, which is needed to 
facilitate this conversion in humans. Furthermore, L-kynurenine did not decrease 
Candida-induced IL-17A production. These data suggest that NADPH-oxidase 
deficiency in humans is not associated with a defective tryptophan metabolism, 
but with a lower Th17 response against fungal pathogens that might explain their 
susceptibility to fungal infections.
 Th17 responses have recently been described as a new T helper subset (54). In 
recent years it has become apparent that the Th17 response is essential for 
antifungal host defense. The recurrent mucosal Candida infections in patients 
with primary immunodeficiency syndromes such as HIES and CMC have been 
specifically linked to a deficiency in their Th17 response (35, 38, 40).
 The role of the Th17 response in the host defense against Aspergillus is 
controversial. On the one hand, IL-17 deficiency is associated with a higher 
susceptibility to Aspergillus infection in mice (55, 56). On the other hand, studies 
suggest that a high IL-17 production is linked to a higher susceptibility to Aspergillus 
infection due to detrimental effects caused by a hyperinflammatory response (30, 
57). These observations do not need to be contradictory, and they might support 
the concept that there is an optimal window for IL-17 response in the host defense 
against Aspergillus. 
 The decreased IL-17 production in response to fungal PAMPs was rather 
unanticipated. We have previously shown that CGD patients have relatively high 
IL-1β production in response to fungal stimuli (58). IL-1β is a driver of Th17 
responses (59) and therefore we predicted a high Th17 response. Furthermore, it 
has been reported that T cells from CGD patients have increased IL-17 and IFN-γ 
production in response to mitogenic stimulation, because NADPH-oxidase-defi-
cient macrophages cannot sufficiently induce Tregs that are needed to control 
pro-inflammatory T helper responses (60). Interestingly we observed no difference 
in αCD3αCD28 induced IL-17 production between CGD patients and healthy 
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ABSTRACT 
Invasive fungal infections are a major threat for patients suffering from chronic 
granulomatous disease (CGD), a primary immunodeficiency caused by a defect in 
the nicotinamide adenine dinucleotide phosphate oxidase (NADPH)-oxidase. 
Interestingly, Aspergillus (Emericella) nidulans is the second most encountered mold 
in CGD patients, causing almost exclusively invasive infections in this specific 
host, and is characterized by its aggressive behavior. A proper diagnosis is 
complicated by the often-mild clinical presentation, the low sensitivity of the 
currently used diagnostic tools, and the difficulties in accurate identification of 
the Emericella species. According to the hitherto accepted view on the role of the 
NADPH-oxidase in the innate host-defense pathway, the pathogenesis of A. nidulans 
in CGD cannot be explained. This synopsis covers the current understanding of 
invasive infections caused by A. nidulans in the CGD patient and is intended to 
direct further research by indicating gaps in our knowledge and to guide optimal 
management strategies. 
INTRODUCTION
Aspergillus nidulans (Teleomorph Emericella nidulans) has been an important research 
organism for studying eukaryotic cell biology for over half a century. It has 
contributed to our understanding of cell cycle control, DNA repair, mutation, 
recombination, cytoskeletal function, mitochondrial DNA structure and human 
genetic disease (1).  Much less attention had been given to A. nidulans as an 
opportunistic pathogen in humans until recently, when it was recognized as a 
major cause of invasive aspergillosis (IA) in patients with chronic granulomatous 
disease (CGD). CGD is a rare (birth prevalence 1:200,000) inherited immunodefi-
ciency disorder of the NADPH-oxidase in which phagocytes fail to generate 
superoxide anion and downstream reactive oxygen species (ROS) (2, 3). CGD is a 
genetically heterogeneous disease caused by mutations in any of the 5 structural 
components of NADPH-oxidase, including the membrane-bound glycoproteins 
gp91phox (phagocyte oxidase), p22phox, and the cytoplasmatic components p47phox, 
p67phox and p40phox (4). As a result of the defect in the key innate host defense 
pathway, CGD patients suffer from life-threatening bacterial and fungal infections 
and inflammatory sequelae. Invasive fungal infections are often the first 
manifestation, revealing the underlying disease. 
 Aspergillus spp. are the most important encountered fungal pathogens (4). In 
more detailed information extracted from the published data of CGD registries, 
the percentage of patients who had at least one infectious episode caused by 
Aspergillus spp. ranges from 26% in Europe (5) up to 46% in Japan (6). Furthermore, 
Aspergillus spp. are the most common isolated causative pathogens in cases of 
pulmonary infections, brain abscesses, and osteomyelitis (2, 3, 5, 7) (Table 1). As a 
cause of death, fungal infections stand at the top with Aspergillus spp. being 
responsible for one-third to half of all deaths. Suggestion was made that CGD 
patients were at greater risk of A. nidulans infection than other immune-compro-
mised patient populations and that A. nidulans was more virulent than A. fumigatus 
based on mortality rates and propensity to spread (8, 9). Although A. nidulans 
behaves more virulent in the CGD patient compared to A. fumigatus, clear incidences 
about IA due to A. nidulans are lacking. Scrutinizing the microbiology database of 
CGD at the National Institute of Health (NIH, Bethesda, MD) revealed six A. nidulans 
infections compared to 17 caused by A. fumigatus. In patients with fungal 
osteomyelitis, A. nidulans has been isolated in up to 50% of the cases (8, 10). Recently, 
we performed an extensive review of all PubMed database notated papers from 
1970 to 2010, regarding invasive fungal infections in patients suffering from CGD. 
In the 116 reported cases, 127 fungal species were isolated: A. nidulans was the 
second most encountered species (23 cases, 18%) preceded by A. fumigatus (44 cases, 
35%). Zygomycotes isolates were found in 9%, whereas Candida species in only 6% (10). 
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Focusing on the Aspergillus species, A. fumigatus was found in 55% followed by A. 
nidulans in 35%. 
 Aspergillus nidulans seems to have a remarkable unique interaction with CGD 
patients as it remains a rare pathogen among other risk groups. In the neutropenic 
host only three cases have been described: two pulmonary IA with highly resistant 
strains (13, 14) and a primary cutaneous infection associated with a Hickman 
catheter (15). In the Transplant-Associated Infections Surveillance Network 
(TRANSNET) report, A. fumigatus was isolated in 187 (44%) of the 425 cases of IA. 
Thirteen (3%) infections were caused by “other Aspergillus species”, however, no 
notification of A. nidulans was made (16). In a cohort of 139 cases of pediatric IA, 
including seven CGD patients, A. fumigatus was isolated in 67 cases (52.8%) compared 
to A. nidulans in only one patient (0.8%) (17).
 Overall, as disease pathology and progression are the results of the complex 
interaction between the pathogen and the host, exploring the host-fungus interface 
will result in more insight and detailed understanding of this challenging frontline, in 
order to optimize diagnostic and therapeutic strategies. This synopsis covers the 
current understanding of invasive infections caused by A. nidulans in the CGD 
patient and addresses important areas for future research aiming at optimizing 
patient care. 
ASPERGILLUS NIDULANS
Species identification and molecular characterizations
Identification of A. nidulans is based predominantly upon the morphology of the 
conidia and conidiophores. Aspergillus nidulans is a homothallic species capable of 
producing the teleomorph (sexual stage) without mating studies. The dual 
nomenclature of members of the Aspergillus section Nidulanti may be confusing 
for the clinician, as the ability of the fungus to produce a sexual state depends on 
the culture conditions. 
 The application of molecular tools has had major impact on the taxonomy of 
fungi. Multilocus sequence-based phylogenetic analyses have emerged as the 
primary tool for inferring phylogenetic species boundaries and relationships 
within subgenera and sections. Sequence analyses of the internal transcribed 
spacer region appears to be appropriate for identification of Aspergillus isolates to 
the subgenus/section level (18). Partial β-tubulin or calmodulin are the most 
promising loci for Aspergillus identification to the species level. 
In vitro susceptibility testing
The efficacy of antifungal agents is different for the various Aspergillus spp., and A. 
nidulans reveals to be more resistant to amphotericin B compared to A. fumigatus Ta
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Diagnosis
Information on diagnostic tools was provided in 22 of the 25 patients reviewed in 
this study. Twenty-one of them fulfilled the criteria for proven invasive mold 
infection. Histopathology and direct microscopy or culture of a biopsy taken 
during open surgery was conclusive in 67% (n=14) of the proven cases. Pulmonary 
radiologic features were present in 75%. Interestingly, beyond description of 
“pulmonary consolidation” and “lung infiltrates”, no specific signs as nodules, air 
crescent formation, halo signs or cavitations were described or could be detected 
on the published images. Computed tomography and magnetic resonance established 
extra-pulmonary extension to soft tissues, bones and spinal cord injury. Local 
extension of disease from lung parenchyma to adjacent structures and osteomyelitis of 
the thoracic skeleton have been found particularly associated with underlying 
CGD (40).
 In four of the reported CGD cases, information about circulating antigens in 
serum could be extracted (25, 33, 34, 36). Three of them were negative despite the 
extensiveness of the disease. Only van ‘t Hek described positive galactomannan 
ratios in a X-linked CGD patient suffering from invasive A. nidulans infection and 
chest-wall invasion (36). Information on diagnostic polymerase chain reaction was 
retrieved in two proven cases and one probable; however, results were negative or 
inconclusive (25, 34, 35). Four cases mentioned strongly positive anti-Aspergillus 
antibodies (27, 29, 33, 38).
Treatment and Outcome
Combined antifungal treatment and extensive and early surgical debridement was 
used in most patients (83%). All patients except two received presumptive treatment 
with amphotericin B. Conventional amphotericin B deoxycholate (range 0.6-1.5 
mg/kg/d intravenously) was used in 91%. Usually, treatment was initiated as a 
monotherapy (71%); combination therapy was started only in six cases by the addition 
of itraconazole, 5-flucytosine or caspofungin. Use of voriconazole was first reported 
in 1998 and used in five cases, only once as a first-line treatment (41). Twelve patients 
(50%) received granulocytes, and 7 patients (30%) received interferon (INF)-γ in 
addition to the antifungal therapy. The use of INF-γ as adjunctive therapy of IA 
in CGD patients has not been investigated by controlled studies and remains 
controversial. In those who did not receive surgery and survived, infection was 
limited to the lung or with minimal involvement of adjacent structures (30, 35).
 Unambiguous data on clinical outcome was lacking, and follow-up ranged 
from “still under treatment” to eight years. At the time cases were published, the 
mortality rate was 32%. The exact mortality rate of A. nidulans invasive infection in 
the CGD patient is difficult to determine, and an underestimation cannot be ruled 
out because of the huge variability in follow-up.
(19). Minimal inhibitory concentrations (MICs) for the mold-active azoles show a 
good susceptibility profile of A. nidulans, particularly for posaconazole (20, 21). 
Although a pediatric dosage has not been defined, posaconazole as salvage therapy 
in CGD shows to be safe and effective (22, 23). Detailed molecular analysis of 33 
international clinical isolates of Emericella spp. showed that of all E. quadrilineata 
strains, half were previously misidentified as E. nidulans. Both species are associated 
with clearly distinct susceptibility patterns, especially to amphotericin B (median 
MICs 2.5 and 0.5 mg/L, for E. nidulans and E. quadrilineata, respectively, P < 0.05) and 
caspofungin (median MICs, 0.32 and 1.83 mg/L, respectively, P < 0.05) (24). These 
observed differences in activity might be clinically important, highlighting the 
relationship between correct species identification and susceptibility testing.
INVASIVE A. NIDULANS INFECTIONS 
Twenty-five cases of IA due to A. nidulans in CGD patients were previously reported. 
The major clinical features are summarized in Table 2. Twenty-three were male, 
and median age was 7.5 years (range, 3-21 years). Of those whose genetic pattern 
was reported (n=19), 89% were X-linked. The most common localization (72%) is 
lung invasion with direct spread to adjacent chest-wall structures (Figure 1). The 
presenting signs and symptoms were often mild with low-grade fever, local pain or 
swelling, malaise and cough, but could be completely silent with asymptomatic 
new lung infiltrates detected during a routine visit. 
Figure 1  Computed tomography scan of A. nidulans infection in a patient with 
chronic granulomatous disease. Note the extensive chest wall invasion and 
subcutaneous infiltration (arrow).
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Table 2   The Major Clinical Features of Invasive A. nidulans Infections in CGD Patients
Case 
(Ref.)
Sex Genetic 
Type
Age, y Previous Fungal Infection Site of Disease Mechanism  
of Spread
Prophylaxis Treatment Surgery Outcome
1(25) M NA 16 No Osteomyelitis, long bone No spread INF-γ ABLC, AMBL, ITC Yes Survived
2(26) M NA 6 No Lung, chest wall, vertebrae Direct TMP-SMX AMB, ABLC, ITC Yes Died
3(27) M X-CGD 20 No Lung, 3rd rib, femur, skull Direct NA AMB, ITC, 5-FC Yes Survived
4(28) M X-CGD 4 No Lung, 8th-9th ribs, T6-L1 vertebrae Direct NA AMB, AMBL, gran Tx Yes Died
5(28) M X-CGD 9 No Lung, 4th rib Direct NA AMB Yes Survived
6(28) M X-CGD 13 Yes, A. nidulans pneumonia  
and osteomyelitis 4th rib  
at the age of 9
Progression of 4th rib lesion, T3-T4 
with paraparesis
Direct NA AMB Yes Survived
7(9) M X-CGD 6 Yes, Aspergillus spp. Lung, pleura No spread No INF-γ AMB, ITC, gran Tx Yes Survived
8(9) M X-CGD 19 No Lung, pleura, chest wall,  vertebrae, 
skin, skull, brain
Direct INF-γ after first event  
but stopped – relapse <1y
AMB, ABLC, ITC, 5-FC, 
gran Tx
Yes Died
9(9) M X-CGD 16 Yes, Aspergillus spp. Lung, pleura, vertebrae, chest wall Direct KTC AMB, ABLC, ITC, gran Tx Yes Survived
10(9) M X-CGD 7 No Lung, pleura, vertebrae, chest wall, 
sinuses, brain
Direct NA AMB, ABLC, gran Tx Yes Died
11(9) M X-CGD 4 No Lung No spread INF-γ until 1 mo before  
A. nidulans infection
AMB, ITC Yes Survived
12(29) M NA 6 No Lung, ribs, vertebrae T1-T8, spinal 
cord
Direct No AMB Yes Died
13(30) M X-CGD 8 No Lung, rib Direct Clindamycin AMB, gran Tx No Survived
14(31) M NA 10 No, but pneumonia not 
 responding to  antimicrobial 
therapy, including  tuber-  
culostatic drugs: subtotal  
right upper lobectomy at 6
Lung, pleura, axillary abcess, 2nd-
3th ribs, vertebrae
Direct No AMB Yes Survived
15 M X-CGD NA NA Lung, brain NA NA NA Survived
16 F NA 4 NA Lung No spread NA AMB No Survived
17 M X-CGD 19 NA Lung, chest wall, brain NA NA AMB, ABLC, ITC, 5-FC, 
FLC, gran Tx
No Died
18(32) F p67phox 3 No, but borderline positive 
Mantoux test, consolidation 
on RX, no improvement with 
tuberculostatic therapy or 
antibiotics
Endocarditis, skin lesions, blood Hematogenous TMP AMB Yes Died
19(33) M X-CGD 21 Yes, A. fumigatus pneumonia  
at the age of 10, brain focus  
at the age of 13
Lung, popliteal abscess, soft  tissues 
hemithorax, spinal cord, T5-T7 
vertebrae
Direct/ Hematog-
enous
TMP-SMX, ITC, INF-γ;  
poor compliance
AMB, AMBL, VOR, CAS, 
gran Tx
Yes Died
20(34) M X-CGD 4 No Lung, T2-T5 vertebrae, spinal cord Direct TMP-SMX, ITC AMB, AMBL, VOR, POS, 
CAS, gran Tx
Yes Survived  
(ex vivo gene 
therapy)
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 Studies on the role of NADPH-oxidase activity in killing A. fumigatus conidia by 
alveolar macrophages (AM) have produced contrasting interpretations. 
Experimental studies with AM from gp91phox-/- mice showed phagocytosis and 
killing rates comparable to AM from normal mice, indicating that NADPH-oxi-
dase-independent mechanisms in murine AM are pivotal to the inhibition of 
conidial germination (41, 45, 46). In contrast, AM from p47phox-/- mice were unable 
to kill A. fumigatus conidia (47). Furthermore, inhibitors of NADPH-oxidase that 
decreased the production of reactive oxidant intermediates inhibited the killing 
of A. fumigatus in normal murine AM (48). By comparing the killing ratio of A. 
fumigatus and A. nidulans by gp91phox-/- AM and healthy AM, we confirmed that 
gp91phox-/- AM were at least as efficient in killing these two species as healthy AM 
are (49). Although differences in animal strains, morphotypes, cell sources, and 
methods to assay the fungal damage might be responsible for this discrepancy, 
this heterogeneity underscores the complexity of fungal resistance and the fact 
that other mechanisms than killing by ROS must be involved as well.
 Reactive-oxygen species like H2O2 seem to act as chemoattractants (50). 
Furthermore, by studying IA in an experimental murine model, it was suggested 
that early polymorphonuclear neutrophil (PMN) recruitment is crucial. PMN 
recruitment to the lungs shows to be slower in gp91phox-/- mice, resulting in 
increased germination. More extensive hyphal proliferation and tissue invasion 
were observed in the lungs of gp91phox-/- mice, indicating that when the lungs are 
exposed to large numbers of conidia, early PMN recruitment and formation of 
PATHOGENESIS AND HOST DEFENSE
By comparing invasive A. nidulans infections in the CGD host (n=25) with those 
caused by A. fumigatus (n=44), A. nidulans infections are often asymptomatic, behave 
more aggressively, and are significantly more likely to result in death. Primary 
lung involvement was followed in 75% (versus 14% for A. fumigatus) by extensive 
tissue destruction and direct spread to adjacent chest-wall structures (8-10). Only 
two studies with p47phox-/- mice provide histopathology data on A. nidulans 
infections, but no direct comparison was made to A. fumigatus infections (42, 43). 
Besides the fact that comparable fatal A. fumigatus infections were observed in the 
X-linked murine CGD model and that the histopathology data do support a role for 
aberrant inflammation, not more can be concluded from these studies.
 Most studies focusing on innate immune responses against Aspergillus spp. 
have used A. fumigatus due to the fact that this species is the most commonly 
encountered causative agent of IA. Knowledge of the host response against other 
Aspergillus spp. is scarce, in particular with respect to A. nidulans. The first line of 
host-defense is directed against conidia, the infective form of the filamentous 
fungi, and consists of macrophages. The macrophages will kill the germinating 
spores intracellularly by mainly non-oxidative processes. The second line of 
defense against mold infections is superoxide production by neutrophils, a 
powerful mechanism to kill the invasive hyphal structures of filamentous fungi 
such as Aspergillus spp., and is missing in CGD (44) (Figure 2). 
Table 2   Continued
Case 
(Ref.)
Sex Genetic 
Type
Age, y Previous Fungal Infection Site of Disease Mechanism  
of Spread
Prophylaxis Treatment Surgery Outcome
21(35) M X-CGD 13 No Lung No spread TMP-SMX, ITC but diarrhea 
and serum levels (-)
AMBL, VOR, CAS No Survived
22(36) M p22phox 5 No Lung, chest wall cutaneous abscess Direct NA AMB, VOR, ITC, gran Tx Yes Survived
23(37) M X-CGD 8 No Lung, 6th rib, chest wall fistula 
over the rib, psoas abcess
Direct TMP-SMX, ITC; stopped  
4 wk prior to A. nidulans 
infection
AMB, AMBL, gran Tx Yes Survived 
(BMT)
24(38) M X-CGD 4 No Lung, chest wall, T8-T11 vertebrae, 
7th rib
Direct NA AMB, 5-FC, ITC gran Tx Yes Survived
25(39) M NA 5 NA Lung, chest wall, vertebrae, spinal 
cord syringomyelia
Direct NA VOR Yes Survived
Abbreviations: 5-FC, 5-flucytosine; ABLC, amphotericin B lipid complex; AMB, amphotericin B 
deoxycholate; AMBL, amphotericin B liposomal; BMT, Bone marrow transplantation; CAS, caspofungin; 
gran Tx, granulocyte transfusion; INF-γ, interferon-gamma; ITC, itraconazole; KTC, ketoconazole; TBF, 
terbinafine; TMP-SMX, trimethoprim-sulfamethoxazole; NA, not available; PCZ, pozaconazole; VOR, 
voriconazole; FLC, fluconazole;
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 oxidative-active aggregates are essential in preventing germination of A. fumigatus 
conidia (45). These data were confirmed by microarray data of murine C57BL/6 and 
gp91phox-/- AM exposed to A. fumigatus conidia in vivo: the most marked early tran-
scriptional changes did not indicate obvious NADPH-oxidase involvement but 
occur in genes involved in PMN recruitment (46).
 We recently explored the central role of the NADPH-oxidase, and the resulting 
ROS, in direct antifungal host defense. In vitro infection of circulating human 
leucocytes revealed that resistance to A. nidulans is not directly ROS related. We 
showed that A. nidulans, in contrast to A. fumigatus, is not susceptible to ROS. 
Infection of healthy PMN and peripheral blood mononuclear cells (PBMCs) by live 
A. nidulans did not result in any measurable ROS release, and the microbicidal 
activity of CGD PMN was maintained toward A. nidulans but not to A. fumigatus (49). 
These results indicate that the etiology of A. nidulans infections in CGD cannot be 
explained by the simple absence of the direct microbicidal effect of ROS. 
 In the early 1980s, it was suggested that abnormal pH regulation within the 
phagosome of CGD phagocytes might have a role in defective killing (51). The basis 
of this assumption was that the initiation of superoxide production is normally 
accompanied by phagosomal alkalinization as a result of the proton-acceptor 
function of superoxide anions. This pH change was proposed to be essential for the 
activation of granule-derived enzymes within the phagosome. Later on, this 
scheme was adjusted by showing that it is the pH-dependent, compensatory 
potassium surge across the vacuolar membrane, which is responsible for the 
release and activation of cationic granule proteins, form the anionic sulphated 
proteoglycan matrix (47). In patients with CGD, however, the NADPH-oxidase 
function, alkalinisation, and potassium influx is absent, resulting in impairment 
of these killing mechanisms. Whether this plays a significant role in the 
pathogenesis of A. nidulans is subject to debate, as earlier virulence studies of A. 
nidulans mutants in p47phox-/- mice indicate that pathogenicity was not influenced 
by fungal virulence factors as catalases and pH responsiveness (42, 43). Interestingly, 
the use of pH response mutants of A. nidulans in neutropenic mice showed a 
dramatic attenuation of ability to cause invasive disease (52). This observation 
shows that extrapolation of data from neutropenic mouse models of IA is 
insufficient to understand the pathophysiology of IA in CGD patients.
 Phagocytic cells possess several non-oxidative fungal mechanisms, including 
antimicrobial peptides (eg, defensins, histatin 5) and hydrolases, which are 
effective in preventing germination or at killing intra- and extracellular fungi 
(53). Drosomycin-like defensin shows antifungal activity (54). This synthetic dro-
somycin-like defensin was designated based on a putative human homologue of 
the Drosophila-derived drosomycin, known for its antifungal properties. In this in 
vitro study, the susceptibility of A. fumigatus and A. nidulans to drosomycin-like 
Figure 2  A. nidulans unique interaction with the CGD host. A functional NADPH- 
oxidase is crucial both as antimicrobial effector complex and as regulator of 
inflammation: a balance that is skewed to a state of hyper-inflammation upon 
interaction with A. nidulans. Various mechanisms known to play a role in the host 
immune response induced by A. nidulans are schematically illustrated. A, Inhaled 
A. nidulans conidia will be killed by alveolar macrophages mainly by nonoxidative 
processes. B, Early PMN recruitment is crucial in preventing germination of A. 
nidulans and is partly NADPH-dependent. The microbicidal activity of CGD PMN is 
maintained toward A. nidulans but not to A. fumigatus. C, CGD patients show to have 
lower expression of PRR. A. fumigatus is able to modulate the host TLR responses. 
Influence of A. nidulans on the CGD PRR expression and modulation of the response 
still needs to be elucidated. D, A. nidulans infections are able to boost the pro- 
inflammatory state of the CGD cell, which results in an increase of measurable 
TNF-α and a decrease of IL-10. L-tryptophan metabolism in human CGD cells is 
normal in response to fungal pathogens; however, IL-17A is strinkingly low in 
respons to A. nidulans and A. fumigatus. E, ROS likely dampen inflammasome 
activation and NADPH-oxidase-defective human PBMC are a source of elevated IL-1β. 
Infection of human CGD leucocytes with A. nidulans has shown significantly more 
IL-1β secretion compared to A. fumigatus. Abbreviations: CGD, chronic granulomatous 
disease; IL, internleukin; NADPH, nicotinamide adenine dinucleotide phosphate; 
PBMCs, peripheral blood mononuclear cells; PMN, polymorphonuclear neutrophils; 
PRR, pattern recognition receptor; TNF, tumor necrosis factor.
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 Innate immune receptors like Toll-like receptors  (TLRs) and complement 
receptors are important in orchestrating the host-defense and may be modulated 
by pathogens during the course of infection. PMN from CGD patients show lower 
expression levels of TLR5, TLR9, CD11b, CD18, CD35, and CXCR1 compared to those 
from healthy controls, whereas similar or increased receptor expressions were 
found in patients without CGD but with bacterial pneumonia (63). A. fumigatus is 
able to modulate the host TLR responses by directly decreasing the capacity of the 
host cells to respond to TLR2 and TLR4 ligation, a mechanism that can be 
interpreted as a means to evade  the host immune system or to interfere with the 
resultant signaling pathways (64). Whether differences in immune receptor 
expression and regulation or modulation during invasive fungal infections in 
CGD patients are relevant for the observed epidemiology has still to be elucidated. 
 Overall, it is clear that the innate response to fungal pathogens serves two 
main purposes: a direct antifungal activity and a regulatory function. Cellular 
mediators may serve both functions, allowing a certain degree of redundancy and 
compensation under specific conditions of either infection or other causes of 
inflammation. Inhibitors of TNF-α are commonly used to control severe 
inflammatory bowel disease in CGD, but these have been complicated by severe 
and sometimes fatal occurrence of fungal infections (65). These observations 
suggest that TNF-α is playing a more prominent role in the host defense in the 
absence of superoxide formation. The absence of ROS and the inflammasome 
activation, resulting in IL-1β production, is another proposed mechanisms for hy-
per-inflammation in CGD patients. ROS likely dampen inflammasome activation 
and NADPH-oxidase-defective human PBMCs are a source of elevated IL-1β (66). 
Infection of human CGD leucocytes with A. nidulans has shown significantly more 
IL-1β secretion compared to A. fumigatus (unpublished data). Current studies are 
conducted to unravel the IL-1β processing in CGD patients infected by A. nidulans 
and A. fumigatus. Targeting the IL-1β secretion provides new potential therapeutic 
options for inflammatory conditions associated in CGD.  Besides anti-fungal 
treatment, targeted dampening of inflammation during an A. nidulans infection in 
the CGD patient definitely needs further investigations. 
CONCLUSIONS
This synopsis summarizes our current understanding of the unique interaction 
between A. nidulans and its preferred host, the CGD patient. The clinical 
epidemiology points out to a specific disease pathology being the result of the 
complex interaction between the pathogen and the host. 
 Fungal pathogenesis is a continuum between infection and inflammation. In 
the CGD host, the absence of a functional NADPH-oxidase complex has both an 
defensin were remarkably different; the growth of A. nidulans was inhibited by the 
synthetic drosomycin-like defensin, but not by drosomycin. In contrast, A. fumigatus 
was susceptible to both of these defensins. The role of defensins and other cationic 
proteins stored in the granules of phagocytes from CGD patients in the host 
defense against filamentous fungi is not yet known and needs to be investigated.   
 It is clear that the almost exclusive contribution of NADPH-oxidase to microbial 
killing is a justified subject of debate, and recent studies indicate a critical role of the 
NADPH-oxidase as regulator of the immune homeostasis at multiple levels (55-57).
 We have observed that the absence of the respiratory burst is associated with 
a dysregulated production of pro- and anti-inflammatory cytokines and further 
contributes to the pathogenesis of IA in CGD patients (58). A more pro-inflammatory 
cytokine response was shown after stimulation with A. fumigatus conidia, while 
the balance shifted to an anti-inflammatory response after hyphal stimulation. 
The opposite was seen in healthy controls. In general, the induction of a T-helper 1 
(Th1)-type response, characterized by IFN-γ, tumor necrosis factor (TNF)-α and 
Interleukin (IL)-12 production, is protective against the development of IA. In contrast, 
defense against IA is impaired by IL-4 and IL-10. The respiratory burst in phagocytes 
is differentially regulated by Th1- and Th2-type cytokines: TNF-α enhances 
superoxide production by neutrophils, while IL-10 impairs the respiratory burst in 
macrophages (44). In a paper by Romani et al. (55), dysregulation of the L-tryptophan 
metabolism in mice with defects in NADPH-oxidase, resulting in overproduction 
of IL-17, has been proposed to link ROS defects with hyper- inflammation and 
susceptibility to pulmonary aspergillosis. However, in humans with CGD, tryptophan 
metabolism was shown to be intact, indicating that the mechanism of fungal 
susceptibility is different in CGD humans from CGD mice (59, 60). We evaluated in both 
gp91phox-/- and p47phox-/- CGD patients the L-tryptophan metabolism and cytokine 
profiles in response to Candida albicans, A. fumigatus and A. nidulans. Indeed, in contrast 
to mice, both CGD genotypes display a normal tryptophan metabolism. PBMCs of 
CGD patients produced more pro-inflammatory cytokines after stimulation, and 
IL-17A production was strikingly low in response to fungal pathogens when 
compared to healthy controls (61). Although it seems that an efficient anti-Aspergil-
lus defense relies more on a Th1 immune response (62), the absence of an adequate 
IL-17 response might contribute to their inability to clear fungal infections. 
 Recently, Segal et al. (56) showed that NADPH-oxidase-dependent, redox- 
mediated signaling is critical for termination of lung inflammation. By challenging 
NADPH-oxidase-deficient p47phox-/- mice and gp91phox-/- mice with intratracheal 
zymosan, they showed that NADPH-oxidase limits lung inflammation by attenuating 
the pro-inflammatory transcription factor NFκβ and by activating Nrf2, a key 
 redox-sensitive anti-inflammatory regulatory transcription factor. Data from 
mononuclear cells from X-linked CGD patients were consistent with these findings.
CHAPTER 5 ASPERGILLUS NIDULANS IN CGD
122 123
5
REFERENCES
1. Galagan JE, Calvo SE, Cuomo C, Ma L-J, Wortman JR, Batzoglou S, Lee S-I, Baştürkmen M, Spevak CC, 
Clutterbuck J, Kapitonov V, Jurka J, Scazzocchio C, Farman M, Butler J, Purcell S, Harris S, Braus GH, 
Draht O, Busch S, D’Enfert C, Bouchier C, Goldman GH, Bell-Pedersen D, Griffiths-Jones S, Doonan 
JH, Yu J, Vienken K, Pain A, Freitag M, Selker EU, Archer DB, Peñalva MA, Oakley BR, Momany M, 
Tanaka T, Kumagai T, Asai K, Machida M, Nierman WC, Denning DW, Caddick M, Hynes M, Paoletti 
M, Fischer R, Miller B, Dyer P, Sachs MS, Osmani SA, Birren BW. 2005. Sequencing of Aspergillus 
nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature 438:1105–1115.
2. Jones LBKR, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, Goldblatt D, Parker L, Cant 
AJ. 2008. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a 
comprehensive national patient-based registry. Clin. Exp. Immunol. 152:211–218.
3. Winkelstein JA, Marino MC, Johnston RB, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, 
Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H. 2000. Chronic granulomatous disease. 
Report on a national registry of 368 patients. Medicine (Baltimore) 79:155–169.
4. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. 2000. Genetic, biochemical, and clinical 
features of chronic granulomatous disease. Medicine (Baltimore) 79:170–200.
5. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, Español T, 
Fischer A, Kurenko-Deptuch M, Mouy R, Petropoulou T, Roesler J, Seger R, Stasia M-J, Valerius NH, 
Weening RS, Wolach B, Roos D, Kuijpers TW. 2009. Chronic granulomatous disease: the European 
experience. PLoS ONE 4:e5234.
6. Kobayashi S, Murayama S, Takanashi S, Takahashi K, Miyatsuka S, Fujita T, Ichinohe S, Koike Y, 
Kohagizawa T, Mori H, Deguchi Y, Higuchi K, Wakasugi H, Sato T, Wada Y, Nagata M, Okabe N, 
Tatsuzawa O. 2008. Clinical features and prognoses of 23 patients with chronic granulomatous 
disease followed for 21 years by a single hospital in Japan. Eur. J. Pediatr. 167:1389–1394.
7. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, Rossi P, Gattorno M, Rabusin 
M, Azzari C, Dellepiane RM, Pietrogrande MC, Trizzino A, Di Bartolomeo P, Martino S, Carpino L, 
Cossu F, Locatelli F, Maccario R, Pierani P, Putti MC, Stabile A, Notarangelo LD, Ugazio AG, Plebani A, 
De Mattia D, IPINET. 2008. Clinical features, long-term follow-up and outcome of a large cohort of 
patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin. Immunol. 126:155–164.
8. Dotis J, Roilides E. 2004. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous 
disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int. J. Infect. Dis. 8:103–110.
9. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. 1998. Aspergillus nidulans 
infection in chronic granulomatous disease. Medicine (Baltimore) 77:345–354.
10. Henriet S, Verweij PE, Holland SM, Warris A. 2013. Invasive fungal infections in patients with 
chronic granulomatous disease. Adv. Exp. Med. Biol. 764:27–55.
11. Soler-Palacín P, Margareto C, Llobet P, Asensio O, Hernández M, Caragol I, Español T. 2007. Chronic 
granulomatous disease in pediatric patients: 25 years of experience. Allergol Immunopathol (Madr) 
35:83–89.
12. Ahlin A, De Boer M, Roos D, Leusen J, Smith CI, Sundin U, Rabbani H, Palmblad J, Elinder G. 1995. 
Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta 
Paediatr. 84:1386–1394.
13. Mohammedi I, Eckert A, Thiebaut A, Piens MA, Malhière S, Robert D. 2005. Fatal Aspergillus nidulans 
pneumonia. Rev Med Interne 26:249–250.
14. Peyrade F, Boscagli A, Roa M, Taillan B, Gary-Toussain M, Dujardin P. 1997. Aspergillus nidulans 
bronchial aspergillosis after treatment of low-grade lymphoma with fludarabine. Rev Med Interne 
18:235–236.
15. Lucas GM, Tucker P, Merz WG. 1999. Primary cutaneous Aspergillus nidulans infection associated with 
a Hickman catheter in a patient with neutropenia. Clin. Infect. Dis. 29:1594–1596.
16. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley 
JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, 
Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, 
impact on displaying an efficient antimicrobial effect as well as a controlled 
inflammatory response. The defective NADPH-oxidase results in an impaired 
direct antimicrobial function but cannot explain the etiology of A. nidulans 
infections in CGD patients. Dysregulated cytokine production, the L-tryptophan 
metabolism, induction of Th17 cells, differential expression of innate immune 
receptors, impaired Nrf2 activity and inflammasome activation are discussed as 
immunological mechanisms underlying the dysregulated inflammatory response 
as observed in CGD upon interaction with A. nidulans. More extensive and in-depth 
analyses of these mechanisms in the unique interaction of A. nidulans in the CGD 
patient will definitely improve the current understanding of the role of the 
NADPH-oxidase in the host-immune response. More insight and detailed 
understanding of this challenging frontline is urgently needed to optimize 
diagnostic and therapeutic strategies for these often devastating invasive infections 
in the CGD patient. In summary, invasive A. nidulans infections are a major threat 
for patients suffering from CGD, while the molecular interaction between A. 
nidulans and the immune cells of the CGD host are hardly explored. 
Footnote page
Potential conflicts of interest. All authors: No reported conflicts.
Financial support. This work was supported by the European Society of Pediatric 
Infectious Diseases/Wyeth fellowship to S.S.V.H. (grant 2008-2010). 
Aknowledgements
We thank our colleague Dimitri Diavatopoulos, PhD, for drawing the figure.
CHAPTER 5 ASPERGILLUS NIDULANS IN CGD
124 125
5
36. van ‘t Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JF. 1998. Successful treatment 
with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am. J. Respir. Crit. Care 
Med. 157:1694–1696.
37. Ozsahin H, Planta von M, Müller I, Steinert HC, Nadal D, Lauener R, Tuchschmid P, Willi UV, 
Ozsahin M, Crompton NE, Seger RA. 1998. Successful treatment of invasive aspergillosis in chronic 
granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mo-
bilized granulocytes, and liposomal amphotericin-B. Blood 92:2719–2724.
38. White CJ, Kwon-Chung KJ, Gallin JI. 1988. Chronic granulomatous disease of childhood. An unusual 
case of infection with Aspergillus nidulans var. echinulatus. Am. J. Clin. Pathol. 90:312–316.
39. Bukhari E, Alrabiaah A. 2009. First case of extensive spinal cord infection with Aspergillus nidulans in 
a child with chronic granulomatous disease. J Infect Dev Ctries 3:321–323.
40. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. 2003. The radiological spectrum of invasive 
aspergillosis in children: a 10-year review. Pediatr Radiol 33:453–460.
41. Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC. 1997. Absence of respiratory burst 
in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and 
inflammatory response to Aspergillus fumigatus. J. Exp. Med. 185:207–218.
42. Chang YC, Segal BH, Holland SM, Miller GF, Kwon-Chung KJ. 1998. Virulence of catalase-deficient 
Aspergillus nidulans in p47(phox)-/- mice. Implications for fungal pathogenicity and host defense in 
chronic granulomatous disease. J. Clin. Invest. 101:1843–1850.
43. Bignell E, Negrete-Urtasun S, Calcagno AM, Arst HN, Rogers T, Haynes K. 2005. Virulence 
comparisons of Aspergillus nidulans mutants are confounded by the inflammatory response of 
p47phox-/- mice. Infect. Immun. 73:5204–5207.
44. Park SJ, Mehrad B. 2009. Innate immunity to Aspergillus species. Clin. Microbiol. Rev. 22:535–551.
45. Bonnett CR, Cornish EJ, Harmsen AG, Burritt JB. 2006. Early neutrophil recruitment and aggregation 
in the murine lung inhibit germination of Aspergillus fumigatus conidia. Infect. Immun. 74:6528–6539.
46. Cornish EJ, Hurtgen BJ, McInnerney K, Burritt NL, Taylor RM, Jarvis JN, Wang SY, Burritt JB. 2008. 
Reduced nicotinamide adenine dinucleotide phosphate oxidase-independent resistance to Aspergillus 
fumigatus in alveolar macrophages. J. Immunol. 180:6854–6867.
47. Reeves EP, Lu H, Jacobs HL, Messina CGM, Bolsover S, Gabella G, Potma EO, Warley A, Roes J, Segal 
AW. 2002. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. 
Nature 416:291–297.
48. Paris S, Wysong D, Debeaupuis J-P, Shibuya K, Philippe B, Diamond RD, Latgé J-P. 2003. Catalases of 
Aspergillus fumigatus. Infect. Immun. 71:3551–3562.
49. Henriet SSV, Hermans PWM, Verweij PE, Simonetti E, Holland SM, Sugui JA, Kwon-Chung KJ, 
Warris A. 2011. Human leukocytes kill Aspergillus nidulans by reactive oxygen species-independent 
mechanisms. Infect. Immun. 79:767–773.
50. Niethammer P, Grabher C, Look AT, Mitchison TJ. 2009. A tissue-scale gradient of hydrogen peroxide 
mediates rapid wound detection in zebrafish. Nature 459:996–999.
51. Segal AW, Geisow M, Garcia R, Harper A, Miller R. 1981. The respiratory burst of phagocytic cells is 
associated with a rise in vacuolar pH. Nature 290:406–409.
52. Bignell E, Negrete-Urtasun S, Calcagno AM, Haynes K, Arst HN, Rogers T. 2005. The Aspergillus 
pH-responsive transcription factor PacC regulates virulence. Mol. Microbiol. 55:1072–1084.
53. Brown GD. 2011. Innate antifungal immunity: the key role of phagocytes. Annu. Rev. Immunol. 
29:1–21.
54. Simon A, Kullberg BJ, Tripet B, Boerman OC, Zeeuwen P, van der Ven-Jongekrijg J, Verweij P, 
Schalkwijk J, Hodges R, van der Meer JWM, Netea MG. 2008. Drosomycin-like defensin, a human 
homologue of Drosophila melanogaster drosomycin with antifungal activity. Antimicrob. Agents 
Chemother. 52:1407–1412.
55. Romani L, Fallarino F, De Luca A, Montagnoli C, D’Angelo C, Zelante T, Vacca C, Bistoni F, Fioretti 
MC, Grohmann U, Segal BH, Puccetti P. 2008. Defective tryptophan catabolism underlies 
inflammation in mouse chronic granulomatous disease. Nature 451:211–215.
Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in 
hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated 
Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50:1091–1100.
17. Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, Prasad P, Steinbach WJ. 2008. 
Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. 
Pediatrics 121:e1286–94.
18. Balajee SA, Houbraken J, Verweij PE, Hong S-B, Yaghuchi T, Varga J, Samson RA. 2007. Aspergillus 
species identification in the clinical setting. Stud. Mycol. 59:39–46.
19. van der Linden JWM, Warris A, Verweij PE. 2011. Aspergillus species intrinsically resistant to 
antifungal agents. Med. Mycol. 49 Suppl 1:S82–9.
20. Araujo R, Pina-Vaz C, Rodrigues AG. 2007. Susceptibility of environmental versus clinical strains of 
pathogenic Aspergillus. Int. J. Antimicrob. Agents 29:108–111.
21. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. 2008. In vitro survey of 
triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 
46:2568–2572.
22. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. 2005. Posaconazole as 
salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal 
infection. Clin. Infect. Dis. 40:1684–1688.
23. Groll AH, Lehrnbecher T. 2008. Posaconazole for pediatric patients: status of development and future 
perspectives. Mycoses 51 Suppl 2:5–11.
24. Verweij PE, Varga J, Houbraken J, Rijs AJMM, Verduynlunel FM, Blijlevens NMA, Shea YR, Holland 
SM, Warris A, Melchers WJG, Samson RA. 2008. Emericella quadrilineata as cause of invasive 
aspergillosis. Emerging Infect. Dis. 14:566–572.
25. Dotis J, Panagopoulou P, Filioti J, Winn R, Toptsis C, Panteliadis C, Roilides E. 2003. Femoral 
osteomyelitis due to Aspergillus nidulans in a patient with chronic granulomatous disease. Infection 
31:121–124.
26. Kim M, Shin JH, Suh SP, Ryang DW, Park CS, Kim C, Kook H, Kim J. 1997. Aspergillus nidulans infection 
in a patient with chronic granulomatous disease. J. Korean Med. Sci. 12:244–248.
27. Neijens HJ, Frenkel J, de Muinck Keizer-Schrama SM, Dzoljic-Danilovic G, Meradji M, van Dongen 
JJ. 1989. Invasive Aspergillus infection in chronic granulomatous disease: treatment with itraconazole. 
J. Pediatr. 115:1016–1019.
28. Sponseller PD, Malech HL, McCarthy EF, Horowitz SF, Jaffe G, Gallin JI. 1991. Skeletal involvement 
in children who have chronic granulomatous disease. J Bone Joint Surg Am 73:37–51.
29. Redmond A, Carre IJ, Biggart JD, Mackenzie DW. 1965. Aspergillosis (Aspergillus nidulans) involving 
bone. J Pathol Bacteriol 89:391–395.
30. Bujak JS, Kwon-Chung KJ, Chusid MJ. 1974. Osteomyelitis and pneumonia in a boy with chronic 
granulomatous disease of childhood caused by a mutant strain of Aspergillus nidulans. Am. J. Clin. 
Pathol. 61:361–367.
31. Altman AR. 1977. Thoracic wall invasion secondary to pulmonary aspergillosis: a complication of 
chronic granulomatous disease of childhood. AJR Am J Roentgenol 129:140–142.
32. Casson DH, Riordan FA, Ladusens EJ. 1996. Aspergillus endocarditis in chronic granulomatous 
disease. Acta Paediatr. 85:758–759.
33. Dellepiane RM, Tortorano AM, Liotto N, Laicini E, Di Landro G, Carnelli V, Pietrogrande MC. 2008. 
Invasive Aspergillus nidulans infection in a patient with chronic granulomatous disease. Mycoses 
51:458–460.
34. Notheis G, Tarani L, Costantino F, Jansson A, Rosenecker J, Friederici D, Belohradsky BH, Reinhardt 
D, Seger R, Schweinitz DV, Wintergerst U. 2006. Posaconazole for treatment of refractory invasive 
fungal disease. Mycoses 49 Suppl 1:37–41.
35. Sallmann S, Heilmann A, Heinke F, Kerkmann M-L, Schuppler M, Hahn G, Gahr M, Rösen-Wolff A, 
Roesler J. 2003. Capofungin therapy for Aspergillus lung infection in a boy with chronic granulomatous 
disease. Pediatr. Infect. Dis. J. 22:199–200.
CHAPTER 5 ASPERGILLUS NIDULANS IN CGD
126 127
5
56. Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminella J, Dennis CG, Vethanayagam RR, Yull FE, 
Capitano M, Wallace PK, Minderman H, Christman JW, Sporn MB, Chan J, Vinh DC, Holland SM, 
Romani LR, Gaffen SL, Freeman ML, Blackwell TS. 2010. NADPH-oxidase limits innate immune 
responses in the lungs in mice. PLoS ONE 5:e9631.
57. Bylund J, MacDonald KL, Brown KL, Mydel P, Collins LV, Hancock REW, Speert DP. 2007. Enhanced 
inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent 
activation of NF-kappa B. Eur. J. Immunol. 37:1087–1096.
58. Warris A, Netea MG, Verweij PE, Gaustad P, Kullberg BJ, Weemaes CMR, Abrahamsen TG. 2005. 
Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to 
Aspergillus fumigatus and other filamentous fungi. Med. Mycol. 43:613–621.
59. De Ravin SS, Zarember KA, Long-Priel D, Chan KC, Fox SD, Gallin JI, Kuhns DB, Malech HL. 2010. 
Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully 
maintained in chronic granulomatous disease. Blood 116:1755–1760.
60. Jürgens B, Fuchs D, Reichenbach J, Heitger A. 2010. Intact indoleamine 2,3-dioxygenase activity in 
human chronic granulomatous disease. Clin. Immunol. 137:1–4.
61. Smeekens SP, Henriet SSV, Gresnigt MS, Joosten LAB, Hermans PWM, Netea MG, Warris A, van de 
Veerdonk FL. 2012. Low interleukin-17A production in response to fungal pathogens in patients with 
chronic granulomatous disease. J. Interferon Cytokine Res. 32:159–168.
62. Chai LYA, van de Veerdonk F, Marijnissen RJ, Cheng S-C, Khoo AL, Hectors M, Lagrou K, Vonk AG, 
Maertens J, Joosten LAB, Kullberg BJ, Netea MG. 2010. Anti-Aspergillus human host defense relies on 
type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 130:46–54.
63. Hartl D, Lehmann N, Hoffmann F, Jansson A, Hector A, Notheis G, Roos D, Belohradsky BH, 
Wintergerst U. 2008. Dysregulation of innate immune receptors on neutrophils in chronic 
granulomatous disease. J. Allergy Clin. Immunol. 121:375–382.e9.
64. Chai LYA, Netea MG, Sugui J, Vonk AG, van de Sande WWJ, Warris A, Kwon-Chung KJ, Kullberg BJ. 
2010. Aspergillus fumigatus conidial melanin modulates host cytokine response. Immunobiology 
215:915–920.
65. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. 2010. Complications of tumor 
necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin. Infect. Dis. 
51:1429–1434.
66. van de Veerdonk FL, Smeekens SP, Joosten LAB, Kullberg BJ, Dinarello CA, van der Meer JWM, 
Netea MG. 2010. Reactive oxygen species-independent activation of the IL-1beta inflammasome in 
cells from patients with chronic granulomatous disease. Proc. Natl. Acad. Sci. U.S.A. 107:3030–3033.
The NADPH-oxidase as regulator  
of inflammation
Decreased Cell Wall Galactosaminogalactan in Aspergillus nidulans  
Mediates Dysregulated Inflammation in the CGD Host 
Stefanie S. V. Henriet, Wendy W.J. van de Sande, Mark J. Lee, Elles Simonetti,   
Michelle Momany, Paul E. Verweij,  Antonius J.M.M. Rijs, Gerben Ferwerda,  
Donald C Sheppard, Marien I. de Jonge,  Adilia Warris
Submitted.
6
CHAPTER 6 DYSREGULATED INFLAMMATION BY A. NIDULANS IN CGD
130 131
6
ABSTRACT
Invasive aspergillosis is a major threat to patients suffering from impaired 
neutrophil function, with Aspergillus fumigatus being the most common species 
causing this life-threatening condition. Patients with chronic granulomatous 
disease (CGD) not only develop infections with A. fumigatus, but also exhibit a 
unique susceptibility to infection with the normally nonpathogenic species 
Aspergillus nidulans. In this study, we compared the inflammatory cytokine response 
of peripheral blood mononuclear cells (PBMCs) from healthy and CGD patients to 
these two fungal species. CGD patients displayed evidence for a chronic hyper-in-
flammatory state as indicated by elevated plasma IL-1β and TNF-α levels.  PBMCs 
isolated from CGD patients secreted higher levels of IL-1β and TNF-α in response to 
A. nidulans as compared with A. fumigatus. The presence or absence of melanin in 
the cell wall of A. nidulans did not alter the cytokine release by healthy or CGD 
PBMCs.  In contrast, A. fumigatus mutants lacking melanin stimulated higher levels 
of pro-inflammatory cytokine release from healthy, but not CGD PBMCs. Purified 
cell wall polysaccharides of A. nidulans induced a much higher level of IL-1β 
secretion by CGD PBMCs than did cell wall polysaccharides isolated from A. 
fumigatus. Using modified A. nidulans strains overexpressing galactosaminogalactan, 
we were able to show that the increased secretion of inflammatory cytokines by 
CGD PBMCs in response to A. nidulans are a consequence of low levels of cell wall 
associated galactosaminogalactan in this species. 
INTRODUCTION
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency 
(1:125,000) that is associated with an intrinsic susceptibility to invasive aspergillosis 
(1). The molecular basis of CGD is well understood: CGD is a group of heterogeneous 
diseases caused by a defect in any of the five structural components of the 
NADPH-oxidase (gp91phox, p47phox, p67phox, p22phox and p40phox). As a result, the 
CGD phagocytic cell is unable to produce reactive oxygen species (ROS). Generation 
of ROS by a functional NADPH-oxidase is important in at least two major functions 
of the innate immune system: antimicrobial killing and the regulation of 
inflammation (2). As such, clinically, CGD patients are characterized by recurrent 
life-threatening infections and inflammatory complications such as colitis-like 
syndromes and formation of granulomata.
 The lifetime incidence of invasive aspergillosis in CGD patients varies between 
25 and 40 %, and is a primary cause of death (3, 4). While Aspergillus fumigatus is the 
most commonly encountered species, patients with CGD are uniquely susceptible 
to invasive infections with Aspergillus nidulans, a nonvirulent fungus that rarely 
causes disease in other immunocompromised patient populations. A. nidulans 
infections in patients with CGD have a greater propensity to disseminate and a 
higher mortality rate than those caused by A. fumigatus (4).
 To date, the immune mechanisms underlying the pathogenesis of invasive A. 
nidulans infections remain poorly understood. Importantly, PBMCs from CGD 
patients produce higher levels of the pro-inflammatory cytokines interleukin 6 
(IL-6), tumor necrosis factor-α (TNF-α) and interferon-γ (INF-γ) upon stimulation 
with Aspergillus species, while IL-17A production is strikingly low compared to 
healthy controls (5). These differences in cytokine production are not related to 
differences in leukocyte viability as CGD phagocytes do not undergo cell death 
more rapidly than healthy cells in response to A. nidulans infection (6). The fungal 
factors underlying this hyperinflammatory response to A. nidulans have not been 
elucidated.
 The constituents of the fungal cell wall play an important role in mediating 
the immune response to Aspergillus.  Cell wall polysaccharides such as galactomannan, 
β-glucan and the recently discovered galactosaminogalactan (GAG) are important 
immune ligands that can modulate cytokine expression (7). Comparative analyses 
of the cell wall composition of A. fumigatus and A. nidulans have demonstrated 
differences between these organisms. The most striking of these differences is 
that the A. nidulans cell wall contains only low levels of the heteropolysaccharide 
galactosaminogalactan (8, Lee et al., submitted), which has recently been found to 
mediate immunosuppression during infection with A. fumigatus (9, 10). In addition 
to cell wall polysaccharides, conidial melanin of A. fumigatus, i.e. 1,8-dihydroxy-
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Fungal strains
A. nidulans (V44-46) and A. fumigatus strains (V45-07; B-5233) are wild type strains, 
originally isolated from patients suffering from invasive aspergillosis. The strain 
RGD-12, which produces albino conidia devoid of melanin, was obtained by 
deletion of the gene alb1 in the strain B-5233 (Δalb1, kind gift of K.J. Kwon-Chung, 
NIH, Bethesda, USA). The alb1 gene codes for a polyketide synthase (pksP) in the 
1,8-dihydroynaphthalene (DHN)-melanin pathway, involved in the biosynthesis of 
conidial pigment (15, 16). The A. nidulans A191 strain, was obtained by deletion of 
the wA gene, resulting in white conidia (17, 18) (ΔwA, kind gift of K.J. Kwon-Chung, 
NIH, Bethesda, USA).
 The A. nidulans strains overexpressing heterologous uge3 (derived from A. 
fumigatus), and necessary for the production of GAG in the cell-wall, was constructed 
as previously described (19, Lee et al., submitted). These strains were grown on 
minimal media supplemented with biotin (50 uL per 1L of medium of 0.5 mg/mL 
biotin stock solution). All other Aspergillus strains were initially grown on a 
Sabouraud glucose agar supplemented with chloramphenicol for 4 to 7 days at 
37°C and subsequently plated on a 1:10 diluted Sabouraud agar. Conidia were 
harvested, filtered and washed as previously described (6). They were stored in 
individual aliquots of 1 x 108/ml at -80°C. To obtain heat killed (HK) conidia, the 
conidial suspension was heat killed for 15 min at 121°C. The growth and killing of 
the Aspergillus isolates was carried out in a LPS-free fashion. Candida albicans ATCC 
MYA-3573 (UC 820) (20) was grown overnight in Sabouraud broth at 37°C, cells 
were harvested by centrifugation, washed twice, and resuspended in culture 
medium. C. albicans was heat-killed for one hour at 100°C. The viability of the fungi was 
checked by culturing at 37°C on fungal agar. No growth was observed following 
heat treatment. 
Extraction of melanin from A. fumigatus and A. nidulans conidia
Melanin was extracted from the strains V44-46 (A. nidulans) and V45-07 (A. fumigatus) 
as previously described (21). In brief, conidia were enzymatically lysed to form 
protoplasts. The protoplasts were incubated with the chaotropic agent guanidine 
thiocyanate (4.0 M) to generate dark particles, which were treated with proteinase 
K to remove residual proteins. The pellet was incubated at 100°C in 6.0 M HCl for 
1 h to obtain pure melanin. Melanin concentration was quantified by weighing 
the dried mass (22). The melanins were suspended in PBS at a stock concentration 
of 10 mg/ml, and sonicated to obtain a homogeneous solution.
Isolated cell wall sugars
Mycelial cell wall sugars of both A. nidulans (FGSC strain A28) and A. fumigatus 
(Clinical strain A237) were isolated as previously described (8). In summary, both 
naphthalene (DHN), is another important fungal cell-wall structure that influences 
the immune response to fungi (11, 12). A. nidulans produces melanin of the 
3,4- dihydroxyphenylalanine (DOPA)-type rather than the DHN-type found in 
A. fumigatus (13). The implications of these differences in fungal cell wall composition 
on fungal pathogenesis in the CGD host are currently an unexplored domain. 
 We hypothesized that differences in cell wall composition between A. nidulans 
and A. fumigatus may lead to altered inflammatory responses in CGD leukocytes. 
Therefore we evaluated the cytokine response of CGD PBMCs to A. nidulans as 
compared to A. fumigatus as well as to cell wall components of these organisms.
MATERIALS AND METHODS
Human PBMCs
After informed consent was given, venous blood was drawn from healthy volunteers 
and five CGD patients (three gp91phox deficient and two p47phox deficient). All 
patients were below the age of 18 and free from any infectious or inflammatory 
diseases. The clinical characteristics of all patients are presented in supplemental 
table 1 (supplemental data). Blood was collected by venepuncture into 10 mL eth-
ylenediaminetetraacetic acid (EDTA) tubes (367525, BD, Plymouth, UK). PBMCs 
were isolated using lymphoprep (Axis-Shield), by density gradient centrifugation 
as previously described (6). Briefly, blood was diluted with an equal volume of phos-
phate-buffered saline (PBS). The lymphoprep was carefully added below the diluted 
blood and centrifuged at 800 x g to separate the plasma from the PBMC fraction 
and the PMN. PBMCs were harvested and counted by hemocytometer. For the 
stimulation assays, 5 x 105 PBMCs in a total volume of 200 µL per well were 
incubated at 37°C and 5% CO2 in round-bottom 96-wells plates (Nunc, Roskilde, 
Denmark) with either 10 ng/ml LPS (derived from E. coli serotype 055:B5, 
Sigma-Aldrich St. Louis), Pam3Cys (10 µg/ml), heat-killed C. albicans, live or heat 
killed (HK) A. fumigatus or A. nidulans in specified concentrations. An extra 
purification step of LPS was performed before use (14). RPMI 1640 GlutaMAX-I 
medium (Invitrogen Life Technologies) + 10% heat inactivated human serum 
(Sigma, H6914) was used as culture medium (CM). After 24 hours, supernatants 
were collected and stored at –20°C until assayed. To exclude a role of cellular 
toxicity during stimulation, the lactate dehydrogenase (LDH) concentrations were 
measured in the supernatants of the PBMCs. The stimuli as used in our experiments 
did not affect cell viability after 24 hours of co-incubation compared to cells 
cultured without any stimulus. 
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healthy controls) were found in the plasma of CGD patients (p<0.01 for IL-1β and 
TNF-α), indicating an intrinsic hyper-inflammatory state. Interleukin-10 levels in 
plasma from CGD patients were not significantly different from those in healthy 
controls (139.7 ± 67.3 pg/ml vs 42.4 ± 34.6 pg/ml). PBMCs isolated from these CGD 
patients also produced an exaggerated pro-inflammatory response upon ex-vivo 
stimulation. Compared with PBMCs isolated from healthy controls, CGD PMBCs 
secreted higher levels of IL-1β and TNF-α after stimulation by the selective TLR4 
ligand LPS (p<0.01 for IL-1β and TNF-α), TLR2 ligand Pam3cys (p<0.01 for TNF-α) 
and C-type lectin agonist C. albicans (n.s.) (Figure 1A, 1B). Interleukin-10 release by 
CGD PBMCs was also increased after stimulation by those ligands although the 
absolute amount of IL-10 secretion was much lower (Figure 1C).
species were cultured in liquid media for 48hrs and the mycelia were obtained by 
gravity filtration and vacuum filtration. The mycelia were washed several times to 
remove traces of media and mechanically homogenized in chilled Tris/EDTA 
buffer and lyophilized. The lyophilized cell wall sugars were suspended in sterile 
and endotoxin free deionized water (Braun, Germany) at a stock concentration of 
2.5 mg/ml, and sonicated to obtain a homogeneous solution. Further dilutions 
were made in CM.
Enzyme-linked immunosorbant assay
The concentration of IL-10, IL-1β, IL-1Ra and TNF-α was measured in cell 
culturesuper natants using enzyme-linked immunosorbant assay (ELISA) (IL-1β and 
IL-1Ra: R&D Systems, Abingdon, UK, and IL-10 and TNF-α: Sanquin, Amsterdam, 
the Netherlands), according to the instructions of the manufacturer.
Fc-Dectin-1 staining
Surface exposure of β-1,3-glucan was measured by immunostaining with an 
Fc-dectin-1 recombinant construct, as previously described (10). Briefly, 1x105 
conidia of indicated strains were grown on glass coverslips in 24 well plates for 12 
hours then fixed with 4% paraformaldehyde in PBS.  The fixed samples were 
blocked with 3% bovine serum albumin supplemented with 0.2% sodium azide in 
PBS, and labelled with 10 µg/mL of Fc-dectin-1 (23) followed by FITC-labeled 
AffiniPure F(ab’) fragment donkey anti-human IgG, FCγ fragment specific (Jackson 
ImmunoResearch).  Stained hyphae were imaged using confocal microscopy (IX81, 
Olympus), excitation 488 nm and emission 519 nm.
 Statistical analysis. Experiments were performed in duplicate, the mean value 
of this duplicate was taken as the value for the particular donor. The differences 
between groups were analyzed using the Mann-Whitney U test. P values of < 0.05 
were considered statistically significant. Data are presented as mean ± standard 
error of the mean (SEM). 
RESULTS
CGD patients exhibit increased baseline levels of inflammatory 
cytokines
One hallmark of CGD is increased inflammation. To analyse the basal levels of 
pro-inflammatory cytokines in CGD patients, plasma was isolated from 4 paediatric 
CGD patients free from any infectious or inflammatory complications and 
compared with healthy controls, repeated at least at three independent time 
points. Significant increased levels of IL-1β (86.96 ± 27.8 pg/ml versus 8.0 ± 0.1 pg/
ml in healthy controls) and TNF-α (124.2 ± 47.3 pg/ml versus 8.3 ± 0.5 pg/ml in 
Figure 1  TNF-α (A), IL-1β (B) and IL-10 (C) cytokine responses of healthy (n=5-7) and 
CGD (n=4) PBMCs after stimulation by 1ng/ml LPS, 10 µg/ml Pam3Cys and 1x10*6/
ml C. albicans. Bar represent means + SEM. * p<0.05.
A
C
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PBMCs and levels were significantly higher compared to healthy PBMCs (p<0.01 
and p<0.05 respectively) (Figure 2A, 2B).  
 Secretion of the anti-inflammatory cytokine IL-10 by CGD PBMCs upon 
stimulation with both fungi was also increased, however the absolute amount of 
IL-10 release was low in all conditions (range 2.3 pg/ml to 162 pg/ml). A. nidulans 
induced higher levels of IL-10 secretion compared to A. fumigatus and this difference 
was significant when heat-killed conidia were used (Figure 2C). No interleukin-10 
release by healthy PBMCs was observed upon stimulation by the two Aspergillus 
species. Collectively, these results suggest that in the absence of a functional 
NADPH-oxidase, the pro-inflammatory state of the CGD PBMCs is increased by 
both Aspergillus species as compared to healthy PBMCs, and that A. nidulans is a 
more potent inducer of IL-1β and TNF-α than A. fumigatus.
Immunomodulatory potential of bound A. nidulans melanin differs 
from A. fumigatus melanin in healthy PBMCs
Fungal melanin is a well-known virulence factor influencing host-pathogen 
interactions. Heat-killed melanized A. fumigatus conidia have been reported to 
induce less pro-inflammatory cytokine release from healthy PBMCs than do albino 
conidia (12). In agreement with this report, we found that healthy PBMCs secreted 
significantly increased levels of the pro-inflammatory cytokines TNF-α (p<0.01) 
and IL-1β (p=0.05) in response to live A. fumigatus conidia devoid of melanin (albino) 
as compared to wild-type (WT) A. fumigatus conidia. A similar trend towards 
increased TNF-α and IL-1β secretion by healthy PBMCs in response to albino as 
compared to WT conidia was seen in A. nidulans, however this difference was not 
statistically significant (Figure 3A). 
Presence of melanin does not influence the pro-inflammatory 
response of the CGD PBMCs upon fungal stimulation
In order to assess the role of A. nidulans conidial melanin in the hyper-inflamma-
tion observed in CGD PBMCs, these cells were stimulated with either WT or albino 
live A. nidulans and A. fumigatus conidia. No differences in IL-1β and TNF-α release by 
CGD PBMCs were observed in response to WT or albino A. nidulans or between WT 
and albino A. fumigatus (Figure 3B). Thus, conidial melanin does not play a significant 
role in modulating the release of pro-inflammatory cytokines by CGD cells in 
response to either species of Aspergillus. 
Aspergillus nidulans induces higher levels of pro-inflammatory 
cytokine production than A. fumigatus in CGD cells
Co-culture experiments were performed to evaluate the ability of A. fumigatus and 
A. nidulans to induce cytokine production in healthy and CGD PBMCs.   Both species 
of Aspergillus induced an increased release of IL-1β and TNF-α by CGD PBMCs as 
compared to healthy PBMCs (Figure 2A, 2B). This induction of pro-inflammatory 
cytokine production was much higher when PBMCs were incubated with live 
organisms as compared with heat-killed organisms for both species.  In both CGD 
and healthy PBMCs, heat-killed A. nidulans conidia led to significantly increased 
levels of IL-1β release than A. fumigatus conidia, (p<0.05 and p<0.01 respectively). 
Live A. nidulans conidia acted as the most potent inducer of IL-1β and TNF-α by CGD 
Figure 2  IL-1β, TNF-α and IL-10 cytokine responses of healthy (n=5) and CGD (n=4) 
PBMC after stimulation by either 5x10*6/ml heat-killed or live A. nidulans and A. fumigatus 
conidia. Bar represent means + SEM. * p<0.05, ** p<0.01.
A
C
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Melanin isolated from A. nidulans or A. fumigatus does not induce  
or modulate cytokine response by PBMCs from healthy individuals 
or CGD patients 
Since fungal melanin has been shown previously to modulate the immune response 
toward C. neoformans and A. fumigatus (12, 24) we next compared the immunogenic 
properties of isolated A. nidulans and A. fumigatus conidial melanin. Isolated melanin of 
both Aspergillus spp. in concentrations up to 1 mg/ml were extremely poor stimulators 
of pro-inflammatory cytokine release by both healthy and CGD PBMCs as indicated 
by the lack of significant IL-1β and TNF-α release in the supernatant (data not 
shown). Isolated melanins from both Aspergillus species were not able to modulate 
the IL-1β and TNF-α release by both healthy and CGD PBMCs stimulated with LPS 
(data not shown) or the albino A. fumigatus and A. nidulans conidia (Figure 3C).
A. nidulans cell wall polysaccharides are responsible for the 
enhanced IL-1β release by CGD PBMCs
We next questioned whether differences in polysaccharide cell wall composition 
between A. fumigatus and A. nidulans could be responsible for the differences in 
inflammatory cytokine production. Both CGD and healthy PBMCs were stimulated 
with an increasing concentration of isolated cell wall polysaccharides (0.01 up to 
25 µg/ml) from both A. nidulans or A. fumigatus. Cell wall polysaccharides of A. 
nidulans induced higher levels of IL-1β secretion by both healthy and CGD PMBCs 
as compared to A. fumigatus cell wall polysaccharides, (Figure 4A, 4B). CGD PBMCs 
secreted higher levels of IL-1β than did healthy PBMCs upon stimulation with 
either cell wall polysaccharide preparation. TNF-α release was also higher by CGD 
PBMCs as compared to healthy PBMCs when stimulated with A. fumigatus derived 
cell wall polysaccharides. However, for A. nidulans derived cell wall polysaccharides, 
CGD PBMCs released higher levels of TNF-α than healthy PBMCs only at lower 
concentrations (< 3.13 µg/ml, Figure 4C, 4D).  IL-10 production by healthy PBMCs 
was minimal while CGD PBMCs released a significant amount of this cytokine in 
response to stimulation by both A. fumigatus or A. nidulans derived cell wall 
poly saccharides (Figure 4E, 4F). In addition, a dose-response relationship was 
observed for TNF-α and IL-1β release by healthy PBMCs in response to cell wall 
polysaccharides starting from a concentration of 0.39 µg/ml. In CGD PBMCs, a 
dose-response relationship was observed for both IL-1β and IL-10 secretion and 
polysaccharide stimulation, but not for TNF-α release.
GAG deficiency in the cell wall of A. nidulans leads to increased  
IL-1β release
Finally, we tested the hypothesis that the low levels of galactosaminogalactan 
(GAG) in the cell wall of A. nidulans could be responsible for the increased IL-1β 
Figure 3  The cytokine response of human healthy PBMCs (A) and CGD PBMCs (B) 
to 1x10*6/ml live albino (ALB, grey bars) or live wild type (WT, black bars) A. 
fumigatus and A. nidulans conidia (n=6-9). Albino A. nidulans (ΔwA) (A. nidulans ALB, 
white bars)  or A. fumigatus (Δalb1) (A. fumigatus ALB, black bars)  induced IL-1β release 
by CGD PBMCs (C) in the presence of increasing concentration (mg/ml) of isolated 
A. nidulans (AN) conidial melanin or A. fumigatus (AF) conidial melanin. The albino 
conidial stimulated cytokine release without isolated melanin was set to 100% 
(n=2). Bar represent means + SEM. * p=0.05, ** p<0.01.
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Figure 4  The IL-1β (A,B), TNF-α (C,D) and IL-10 (E,F) cytokine response of healthy 
PBMCs (n=4) and CGD PBMCs (n=3) after stimulation with increasing concentrations 
of isolated cell wall sugars of A. fumigatus or A. nidulans. Bars indicate SEM.
A B
C D
E F
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release by PBMCs in response to this organism. The reduced expression of GAG by 
A. nidulans is due to decreased expression of ugeB, encoding an epimerase required 
for the synthesis of N-acetylgalactosamine (GalNAc) and the subsequent production 
of GAG.  Heterologous expression of the orthologous A. fumigatus uge3, increases cell 
wall GAG production in A. nidulans to levels similar to A. fumigatus [Lee et al, 
submitted]. Therefore to analyse the contribution of GAG to inflammatory cytokine 
production by PBMCs, A. nidulans strains overexpressing GAG (uge3 complemented 
A. nidulans strain) were compared with wild-type A. nidulans for their ability to 
induce IL-1β secretion by these cells. Both healthy PBMCs and PBMCs treated with 
the NADPH-oxidase inhibitor DPI (10µM) were stimulated with this A. nidulans 
strain. Overexpression of GAG in the A. nidulans cell wall resulted in a significant 
(p<0.01) decrease of IL-1β release mimicking the A. fumigatus profile of cytokine 
Figure 5  (A) The IL-1β release of healthy PBMCs (white bars) and PBMCs treated 
with the NADPH-oxidase inhibitor DPI and stimulation with live A. nidulans strains, 
live A. nidulans strains overexpressing A. fumigatus uge3 (A. nidulans + uge 3), and A. 
fumigatus. Bars represent mean ± SEM (n=6). * p<0.05, ** p<0.01 (B) The IL-1β cytokine 
and IL1-Ra release of healthy PBMCs (white bars) and CGD PBMC with live A. nidulans 
live A. nidulans strains and live A. nidulans strains overexpressing A. fumigatus uge3 
(A. nidulans + uge 3).The cytokine release after stimulation with WT live A. nidulans 
strains was set to 100 %. Bars represent mean ± SEM (CGD, n=2). The cytokine 
release after stimulation with WT live A. nidulans strains was set to 100 %. Bars 
represent mean ± SEM (CGD, n=2). 
A B
Figure 6  Detection of β-1,3-glucan exposure on the hyphal surface of A. fumigatus, 
A. nidulans, A. nidulans overexpressing A. fumigatus uge3 (comparable amounts of 
galactosaminogalactan as A. fumigatus) and as a control Δuge3 A. fumigatus (no ga-
lactosaminogalactan on the outer cell wall) by immunostaining with Fc-dectin-1 
antibody by fluorometry.
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 The mechanism underlying the hyperinflammatory response of CGD PBMCs 
to Aspergillus species remains unknown, although there are multiple possible 
explanations for these observations.  Differences in PRR expression between 
healthy and CGD cells might influence the observed cytokine profiles. Innate 
immune receptors like Toll-like receptors (TLRs) and complement receptors are 
important in orchestrating the host–defense and may be modulated by pathogens 
during the course of infection (28). PMN from CGD patients show lower expression 
levels of TLR5, TLR9, CD11b, CD18, CD35, and CXCR1 compared to those from 
healthy controls (29). The distribution and expression of Dectin-1 and the man-
nose-receptor on the CGD phagocyte is as yet unknown. Whether differences in 
immune-receptor expression and regulation or modulation during invasive fungal 
infections in CGD patients are relevant for the observed cytokine profiles between 
both species and as such the unique fungal epidemiology in the CGD host has still 
to be elucidated. An alternate hypothesis is that the intracellular pathways leading 
to pro-inflammatory cytokine release are differentially activated in the absence of 
a functional NADPH-oxidase. The innate-immune response against A. fumigatus 
involves both the expression and synthesis of pro-IL-1β, as well as the Syk-induced 
activation of the NLRP3 inflammasome and caspase-1, allowing processing and 
secretion of the mature cytokine (30). The activity of these pathways in the context 
of CGD remains unexplored.
 Invasive aspergillosis in the CGD host is the result of impaired direct 
antifungal effector function, as well as defective modulation of inflammation in 
response to fungal products (31). These two functions of the NADPH-oxidase 
complex are stimulus dependent and stimulus specific as shown by the unique 
interaction of A. nidulans with the CGD host (32).  Previous work from our group 
indicates that killing of A. nidulans is largely determined by NAPDH-oxidase 
independent mechanisms and that A. nidulans is more sensitive to extracellular 
killing by NADPH-oxidase dependent NET-osis compared to A. fumigatus (6, Lee et 
al., submitted).  Experiments in CGD mice have demonstrated that A. nidulans 
strains induce excessive inflammation and death from invasive pulmonary 
aspergillosis (33). These results suggest that excessive inflammation may play an 
important role in the pathogenesis of A. nidulans infections in the CGD host. Our 
data support this hypothesis as we observed that while CGD PBMCs responded 
with the production of high levels of inflammatory cytokines in response to both 
Aspergillus species, the induction of IL-1β and TNF-α was more dramatic with A. 
nidulans compared with A. fumigatus. 
 The fungal cell wall consists of polysaccharides (e.g. galactomannan, chitin, 
β(1-3)glucan, α(1-3)glucan), peptides (e.g. hydrophobins) and melanin, and harbours 
many of the fungal pathogen associated molecular pattern molecules (PAMPs) 
recognized by host pattern recognition receptors (PRR) (7).  Cell wall melanin 
induction. The decrease of IL-1β release was more pronounced in the absence of a 
functional NADPH-oxidase complex as compared to healthy PBMCs (Figure 5A). 
Importantly, the differences in induction of IL-1β secretion were not likely due to 
differences in β-glucan exposure, as immunofluorescence studies using recombinant 
Fc-Dectin-1 demonstrated no difference in β-glucan exposure between these 
strains (Figure 6). Recently, the anti-inflammatory property of GAG has been 
linked to the ability of soluble GAG-related induction of interleukin-1 receptor 
antagonist (IL-1Ra) (37). Consistent with these reports, cell wall polysaccharides 
isolated from A. fumigatus stimulated higher levels of IL-1Ra release by PBMCs than 
did cell wall polysaccharides isolated from A. nidulans.  This increase in IL-1Ra 
release was seen with PBMCs from both healthy controls (p < 0.05 compared to A. 
nidulans cell-wall polysaccharides) as CGD patients (n.s).   Surprisingly however, 
overexpression of GAG by uge3-complemented A. nidulans strains did not result in 
increased IL-1Ra induction by healthy PBMCs or NADPH-oxidase defective PBMCs 
isolated form CGD patients (Figure 5B). 
 Collectively, these results support our hypothesis that the low levels of GAG in 
the A. nidulans cell wall lead to the dysregulated inflammation by CGD PBMCs upon 
interaction with A. nidulans and to increased IL-1β release. Furthermore, these 
differences in IL-1β release are not the result of GAG mediated induction of IL-1Ra 
secretion. 
DISCUSSION
The results of this study demonstrate that CGD patients are characterized by a 
state of hyper-inflammation, as shown in vitro by specific pathogen recognition 
receptor (PRR) stimulation, and in vivo by increased concentrations of plasma 
pro-inflammatory cytokines in the absence of infection. A. nidulans enhances the 
inflammation in the CGD patient to a greater extent than A. fumigatus as illustrated 
by a significantly higher release of IL-1β. Further, we observed that differences in 
cell wall GAG content underlies the differences in the inflammatory response of 
CGD PBMCs to these species and may contribute to the unique pathogenicity of 
A. nidulans in the CGD host. 
 Hyperinflammation in the CGD patient is a clinically well-recognised 
phenomenon characterized by prolonged inflammatory reactions and granulomata 
formation (25-27). The exaggerated cytokine response to Aspergillus as observed in 
our study, are consistent with this phenomenon. Further, elevated cytokine levels 
were found in the plasma of young CGD patients in the absence of clinically 
apparent infections or other inflammatory complications. To the best of our 
knowledge, this finding has not been described, and underscores that CGD patients 
display intrinsic dysregulated inflammation even in the absence of infection (2). 
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 Finally, while others have reported that the addition of 10 µg/ml soluble GAG 
in combination with heat-killed Aspergillus isolates increased the stimulation of 
IL-1Ra release by PBMCs (37), overexpression of  GAG in A. nidulans did not result in 
increased induction of IL-1Ra secretion by PBMCs.  Only by using isolated cell wall 
polysaccharides from both A. fumigatus and A. nidulans, we were able to observe 
differences in the amounts of IL-1Ra secretion by PBMCs. It is possible that 
differences in the final concentrations achieved by fungal shedding of soluble GAG 
versus the addition of purified carbohydrate, and/or differences in the activities of 
the extracted soluble GAG alone versus native GAG may explain the observed 
differences in PBMC response. 
 The exact immunomodulating mechanisms of soluble GAG and cell wall 
associated GAG in the fungal pathogenesis in particular the CGD host remains 
unclear and needs to be further elucidated. GAG has been shown to protect CGD 
mice from experimental colitis (37), and the possibility that soluble GAG may be 
beneficial to dampen the hyperinflammation in vivo during invasive aspergillosis 
by Aspergillus nidulans will be the subject of future studies.
 In conclusion, we found that the unique polysaccharide cell-wall composition 
of A. nidulans contributes to the dysregulated inflammation during invasive 
aspergillosis in the CGD host. Low amounts of GAG in the A. nidulans cell wall seem 
to result in enhanced pathogenesis of invasive infections as observed in the CGD 
host. Further studies are urgently needed to unravel the specific interaction of the 
fungal cell wall components with their corresponding PRR on the various immune 
cells from specific hosts.
protects microbial cells from oxidative stress, modulates immune responses and 
has been linked to virulence in several human pathogenic fungi (24, 34-36). 
Melanin of A. fumigatus cloaks conidial PAMPs from recognition by host PRR 
resulting in impaired cytokine response (12). Surprisingly however we found that 
the presence or absence of melanin in either A. fumigatus and A. nidulans did not 
affect the release of TNFα and IL-β by CGD PBMCs. These findings suggest that the 
recognition of A. fumigatus and A. nidulans by CGD PBMCs leading to pro-inflamma-
tory cytokine release is not influenced by the presence of conidial melanin and 
suggests that hyphal factors may play a more important role in governing the 
cytokine response by CGD PBMCs.  
 In light of these findings we tested the hypothesis that hyphal cell wall poly-
saccharides play a key role in inducing inflammatory cytokine release by CGD 
PBMCs. Consistent with this hypothesis, exposure of PBMCs to hyphal cell wall 
polysaccharide preparations resulted in the induction of pro-inflammatory 
cytokine release.  Both live organisms and cell wall polysaccharides induced 
higher levels of IL-1β secretion by CGD PBMCs as compared to healthy cells. 
Additionally, stimulation with cell wall polysaccharides isolated from A. nidulans 
resulted in the secretion of higher levels of this cytokine in both types of PBMCs, 
suggesting that differences in cell wall polysaccharide composition may contribute 
to the hyperinflammatory response of PBMCs to A. nidulans.   Recent studies have 
found that the cell wall of A. nidulans contains low levels of GAG, a heteropolysac-
charide composed of α1,4-linked galactose and N-acetylgalactosamine.  To test if 
the higher levels of IL-1β release by PBMCs could be related to this low level of GAG, 
we utilized strains of A. nidulans engineered to express cell wall associated GAG to 
levels similar to A. fumigatus.  Increasing the cell wall GAG content of A. nidulans 
resulted in similar levels of IL-1β expression by PBMCs to that induced by A. 
fumigatus. Collectively these data suggest that the low amount of GAG produced by 
A. nidulans underlies the increased secretion of IL-1β by PBMCs.
 There are multiple possible mechanisms whereby cell wall GAG mediates the 
suppression of IL-1β expression by PBMCs. Galactosaminogalactan has been reported 
to mediate immunosuppression through a number of mechanisms including: 
masking of cell wall β-glucans, induction of IL-1Ra secretion, and NK-cell dependent 
leukocyte apoptosis (9, 10, 37). It is unlikely that GAG mediated cloaking of 
β-glucans plays a significant role in the differences in cytokine release by PBMCs 
observed in this study, as immunofluorescence studies using Fc-Dectin-1 showed 
no differences in the degree of β-glucan exposure between A. fumigatus, A. nidulans 
and the A. nidulans expressing increased amounts of GAG.  Similarly, no differences 
in the degree of cell injury were observed in PBMCs infected with A. fumigatus and 
A. nidulans.  
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SUPPLEMENTAL FILE
Table 1  Clinical characteristics of the chronic granulomatous disease patients
Patient Sex Age Disease history Active  
infection  
at time  
of exp.?
Interferon-γ  
at time  
of exp.?
Mutation
1 Male 16 Aspergillus fumigatus 
infection  
(at age 5 years), 
no inflammatory 
complications
No No CYBB 
(gp91-phox)
2 Male 9 Mucormycosis  
(at age of 10 months), 
no inflammatory 
complications
No No NCF1 
(p47-phox)
3 Male 9 No history of invasive 
fungal disease, 
no inflammatory 
complications
No No NCF1
(p47-phox)
4 Male 19 Aspergillus nidulans 
infection  
(at age of 5 years),  
A. fumigatus infection  
(8 years), no 
inflammatory 
complications
No Yes CYBB 
(gp91-phox)
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ABSTRACT
Invasive aspergillosis is a major threat to patients with chronic granulomatous 
disease (CGD). Fungal pathogenesis is the result of a diminished antifungal 
capacity and dysregulated inflammation. A deficient NADPH-oxidase complex 
results in  defective phagolysosomal alkalization. To investigate the contribution 
of defective pH regulation in phagocytes among patients with CGD during fungal 
pathogenesis, we evaluated the effect of the acidotropic, antimalarial drug 
chloroquine (CQ) on the antifungal capacity of polymorphonuclear cells (PMNs) 
and on the inflammatory response of peripheral blood mononuclear cells (PBMCs). 
Chloroquine exerted a direct pH-dependent antifungal effect on Aspergillus 
fumigatus and Aspergillus nidulans; it increased the antifungal activity of PMN from 
patients with CGD at a significantly lower concentration, compared with healthy 
individuals; and decreased the hyperinflammatory state of PBMCs from patients 
with CGD, as observed by decreased tumor necrosis factor α and interleukin 1β 
release. Chloroquine targets both limbs of fungal pathogenesis and might be of 
great value in the clearance of invasive aspergillosis in patients with CGD.
INTRODUCTION
Chronic granulomatous disease (CGD) is a rare inherited immunodeficiency 
disorder of the NADPH-oxidase complex. Patients are at increased risk of life- 
threatening invasive fungal infections, particularly invasive aspergillosis (1). 
Aspergillus fumigatus is the most commonly encountered species, followed by 
Aspergillus nidulans, with the former detected in approximately one-third of all 
cases of invasive aspergillosis in patients with CGD (2).  A. nidulans  causes invasive 
infections almost exclusively in this specific host and is characterized by its 
aggressive behavior and high case-fatality rate (3). Since the NADPH-oxidase 
complex acts both as an antimicrobial effector molecule and a regulator of 
inflammation, fungal pathogenesis in patients with CGD is the result of an 
imbalance of antifungal capacity and regulation of inflammation. The defective 
NADPH-oxidase complex results in a lack of superoxide production, an 
accumulation of protons, and impaired alkalization of the phagolysosomes. In the 
early 1980s, it was suggested that abnormal pH regulation within phagosomes 
from patients with CGD might have a role in defective killing capacities (4). The 
basis of this assumption is that the initiation of superoxide production is 
accompanied by an influx of K+ and a rise in pH as a result of the proton-acceptor 
function of superoxide anions. This pH change is proposed to be essential for the 
release and activation of granule-derived enzymes within the phagosome (5).  In 
patients with CGD, this pH dysregulation is of clinical importance, as supported 
by the fact that upon normalization of the phagocytic pH in CGD phagocytes, the 
ability to kill Staphylococcus aureus is restored (4). 
 In addition to this impaired antifungal defense system, the absence of the 
oxidative burst in phagocytes from patients with CGD leads to a dysregulated 
inflammatory response (6). Several studies indicate hyperresponsive production of 
tumor necrosis factor (TNF)-α and interleukin (IL)-6 in patients with CGD, both 
upon encountering A. fumigatus and without any obvious stimulus (6-8). The 
excessive inflammation is thought to play a role in the outcome of invasive 
aspergillosis in patients with CGD; limiting this exaggerated inflammatory 
response might decrease tissue damage and improve outcome. 
 The antimalarial drug chloroquine (CQ) is an acidotropic agent that passively 
diffuses into acidic organelles. It has shown to have a direct antifungal effect on 
Histoplasma capsulatum and Cryptococcus neoformans, possibly by accumulation in the 
fungal vacuole (9-11). CQ, being a weak base, is able to raise the endocytic and 
lysosomal pH of eukaryotic cells (12, 13). On entering the phagocytic cell, it diffuses 
into the acidic endosomes and can reach a concentration that is up to 10 000-fold 
higher than its extracellular levels (14). Earlier studies have shown that the 
addition of CQ to human mononuclear cells has an additive effect on the killing of 
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XTT assay
The XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-carboxanilide 
sodium salt) assay of fungal viability described previously was modified as follows 
(20). Each well of a 96-well plate was filled with 100 µl of CQ  (chloroquine 
diphosphate salt; Sigma-Aldrich, St. Louis, MO) in different concentrations and 100 
µl of live, resting conidia at concentrations of  2 x 106/ml. CQ was diluted in MilliQ 
and sterilized through a 0.2-mm filter membrane. Conidial viability was analyzed 
after 18 hours of incubation at 37°C in 5% CO2 (20). 
Effect of pH on the antifungal activity of CQ
To analyze the effect of pH on the antifungal activity of CQ, the pH of the medium 
was set at pH 6, pH 7 and pH 8. The medium containing different concentrations of 
CQ was buffered with 50 mM MES for pH 6, 50 mM HEPES for pH 7, and 50 mM Tris 
for pH 8. By titration of hydrochloric acid or sodium hydroxide the specific pH values 
were obtained. Each well of a 96-well plate was filled with 100 µl of CQ solution in 
buffered medium with different pH values and 100 µl of live, resting conidia at a 
concentration of 2 x 106 conidia/ml. Fungal damage was analyzed by the XTT assay. 
In addition, 100 µl of the supernatant was transferred to a new 96-well plate to 
determine effective maintenance of the pH value during the experiment. The OD of 
the supernatant was measured at 560 nm. Since the growth medium contains the 
acid-base indicator phenol red, the absorption properties of phenol red were 
correlated with the pH of the growth medium, as described by Lancz et al. (21). 
Antifungal activity of PMNs in the presence of CQ
Each well of a 96-well plate was filled with 100 µl of PMNs from healthy volunteers 
(hereafter, “healthy PMNs”) or patients with CGD (hereafter, “CGD PMNs”) at a 
concentration of 1 x 105 PMNs/ml. Cells were preincubated with 50 µl of CQ for 1 
hour to allow uptake of CQ, and 50 µl of live, resting  conidia at a concentration of 
4 x 106 conidia/ml. CQ concentrations of up to 100 µM (51.6 µg/ml) were evaluated 
based on the basis of the drug’s  correlation with the immunomodulatory 
therapeutic dosage of 400 mg daily given to patients with rheumatoid arthritis 
(22). After incubation for 18 hours, PMNs were lysed by addition of 100 µl of saponin 
0.005% for 30 minutes at 37 °C and underwent centrifugation at 3000 x g for 10 
minutes. Cell lysis was confirmed microscopically. Conidial viability was analyzed 
by the XTT assay. Wells containing PMNs or CQ alone were used as negative 
controls, while wells containing conidia alone were used as positive controls. 
Cytokine-stimulation assays
PBMCs from healthy volunteers (hereafter, “healthy PBMCs”) or from patients with 
CGD (hereafter, “CGD PBMCs”) were stimulated with LPS  (derived from Escherichia 
both H. capsulatum and C. neoformans (11, 15). In addition to the antifungal effect of 
CQ, this drug has been effective in the treatment of diseases associated with 
increased release of proinflammatory cytokines, such as rheumatoid arthritis (16). 
CQ is able to reduce the proinflammatory cytokine release of mononuclear 
phagocytes stimulated by lipopolysaccharide (LPS), and to antagonize TNF-α 
expression induced by fungi (such as C. neoformans and Candida albicans) by a 
mechanism suggested to be dependent on alkalization of endolysosomes (17-19). 
 To clarify the contribution of defective alkalization of phagolysosome during 
fungal pathogenesis in patients with CGD, we evaluated the in vitro effect of CQ 
on fungicidal effector mechanisms and cytokine release by phagocytes from 
healthy volunteers and patients with CGD stimulated with A. fumigatus and A. 
nidulans. We hypothesized that the addition of CQ would enhance the antifungal 
activity of phagocytes from patients with CGD by raising the pH in phagolysosomes 
and downregulating the exaggerated proinflammatory response. 
METHODS
Human leukocytes
Venous blood was drawn from healthy volunteers, three patient with CGD and 
gp91phox-deficiency and two patients with CGD and p47phox-deficiency after 
informed consent was obtained. Peripheral blood mononuclear cells (PBMCs) and 
polymorphonuclear leukocytes (PMNs) were isolated by use of Lymphoprep (Axis- 
Shield, Oslo, Norway). Briefly, blood was anticoagulated with lithium heparin (BD 
Vacutainer) and diluted with an equal volume of phosphate-buffered saline (PBS). 
The diluted blood was carefully added to the top of the Lymphoprep and centrifuged 
at 800 x g. PBMCs were harvested, washed twice in PBS, and counted by use of a 
hemocytometer. To remove the erythrocytes from the PMNs, the pellet was 
shocked at least twice with an ice-cold lysing reagent (NH4Cl, Na2EDTA, KHCO3). 
Subsequently, cells were washed and resuspended in PBS. Roswell Park Memorial 
Institute 1640 GlutaMAX-I medium (Invitrogen Life Technologies) plus 10% heat-in-
activated human serum was used as culture medium for all cell experiments.
Fungal strains
Fully molecularly characterized A. nidulans (V44-46) and A. fumigatus (V45-07) 
strains, originally isolated from patients with CGD who had invasive aspergillosis, 
were used. The Aspergillus spp. were grown and prepared in a LPS-free fashion as 
described previously (20). 
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 In a constant acidic environment (pH 6) no difference in fungal damage due to CQ 
was observed between the Aspergillus species (Figure 3A). However, increasing the 
pH of the medium to 8 resulted in more-exaggerated differences in the susceptibility 
coli serotype 055:B5; Sigma-Aldrich) after incubation for 1 hour with CQ at 
concentrations up to 100 µM. An extra LPS-purification step was performed before 
use (23). Each 96-well plate was filled with 100 µl of healthy or CGD PBMCs at a 
concentration of 1 x 106 PBMCs/ml. Fifty microliters of LPS were added to obtain a 
final concentration of 1 ng/ml.  The plates were incubated for 18 hours at 37 °C and 
centrifuged at 3000 x g. Finally, 180 µl of culture supernatant was removed for 
measurement of cytokines. TNF-α and interleukin 1β  (IL-1β) were measured by 
specific enzyme-linked immunosorbent assays (Sanquin Blood Supply, Amsterdam, 
the Netherlands, and R&D Systems, Oxon, United Kingdom), using specific monoclonal 
antibodies according to the manufacturer’s instruction. Wells containing only 
PBMCs were used as negative controls, and LPS-stimulated cytokine release without 
the addition of CQ was set to 100%. The release of lactate dehydrogenase was 
measured to assess cell viability for each condition.
Statistical analysis
Each experiment with human cells was performed in quadruplicate for the XTT 
assay and in duplicate for the cytokine stimulation assay. Mean values ± standard 
errors of the means were calculated for all of the experiments under the same 
conditions. Comparisons between > 2 mean values were analyzed by analysis of 
variance, using a Bonferroni-adjusted level of significance. P values of <0.05 were 
considered statistically significant.
RESULTS
CQ Has a direct antifungal activity against A. fumigatus and A. nidulans 
We first tested the direct antifungal activity of CQ at concentrations ranging from 
0.1 mM to 100 mM. We observed a direct dose-response relationship between CQ 
concentration and fungal damage for both Aspergillus species. A CQ concentration 
of ≥ 0.25 mM resulted in significant fungal damage of A. fumigatus (P < 0.0001), 
while fungal damage of A. nidulans occurred at ≥ 0.5 mM (P < 0.05), a two-fold higher 
concentration (Figure 1). There was significantly more damage to A. fumigatus than 
to A. nidulans (P < 0.0001) in the range of 0.25 mM – 1 mM CQ (Figure 1). 
Antifungal activity of CQ is pH dependent 
We next assessed the influence of the environmental pH on the antifungal activity 
of CQ. An alkaline environment (pH 8) increased the antifungal activity at a fixed 
concentration (10 mM) against A. fumigatus, as well as against A. nidulans (P < 0.0001) 
(Figure 2).
Figure 1 Antifungal activity of chloroquine assessed by the XTT assay. A chloroquine 
concentration of ≥ 0.25 mM has significant antifungal activity against Aspergillus 
fumigatus (P <0.0001). Significant fungal damage of Aspergillus nidulans occurred at a 
chloroquine concentration of ≥ 0.5 mM (P <0.05). A. fumigatus is more susceptible 
than A. nidulans to chloroquine concentrations of ≥ 0.25 mM to ≤ 1 mM. Error bars 
indicate standard error of the mean (n=12). * P <0.0001.
Figure 2 The antifungal activity of a fixed concentration ( 10mM) of chloroquine 
increases in an alkaline environment. An increase of fungal damage at pH 8 for 
Aspergillus fumigatus and Aspergillus nidulans was observed. Error bars indicate 
standard error of the mean (n=3). * P <0.0001.
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CQ Inhibits LPS-induced TNF-α and IL-1β release by healthy  
and CGD PBMCs  
To investigate the immunomodulating effect of CQ, we assessed its effect on 
cytokine release by PBMCs. We observed a higher LPS-induced release of TNF-α and 
IL-1β by CGD PBMCs compared to healthy PBMCs (data not shown). We showed a 
dose-dependent decrease of IL-1β release by healthy and CGD PBMCs at a CQ 
concentration of ≥ 5 µM (P < 0.0001). A decrease in TNF-α release by healthy PBMCs 
was observed in the presence of ≥ 10 µM CQ (P < 0.001), while higher concentrations 
of CQ (≥ 50 µM) were needed to inhibit TNF-α release by CGD PBMCs (P < 0.0001) 
(Figure 5). No loss of cell viability in the presence of the different concentrations of 
CQ used was observed, as indicated by lactate dehydrogenase concentrations in the 
media. These results are consistent with previous cell-viability studies (19, 24).
of the two species to CQ. A. fumigatus was significantly more susceptible to the 
antifungal effect of CQ than A. nidulans (P < 0.001) in a pH 8 environment (Figure 
3B). Changing the pH of the culture medium in the absence of CQ did not itself 
result in fungal damage (data not shown). Moreover, the pH of the growth media 
remained stable, with only very minor deviations (pH ± 0.3) over the incubation 
period in the different experiments performed (data not shown).
CQ Increases the antifungal activity of healthy and CGD PMNs
To further investigate the antifungal activity of CQ as a lysosomotropic and 
acidotropic agent, we assessed its effect in the presence of healthy and CGD PMNs. 
The addition of 100 µM CQ increased the antifungal activity of healthy PMNs 
against A. fumigatus by 75% (P < 0.05) (Figure 4A). The same trend was seen for A. 
nidulans, although these results were not significant (P = 0.23). Remarkably, a 20-fold 
lower concentration of CQ (5 µM) increased the antifungal activity of CGD PMNs 
against A. fumigatus by 63% (P < 0.0001) (Figure 4B). CQ did not influence the 
antifungal activity of CGD PMNs against A. nidulans.
Figure 3  Antifungal activity of chloroquine in media with different pH values. A, 
At pH 6, no significant difference in antifungal activity against Aspergillus fumigatus 
versus Aspergillus nidulans is seen. B, At pH 8, A. fumigatus is significantly more 
susceptible than A. nidulans to the antifungal activity of chloroquine. Error bars 
indicate standard error of the mean (n=3). * P <0.01, ** P <0.001.
Figure 4  The effect of chloroquine on the antifungal activity of polymorphonu-
clear leukocytes (PMNs) from healthy volunteers (hereafter, “healthy PMNs”) and 
PMNs from patients with chronic granulomatous disease (hereafter, “CGD PMNs”). 
Antifungal activity of PMNs without chloroquine was set to 1. Chloroquine 
increases the antifungal activity against A. fumigatus for  healthy PMNs at 100 µM 
(75% ± 31%; n=8; A) and for CGD PMNs at 5 µM (63% ± 10%; n=5; B). Error bars 
indicate standard error of the mean. *P <0.05. ** P <0.0001.
A
A
B
B
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observed in the presence of ≥ 5 µM  (P < 0.01) and ≥ 10 µM (P < 0.0001) CQ respectively, 
while higher concentrations of CQ (≥ 50 µM) were needed to significantly inhibit 
TNF-α and IL-1β  release by CGD PBMCs (P < 0.01 for both). In contrast, significant 
inhibition of TNF-α and IL-1β was already observed with 5 µM CQ upon A. nidulans 
infection of both healthy PBMCs (P < 0.01 and P < 0.0001, respectively) and CGD 
PMBCs (P < 0.05 and P < 0.0001, respectively).
CQ Inhibits A. fumigatus- and A. nidulans-induced TNF-α and IL-1β 
release by healthy and CGD PBMCs  
Finally we evaluated the fungal immunomodulatory potential of CQ by incubating 
A. fumigatus and A. nidulans conidia with healthy and CGD PBMCs. A. fumigatus and 
A. nidulans stimulation in the presence of CQ resulted in a dose-dependent decrease 
of TNF-α and IL-1β release by both healthy and CGD PBMCs (Figure 6). A significant 
decrease in A. fumigatus-induced TNF-α and IL-1β release by healthy PBMCs was 
Figure 5  The effect of chloroquine on cytokine release by peripheral blood 
mononuclear cells (PBMCs) from healthy volunteers (hereafter, “healthy PBMCs”) 
and PBMCs from patients with chronic granulomatous disease (hereafter, “CGD 
PBMCs”). Bars indicating 0 on the x-axis are lipopolysaccharide (LPS)-stimulated 
PBMCs without chloroquine. The LPS-stimulated cytokine release without 
chloroquine was set to 100%. Chloroquine reduces LPS-induced tumor necrosis 
factor α (TNF-α; A) and interleukin 1β (IL-1β; B) release by healthy PBMCs (n = 6). 
Chloroquine reduces IL-1β release by CGD PBMCs (n = 4–5; D), whereas higher 
concentrations are necessary to reduce the release of TNF-α (C). Error bars indicate 
standard error of the mean. *P < 0.001, **P < 0.0001.
Figure 6  The effect of chloroquine on cytokine release by peripheral blood 
mononuclear cells (PBMCs) from healthy volunteers (hereafter, “healthy PBMCs”) 
and PBMCs from patients with chronic granulomatous disease (hereafter, “CGD 
PBMCs”) after Aspergillus fumigatus and Aspergillus nidulans stimulation. Bars 
indicating 0 on the x-axis are PBMCs without chloroquine. The LPS-stimulated 
cytokine release without chloroquine was set to 100%. Chloroquine reduces A. 
fumigatus- and A. nidulans-induced tumor necrosis factor α (TNF-α; A) and interleukin 
1β (IL-1β; B) release by healthy PBMCs (n = 6; *P < 0.01, **P < 0.0001). Chloroquine 
reduces A. fumigatus- and A. nidulans-induced TNF-α (C) and IL-1β (D) release by CGD 
PBMCs (n = 3; *P < 0.05, **P < 0.01, ***P < 0.0001). Error bars indicate standard error 
of the mean.
A
A
C
C
B
B
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A. nidulans, but findings from study a study could strengthen this hypothesis. Once 
accumulated, CQ has an antifungal effect through yet unknown mechanisms. 
Differences in alkalization of the fungus or inhibition of the activity of proteins 
and enzymes may result in the different susceptibility between A. fumigatus and A. 
nidulans. Future research is required to investigate the mechanisms underlying the 
antifungal activity of CQ and the increased susceptibility of A. fumigatus, compared 
with A. nidulans.
 The next step was to investigate the additional antifungal activity of PMNs on 
Aspergillus species in the presence of CQ. We found an enhanced antifungal activity 
of both healthy and CGD PMNs. Remarkably, for healthy PMNs this increase 
occurred at 100 µM CQ, while for CGD PMNs this increase was already seen at 5 µM 
CQ, a 20-fold lower concentration. The absence of phagolysosomal alkalization in 
CGD PMNs might be responsible for an increased diffusion of CQ into the relative 
acidic environment of the CGD cell. Consequently, the same extracellular 
concentration of CQ would result in a higher intracellular concentration in the 
CGD PMNs as compared to the healthy PMNs, resulting in increased antifungal 
activity of CGD PMNs at lower CQ concentrations. 
 Lack of phagosomal alkalization in the CGD phagocytic cell is suggested to 
play a key role in the direct antimicrobial activities of the phagocyte. Reeves et al. 
demonstrated that killing activity of PMNs is not directly related to reactive 
oxygen species, but is mediated through activation of proteases by a K+ flux that 
crosses the membrane in a pH-dependent manner, followed by release and 
activation of granule-derived anti-microbial enzymes (5). Considering that one 
property of CQ involves alkalizing the neutrophil lysosome, it is suggested that CQ 
improves the antimicrobial function of neutrophils via pH change, mainly by 
non-oxidative mechanisms. The enhanced antifungal activity and the differences 
between healthy and CGD PMNs, suggest a clear relationship with the alkalizing 
properties of CQ. 
 An additional proposed mechanism of enhanced fungal killing through CQ is 
by limiting iron availability (28-30). Iron acquisition is critical for the survival of 
numerous pathogenic fungi in mammalian hosts (31). Siderophore-mediated iron 
uptake is essential to the survival of A. fumigatus and A. nidulans (32, 33). PMNs are 
able to provide iron uptake by the reduction of Fe3+, resulting in the release of iron 
from transferrin. Iron restriction has been proposed to cause increased antifungal 
activity of monocyte-derived macrophages against C. neoformans (11). Considering 
the iron-dependent survival of Aspergillus species, CQ might reduce its growth via 
restricting the iron release from transferrin of PMN. 
 Absence of the respiratory burst is associated with dysregulated cytokine 
production, resulting in more proinflammatory cytokine release, which further 
contributes to the pathogenesis of invasive aspergillosis in patients with CGD (8). 
DISCUSSION
In this study, we demonstrate that CQ has antifungal properties and downregulates 
the exaggerated proinflammatory cytokine response, as seen in CGD PBMCs. A direct 
antifungal effect of CQ on both A. fumigatus and A. nidulans was found.  This effect 
is enhanced in an alkaline environment. A. fumigatus is more susceptible than A. 
nidulans to CQ, and this difference is even more pronounced in an alkaline 
environment. Furthermore, CQ increases the antifungal activity of healthy and 
CGD PBMCs. Interestingly, this enhanced antifungal activity occurs at a significant 
lower CQ concentration in association with CGD PMNs as compared to healthy 
PMNs. Finally, CQ decreases both LPS-induced and A. fumigatus- and A. nidulans- 
induced release of TNF-α and IL-1β by healthy and CGD PBMCs.
 Previous studies showed accumulation of CQ into the acidic food vacuole of 
the parasite Plasmodium falciparum (25). Accumulation of quinacrine, an 
antiprotozoal drug like CQ, has been linked to its increased antifungal effect on C. 
neoformans (9, 10). Aspergillus species also contain acidic vacuoles (26), which are 
therefore a reasonable location for the accumulation of CQ. The accumulation of 
CQ or quinacrine in parasites and yeasts has been shown to be maximally enhanced 
in an alkaline environment and diminished in an acidic environment, as expected 
for a weak base (9, 25). 
 We observed a direct pH-dependent antifungal effect of CQ on both A. fumigatus 
and A. nidulans.  A higher extracellular pH resulted in increased fungal damage at 
a constant concentration of CQ, suggesting an increased diffusion rate of CQ into 
the fungal organisms. Direct antifungal activity of CQ against A. fumigatus conidia 
has only been investigated in a study evaluating the contribution of the pksP gene 
of A. fumigatus in intracellular processing of conidia. At a 6-hour timepoint, no 
effect on conidial viability was observed at CQ concentrations of ≤ 1 mM in a 
pH-neutral or acidic environment (27).  These data do not conflict with ours. Higher 
concentrations of CQ and an extended incubation period are needed to observe the 
antifungal effect, and an alkaline environment would lead to an increased 
antifungal activity of CQ at a given concentration. In an acidic environment, less 
CQ would diffuse into the Aspergillus species and, consequently, less killing would 
be observed.
 Interestingly, a higher concentration of CQ was necessary to cause fungal 
damage of A. nidulans. We hypothesize that the difference might be explained by 
two mechanisms: variation in diffusion rates of CQ into the fungus or/and different 
intracellular resistance against the activity of CQ. Since diffusion of CQ is pH 
dependent, a lower intracellular pH of A. fumigatus as compared to that for A. 
nidulans might result in different diffusion rates of CQ and, consequently, 
antifungal activity. No study has compared the intracellular pH of A. fumigatus and 
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Reactive oxygen species likely dampen inflammasome activation, and NADPH- 
oxidase complex defective PBMCs are a source of elevated IL-1β release (34, 35). 
Therefore, immunomodulating agents, besides antifungal treatment, that target 
the dampening of inflammation during invasive aspergillosis in patients with 
CGD may be worthwhile to explore. CQ is known for its immunomodulatory 
properties and is used in patients with rheumatoid arthritis and lupus (16, 36). 
Furthermore, CQ has been shown to antagonize the proinflammatory cytokine 
response to opportunistic fungi such as C. neoformans and C. albicans by alkalizing 
the fungal phagolysosome. The therapeutic efficiency of hydroxychloroquine was 
reported in treatment of granulomatous complications in CGD (37). Our results 
show that IL-1β and TNF-α release, upon stimulation with LPS and Aspergillus 
species, by both healthy and CGD PBMCs can be inhibited by CQ. Interestingly, 
during A. nidulans infection a significantly decrease of both TNF-α and IL-1β release 
by healthy and CGD PBMCs was already seen at lower concentrations, compared 
with observations during A. fumigatus infection.
 Jang et al. have studied the mechanisms by which CQ leads to a diminished 
TNF-α and IL-1β production in human monocytes and showed that different 
mechanisms were involved for specific cytokines (17). In LPS-stimulated monocytes, 
CQ blocks the conversion of cell-associated TNF-α precursor to mature soluble 
protein, whereas it reduced the levels of IL-1β messenger RNA, at least in part, by 
decreasing their stability and by a pH-dependent mechanism. The alkalizing effect 
of CQ as a weak base was a more important factor responsible for the decrease in 
IL-1β release, compared with TNF-α release. The more pronounced effect on IL-1β 
release might be especially beneficial in patients with CGD, since infection of 
human CGD leucocytes with A. fumigatus or A. nidulans leads to exaggerated IL-1β 
secretion. The increased immunomodulatory effect of CQ on A. nidulans-induced 
IL-1β release is remarkable, especially because we observed a significantly higher 
level of IL-1β release after infection with A. nidulans, compared with infection with 
A. fumigatus (unpublished data). Studies to unravel the IL-1β processing in patients 
with CGD infected by A. nidulans and A. fumigatus and the influence of CQ on this 
process are ongoing. 
 In summary, CQ has antifungal properties and dampens the inflammatory 
response of CGD cells in vitro. The antifungal activity of CQ might be beneficial in 
the clearance of fungal infections in patients with CGD. More importantly, the 
immunomodulating effect of CQ should be considered for dampening the hyper-
inflammatory state in patients with CGD, and thereby reducing their inflammatory 
complications and further improve life expectancy and quality of life. Future 
research is necessary to translate these promising findings to clinical practice.
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The aim of the studies presented in this thesis was to explore the unique host- 
pathogen interaction and pathogenicity of the generally considered non-pathogenic 
fungus Aspergillus nidulans in patients suffering from chronic granulomatous 
disease (CGD). CGD is a genetically heterogeneous disease caused by a defect in any 
of the five structural components of the nicotinamide adenine dinucleotide 
phosphate (NADPH)-oxidase complex. In vivo, the NADPH-oxidase is a critical regulator 
of the innate immunity. This thesis contributes to a further understanding of the 
central role of the NADPH-oxidase in fungal pathogenesis by detailed unravelling 
of the interplay between A. nidulans and the CGD host and opens a new dimension 
in treatment possibilities. 
The syndrome “fatal granulomatous disease of childhood” (1) was firstly described 
in 1957. Only 7 years later, and before the underlying cellular mechanism causing 
CGD was discovered, Redmond and colleagues published the first unique 
observation of A. nidulans infection causing fatal granulomatous pulmonary 
infection and extensive osteomyelitis in a 6-year old boy (2). It was Segal in 1998 
who recognized A. nidulans as a distinct, but frequently occurring pathogen in 
CGD and who made doctors aware that its isolation carries more severe implications 
than that of Aspergillus fumigatus (3). In the following years, epidemiological studies 
have further established the observation that A. nidulans is more frequently the 
causative agent of invasive aspergillosis in patients suffering from CGD compared 
to the classical risk group, the haemato-oncological patients during neutropenia. 
In view of such a particular observation, explanations might be found and 
hypotheses can be risen, taking into account 3 aspects relevant to the establishment 
and diagnosis of infection: (1) exposure, are there any differences in environmental 
factors and exposure to A. nidulans between these two groups; (2) identification, are 
there any differences in recovery and identification of A. nidulans from clinical 
samples from both patient groups in comparison with A. fumigatus; or, (3) host- 
pathogen interaction, is the higher incidence of A. nidulans infections in CGD 
patients explained by a specific defect in the innate immune system, resulting in 
a uniquely higher susceptibility of CGD patients for A. nidulans in addition compared 
to that for A. fumigatus. This point is the key-question addressed by this thesis in 
which we strengthen and add new insights to the hitherto accepted view on fungal 
pathogenesis in patients suffering from CGD. 
 Before discussing our recent in vitro observations concerning the unique 
interaction between A. nidulans and its preferred host, the CGD patient, the aspects 
of exposure (environmental epidemiology) and identification (diagnostic issues) 
need to be addressed. 
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the air is an important aspect in the care of both CGD and haemato-oncology 
patients. The CGD trust has developed specific recommendations to prevent exposure 
to fungal spores and thereby prevention of disease [http://www.cgdsociety.org].
 Occasionally, fungal spores are released in clouds, causing large variations in 
conidial counts. Construction works within a hospital building or on adjacent sites 
may consequently lead to micro-epidemics of invasive aspergillosis, but have never 
been observed to be caused by A. nidulans (17)[ http://www.outbreak-database.com].
 Unfortunately, no data is available about fungal colonization in the CGD host. 
Fungal respiratory tract colonization has been relatively frequently evaluated in 
the cystic fibrosis patient. Interestingly, A. nidulans is seldom reported. Of the 3336 
respiratory samples from 287 Danish CF patients, A. fumigatus was the most 
frequently isolated species in almost 40% while A. nidulans was isolated only twice 
(18). These results are coherent with those of the Dutch National Cystic Fibrosis 
Fungal Bank, which collects all fungal sputum isolates of CF patients in the 
Netherlands: only one A. nidulans isolate has been reported in the 4267 positive 
fungal sputum samples, while A. fumigatus was isolated in the majority of samples 
(2971 samples) (personal communication).  A study of fungal colonization in cattle 
and donkey handlers published in 1979 showed A. flavus being the pre-dominant 
species of pharyngeal colonization (11 isolates out of the 300 pharyngeal swabs), 
followed by A. fumigatus. A. nidulans was isolated once. Although no data could be 
retrieved about the A. nidulans air concentration, this study shows that in an 
environment of high fungal exposure, A. fumigatus is definitely more commonly 
isolated in healthy hosts compared to A. nidulans (19).
 In order to understand the process and relationship of exposure, colonization, 
infection and disease in the CGD host, longitudinal studies are needed, to test the 
hypothesis that Aspergillus species colonization is host-specific, and differs from 
what would have been anticipated from its profusion in the air (20).
 In conclusion, the CGD patient and the classical chemotherapy induced 
neutropenic host are exposed to the same environmental niche of Aspergillus spp. 
The distribution of A. nidulans in the environment is less than A. fumigatus. The 
exposure, qualitatively speaking, of both the CGD patient and the haemato-onco-
logical patient is the same. Quantitatively, there is a huge difference as the CGD 
patient has a lifelong exposure associated with a high risk developing invasive 
aspergillosis, compared to a relatively short exposure of the haemato-oncological 
host with neutropenia. More studies are needed to evaluate the role of the host 
environment of the lung in colonization and whether fungal colonization of the 
CGD lung is dominated by A. nidulans.
ENVIRONMENTAL EPIDEMIOLOGY
Aspergillus species are ubiquitous airborne saprophytic fungi. Their natural niche 
is the soil and decaying vegetation. Aspergillus spp. sporulate abundantly and 
environmental surveys indicate that all humans inhale at least several hundred 
Aspergillus conidia per day. Consequently, transmission by air is the main route of 
the conidia infecting the lungs. Information on the ‘normal’ conidial air load of 
non-fumigatus Aspergillus species is difficult to retrieve as most environmental surveys 
are focused on A. fumigatus due to its clinical relevance. In the few, geographically 
widespread studies, substantial variation and seasonality are noted. A study about 
environmental levels of Aspergillus spp. isolated in air samples in the province of 
Madrid, revealed A. fumigatus in 54% of the total Aspergillus isolates, compared to 
only 5% of A. nidulans (4). The investigation of airborne fungi inside and outside the 
homes of asthmatic children and control subjects in Delhi, India, showed a low 
overall prevalence of 11.0% and 8.2% respectively of Aspergillus species, with 
comparable A. nidulans and A. fumigatus occurrences (10% to 15% of the Aspergillus 
species recovered both indoor and outdoor) (5). In a study performed in Kolkata, 
India, evaluating the composition and variability of airborne fungal spores in an 
outdoor environment in Kolkata suburb, the predominant fungal genus was 
Aspergillus spp (40%) of which 20% was identified as A. fumigatus compared to 15% A. 
nidulans (6). These studies suggest that although important geographic variations 
exist in Aspergillus spp. airlevels, the environmental conidial concentration of A. 
nidulans is less than that of A. fumigatus. 
 The lifetime incidence of Aspergillus infections in CGD before the advent of 
specific antifungal prophylaxis varied between 25 and 40% (7, 8). In comparison, 
the incidence of invasive aspergillosis in children undergoing allogeneic haema- 
topoietic stem cell transplantation (HSCT) or those treated for an haematological 
malignancy varies between 2% and 16% (9-13).
  Aspergillus fumigatus is the most commonly isolated species in CGD, closely 
followed by A. nidulans. In the haemato-oncological patients, A. nidulans is rarely 
reported. CGD patients spend most of their lifetime outside of the hospital while 
haemato-oncological patients do spend a substantial amount of their ‘vulnerable’ 
time during their disease period in a hospital ward. The current recommendation 
for use of high efficiency air filters (HEPA) in bone marrow and haematology units 
reduces the risk of nosocomial aspergillosis to almost zero (14). Previous colonisation 
of the lower respiratory tract can lead to invasive pulmonary aspergillosis during 
hospital admission in haemato-oncology patients, as shown by Einsele and 
colleagues(15). This observation is coherent with molecular strain typing studies, 
indicating that a significant number of Aspergillus infections are acquired outside 
the health care setting (16). Prevention of exposure to abundant fungal spores in 
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accepted antimicrobial role of the NADPH-oxidase displaying a direct microbicidal 
activity by the resultant reactive oxygen species. 
 Activation of the NADPH-oxidase leads to the production of superoxide anions. 
Superoxide anions are unstable and will convert either spontaneously or by the 
superoxide dismutase enzyme to hydrogen peroxidase. Myeloperoxidase converts 
hydrogen peroxide in turn to the highly microbicidal hypochlorous acid. Myelop-
eroxidase (MPO) deficiency is common (1/2000-4000 in general population) but in 
contrast to CGD it is usually asymptomatic. Increased susceptibility to Candida 
infections may be observed (less than 5%), especially if other predisposing 
conditions such as diabetes are present (24). In MPO deficient mice, antifungal 
activity against Aspergillus spp. is only slightly impaired (24). In humans, no 
Aspergillus spp. infections in MPO deficient patients have been published. In 
contrast to the crucial role of the NADPH-oxidase and the production of superoxide 
anions itself, the microbicidal endproducts of MPO and SOD activity are redundant 
for normal fungal host-response in an otherwise healthy hosts. 
 Activated NADPH-oxidase is the major source for reactive oxygen species in 
phagocytes, but other ROS generating systems do exist. Mitochondria do have a 
respiratory chain. Question remains whether mitochondria can modulate host 
defence and whether a functional mitochondrial respiratory chain can contribute 
to the antimicrobial effector function of phagocytes. Wiese et al. showed that the 
mitochondrial respiratory chain contributed to the antimicrobial activity of 
macrophages to a different extent depending on the microbial species (E. coli versus 
S. aureus) (25). They found that the effect was independent of the phagocytic NADPH- 
oxidase or the inducible NO synthase, another reacting oxygen intermediate 
generating system. Furthermore, West et al. demonstrated that activation of 
specific toll-like receptors in macrophages leads to recruitment of mitochondria to 
phagosomes and to augmentation of mitochondrial reactive oxygen species 
production (26). These results suggest that mitochondrial ROS is an important 
component of species-specific antimicrobial responses and further establish 
mitochondria as hubs for innate immune signaling. The role of mitochondrial ROS 
in CGD acting as a fungicidal agent towards A. nidulans needs to be explored.
 Reactive oxygen species join nitrogen intermediate products, the result of 
inducible nitric oxide synthase pathway (iNOS), to form reactive metabolites like 
peroxynitrite anions, with highly microbicidal and inflammatory properties. In 
vitro, cell-free iNOS generating systems show to have antimicrobial properties 
against Burkholderia cepacia and Chromobacterium violaceum, both CGD pathogens. 
Peroxinitrite, the resultant of NO and superoxide anion, shows merely fungistatic 
properties against Aspergillus spp. but is candidacidal (27). In human iNOS 
deficiency has not yet been demonstrated. Knockout mice lacking iNOS have 
increased susceptibility to various infections, including Mycobacterium tuberculosis, 
DIFFERENCES IN IDENTIFICATION
The second suggestion for the unique epidemiological observation of A. nidulans in 
the CGD host, is that invasive diagnostic measures and consequently the recovery 
and identification of A. nidulans is less feasible in other risk groups.
 The reported proportion of proven invasive fungal infection (IFI) versus 
probable and possible disease, as defined by the EORTC/MSG criteria (21) applying 
to patients with cancer, is in patients suffering from chronic granulomatous 
disease disproportionally high. In our literature review (chapter 2) we described 
116 CGD patients with invasive fungal disease of which more than 90% were 
proven infections (22). Invasive fungal infection among transplant patients as 
reported in The Transplant-Associated Infection Surveillance Network (TRANSNET) 
showed that in the cohort of 2001-2006, only 42% of the IFI were proven (23).  The 
question may be asked if among those probable infections, the incidence of 
non-fumigatus Aspergillus species, including A. nidulans is substantially higher. 
Although we cannot verify this, the distinct clinical phenotypes of invasive 
aspergillosis caused by A. nidulans compared to A. fumigatus in the CGD host clearly 
points out to a unique host-pathogen interaction rather than an external factor as 
possible differences in recovery and identification. We conclude that, although 
clear reporting biases exist, the differences in recovery and identification are not 
the explanation of the disproportionally high prevalence of A. nidulans infections 
in CGD patients.
HOST-PATHOGEN INTERACTION
The key question addressing the specific immune defect of the CGD host and its 
susceptibility to A. nidulans is the central theme of this thesis: in particular, is the 
higher incidence of A. nidulans infections in the CGD patients explained by the 
absence of the NADPH-oxidase complex, which would have more consequences, 
direct or indirect for an efficient host defence against A. nidulans compared to A. 
fumigatus? 
The NADPH-oxidase as antimicrobial effector complex
The mechanisms by which the NADPH-oxidase and it metabolites kill pathogens 
are complex and incompletely understood. We concluded in chapter 3 that the 
antifungal effector mechanisms against A. nidulans are distinctive from those 
against A. fumigatus and, surprisingly, that human leucocytes without a functional 
NADPH-oxidase efficiently kill A. nidulans suggesting fungicidal activity by NADPH- 
independent mechanism. These important findings are in contrast to the hitherto 
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than a distinct clinical characteristic of the CGD patient e.g. as sterile colitis or 
granulomata formation. 
 Dysregulation of the L-tryptophan metabolism in mice with defects in NADPH 
oxidase, resulting in overproduction of interleukin-17, has been proposed to link 
ROS defects with hyperinflammation and susceptibility to pulmonary aspergillosis 
(34). In this thesis we assessed the L-tryptophan metabolism and cytokine profiles 
in response to different fungal pathogens in CGD patients. We show that CGD 
patients display a normal L-tryptophan metabolism and although PBMCs of CGD 
patients produce more proinflammatory cytokines after stimulation, fungal 
(Candida albicans, A. fumigatus and A. nidulans) induced IL-17A production is strikingly 
low compared with healthy controls. Mitogenic stimulation of T-cells isolated from 
CGD patients did not result in an impaired IL-17 production supporting a pathogen 
specific mechanism. At present, it is not clear if the impaired IL-17 response to 
fungal pathogens in CGD patients plays an additional role in the occurrence and 
pathogenesis of invasive fungal infections.  
 The recurrent mucosal Candida infections in patients with primary immuno-
deficiency syndromes like hyper-IgE syndrome (HIES) and chronic mucocutaneous 
candidiasis (CMC) have been specifically linked to a deficiency in the Th17 response. 
Current knowledge points to a differential role of IL-17: it is of importance in the 
resistance to mucocutaneous fungal infections, but in invasive fungal infections it 
is less well defined. Further studies are needed to unravel the exact mechanisms 
by which the lower IL-17 production contributes to the increased susceptibility of 
the human CGD host to invasive Aspergillus infections. Influence on the microbiome 
and colonisation pattern, and in turn the effect of the microbiome on the host 
defence, as shown for CMC and HIES (35), both characterized by impaired Th17 
responses, is an interesting concept. Further attention may be given to the role of 
IL-17 in maintaining mucosal barrier integrity in the lung and protection to 
pathogenic insults through preserving tissue integrity by enhancing synthesis of 
tight junction proteins (36). It is an attracting hypothesis that a first hit is needed, 
before A. nidulans becomes invasive. Old studies in plant pathology support this 
hypothesis (37). Another mechanism of the protective effect of IL-17 is the induction 
of antimicrobial peptides secreted by bronchial epithelial cells such as β-defensins, 
which in turn have been shown to exert Aspergillus spp. specific activities (38, 39). 
Inversely, studying the direct effect of IL-17 on the fungi itself is an intriguing 
topic. IL-17 is able to bind on the conidial surfaces, in a way of “sensing host 
immunity” followed by significant interference on host-pathogen interplay by 
affecting fungal morphology and virulence (40). 
 The observed hyperinflammatory phenotype of the CGD patient is thought to 
be the consequence of the absence of ROS-mediated downregulation of intracellular 
signalling pathways and inflammatory cell recruitment. One could argue that any 
Leishmania spp. and Salmonella enterica. iNOS deficient mice are resistant to 
candidiasis. The role of iNOS in invasive aspergillosis has not been studied so far. 
Mice deficient in both NADPH oxidase and iNOS activities are far more susceptible 
to infections than single gene-deficient host models, which supports distinct but 
interacting roles of these two pathways (28). As such, mice deficient in iNOS and 
for phagocyte oxidase (gp91phox) show increased susceptibility to candidiasis, 
however, this was not related to decreased killing ability but to excessive 
inflammation (29). Overall, unraveling the contribution of nitrogen intermediate 
products and mitochondrial reactive oxygen species in fungal pathogenesis of the 
CGD host seems a challenging future research topic. 
 Beyond the direct microbicidal acitivity of the products of the NADPH-oxidase, its 
activation is coupled to extra- and intracellular release of preformed antimicrobial 
proteases. Adequate phagolysosomal alkalization and the pH-dependent compensatory 
potassium surge across the vacuolar membrane are essential steps for the release 
and activation of cationic granule proteins from the anionic sulfated proteoglycan 
matrix (30). Results of in vitro studies and murine studies are currently conflicting 
about the exact role of the absent NADPH-oxidase function and its relation with a 
defective alkalization and absent potassium influx in the microbial pathogenesis. 
The absence of the rodlet layer, a process occurring during germination, resulted 
for A. nidulans, in contrast to A. fumigatus, in the induction of a basic character, a 
marked decrease in hydrophobicity and in electronegativity of conidia (31). 
Question is whether this might be responsible for the conserved killing ability of 
the CGD phagocytic cell towards A. nidulans, through binding of the cationic 
granule proteins on the remaining negatively charged A. nidulans. 
 Neutrophil NADPH oxidase activation is linked to extracellular release of 
granule proteins, DNA and chromatin forming the neutrophil extracellular traps 
(NETs). NETs target fungi in a nonspecific way and its role in arresting fungal 
growth, fungal killing or protecting the fungi against further neutrophil attack is 
still under debate.  Reconstitution of the NADPH-oxidase activity by gene therapy 
resulted in a restored protection against A. nidulans infections (32). The authors 
linked this effect to the restoration of the NET formation by calprotectin-mediated 
mechanisms. Question remains whether reconstitution of other NADPH-dependent 
mechanisms, such as direct effects or indirectly via IDO activity, autophagy 
or counteracting the hyperinflammation, rather than the restoration of the 
capability of NET formation, will lead to resistance against Aspergillus infections 
(33).
The NADPH-oxidase as regulator of inflammation
In chapter 4 we strengthen the hypothesis that hyperinflammation is a major 
accomplice in the pathogenesis of invasive aspergillosis in the CGD host rather 
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THE PATHOGEN
In this thesis, we investigated the host-immune interaction between A. nidulans 
compared to A. fumigatus and polymorphonuclear cells or PBMCs of patients 
suffering from CGD. Most of current knowledge on fungal host-pathogenesis with 
regard to inflammatory responses is based on infection models with inactivated, 
e.g heat-killed or formaldehyde inactivated, microorganisms. Use of fixed, killed 
conidia and or hyphae gives the researcher the possibility to study static 
interactions between the host and the pathogen. Inactivated pathogens have been 
taken as inert opponents full of PAMPs. This is a rather unidirectional view on the 
host-pathogen “interaction” in which we evaluate in a controlled way the effect of 
the pathogen, in a fixed state of his development, on the immune system. It 
completely ignores the influence of the immune system on the pathogen and how 
the pathogen itself is able to counteract the “attack” of the immune system. 
 In vivo, resting conidia are metabolically quiescent. Once they are in a suitable 
environment swelling of the conidia begins within hours and is followed by the 
germination and elongation of hyphae. The conidial maturation triggers a 
profound morphological change that involves the loss of the proteinaceous 
hydrophobic layer and the exposure of the inner cell wall. This cell wall is 
composed mainly of polysaccharides consisting of b-glucan, mannan, chitin and 
galactomannan (42). It is important to recognize that the morphological state of 
the Aspergillus spp. is critical to its recognition by the host. Our in vitro observations 
of fungal growth show a substantially slower germination rate of A. fumigatus 
(1x10*6/ml at 8h shows 20-30% germination, with hyphal length ranging from 8.7 
to 11.6 mm) compared to A. nidulans (1x10*6/ml at 8h shows > 90% germination with 
hyphal length ranging from 17.4 to 46,4 mm). Striking differences in individual 
cell wall, which may become significant in host recognition and host defence as 
indicated in our study, do exist. A. nidulans and A. fumigatus conidia are covered by 
a different melanin type, and their rodlet layer and individual sugar cell-wall 
polysaccharide composition differ (43-45). Nevertheless, hardly any data is 
available about the individual PAMPs present on those two Aspergillus species 
playing a role in the host-pathogen interaction.
 From the host site of view, reactive oxygen species play important roles in 
antimicrobial killing, in signalling and in regulation of inflammatory processes. 
But from the pathogen’s perspective, ROS do trigger oxidative stress responses and 
regulate morphogenesis in fungal cells, which in turn might have huge 
implications in the pathogenesis. Candida albicans morphology has been shown to 
be influenced by hydrogen peroxide, and intracellular ROS is important for 
maintaining polarized growth of A. nidulans (46). As fungal growth and 
morphogenesis are crucial steps in host-pathogen recognition, to understand the 
foreign stimulus would exacerbate this phenotype. Our results show that A. 
nidulans induces a significantly higher inflammatory response compared to A. 
fumigatus, which is characterized by an exaggerated release of IL-1β and TNF-α 
(chapter 6 in this thesis). By analysing different cell wall components obtained 
from both A. fumigatus and A. nidulans and comparing their ability to stimulate 
cytokine release, we were able to show that the unique polysaccharide cell wall 
composition of A. nidulans is responsible for the observed effect. 
 Differences in immunomodulatory cell-wall components as galactosaminoga-
lactan, hydrophobic rodlet layers and their biochemical properties differentially 
influence the host-pathogen interface of A. nidulans and A. fumigatus in front of CGD 
host cells. We suggest that the decreased galactosaminogalactan content in the A. 
nidulans cell wall, which is a known immune-suppressive polysaccharide of A. 
fumigatus, is responsible for the exaggerated inflammatory response. Investigation 
of the influence of individual polysaccharides, or the expression of other pathogen 
associated molecular patterns (PAMPs) by the individual Aspergillus species, and 
investigation of the differences in pathogen recognition receptor (PRR) expression 
between healthy and CGD cells is a crucial next step to take. The observation of a 
higher pro-inflammatory cytokine release by A. nidulans in the CGD host is robust 
and persistent. Hyperinflammation is the Achilles tendon of the CGD host, and 
invasive A. nidulans infections in the CGD host seem to be much more the result of 
host damage due to exaggerated host response rather than a defective clearing of 
the pathogen. These findings do have major implications in the direction of new 
treatment strategies. They need to target the dysregulated inflammation being at 
least partly responsible for the induced host damage and detrimental outcome of 
invasive A. nidulans infections in CGD host.
 We show that the hyperinflammation induced by A. nidulans is IL-1β mediated. 
Further studies are needed to unravel the IL-1β processing in patients with CGD 
infected by A. nidulans and A. fumigatus. Preliminary data indicate post-transcrip-
tional differences in pro-IL-1β processing between A. nidulans and A. fumigatus. 
IL-1β-dependent mechanisms, such as decreased autophagy and increased 
inflammasome activation, are linked to the pathological conditions in CGD and 
may play a role in the pathogenesis of invasive aspergillosis in CGD. The improved 
insight in the molecular pathophysiology has provided us, and others, with new 
targets for treatment.  The alkalizing effect of the old malarian drug chloroquine, 
being a weak base, and its well-known immunomodulating effect as observed in 
patients with rheumatoid arthritis, led us to investigate its effect on the hyperin-
flammation caused by A. nidulans. We observed a potent decrease of the fungal 
induced IL-1β release. Others have shown that the decreased autophagy and 
increased inflammasome activitation can be restored by IL-1β receptor blockade in 
CGD patients (41). 
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disease (53) probably by reduction of the inflammatory mediators implicated in 
the granuloma formation. Moreover, in contrast to corticosteroids commonly used 
in the treatment of granulomata, hydroxychloroquine is a drug that does not 
increase the risk of infectious adverse events. It is definitely worthwhile further 
studying the role of chloroquine, and other chloroquine compounds, as a prophylactic 
drug in chronic granulomatous disease as it harbours a great potential targeting 
both infectious and inflammatory complications.
 In line with the above-mentioned concept, the next step is the evaluation of 
IL-1β receptor blocking, e.g. Anakinra®, as adjuvant treatment during invasive A. 
nidulans infections in the CGD patient. Beneficial effects of blocking IL-1b by 
dampening the inflammasome activation and restoring the defective autophagy, 
have been observed in patients suffering from CGD colitis treated with the IL-1R 
antagonist Anakinra® (41). The possible beneficial role of IL-1R blocking as 
additional immunomodulatory treatment in invasive aspergillosis, specifically 
due to A. nidulans, is an intriguing domain of further research.
 To date, haematopoietic stem-cell transplantation (HSCT) is the only curative 
option for patient with chronic granulomatous disease (54), and has also been used 
to treat refractory invasive fungal infections in CGD with variable outcome (55). 
The complexities of the clinical phenotype of chronic granulomatous disease, on one 
hand, and the perceived and real risks associated with HSCT, on the other, have 
prevented many patients with this devastating disease from getting this curative 
treatment. Gene therapy, looking promising in several single gene primary immu-
nodeficiencies such as severe combined immunodeficiencies (SCID), is currently 
not an available treatment option due to the need for improved and safer vectors. 
Although functional correction of only a minor fraction of cells (approximately 
10%) provides complete clinical protection, as learned from many X-linked CGD 
carriers, the absence of growth or survival advantage of the transduced stem cells 
in the marrow or in the tissue is a great point of concern as well (56). 
 As long as a cure is not feasible for the majority of the patients with CGD, 
supportive treatment, e.g. the management of invasive fungal complications, the 
main cause of premature death in CGD patients, needs to be improved. 
CONCLUSION
The studies presented in this thesis have provided us with new insights in the 
understanding of invasive aspergillosis in the CGD patient and have opened new 
avenues in the treatment of those, often fatal, fungal infections.
 More specifically, the absence of a functional NADPH-oxidase leads to 
exaggerated inflammation and harmful IL-1β release while fungal killing is only 
virulence of A. nidulans in the CGD host, more research is needed to understand the 
ability and how those fungi react to these different oxidative stress responses. 
Infections by opportunistic fungi have traditionally been viewed as microbial 
insults towards a weakened host. Fungal sensing of a host’s immune environment 
might render this process more elaborate than previously thought. Studying the 
pathogen’s response to being recognized by the host cells, e.g. the ability to respond 
to antifungal mechanisms by the host, will create insights into new and potentially 
important dimensions of the specific host-pathogen interaction.
NEW TREATMENT STRATEGIES
Ultimately, an improved insight in molecular interaction of Aspergillus species and 
CGD host should result in the design of new management strategies.
 Up to now, the treatment guidelines for haemato-oncology patients with 
invasive aspergillosis can be followed in patients with CGD keeping in mind that 
non-fumigatus Aspergillus species, like A. nidulans, may require a different antifungal 
treatment (31, 47). The use of adjunctive immunomodulatory treatment options as 
INF-g and granulocyte transfusions, while conceptually robust in CGD, is unproven 
and remains anecdotal (48-50). In this thesis we concluded that A. nidulans 
pathogenicity and disease is the result of imbalanced inflammation rather than 
impaired direct antifungal host mechanisms. Consequently, medical treatments 
aiming at killing the fungus (e.g. anti-fungal drugs) are expected to incompletely 
target the disease process. In chapter 7 we translated our new insights into the 
pathogenesis of A. nidulans infections in the CGD host into promising new 
treatment options. We show that the old malarial drug chloroquine has antifungal 
properties and dampens the inflammatory response of CGD cells in vitro. 
Chloroquine targets both limps of fungal pathogenesis and may be of great value 
in the treatment of invasive aspergillosis in patients with CGD. A first step in 
implementation of these findings is the evaluation of antifungal and anti-inflam-
matory potential of the less toxic compounds e.g. hydroxychloroquine. Prolonged 
treatment with chloroquine has been complicated by severe retinopathy. Hydroxy-
chloroquine is an antimalarial agent licensed for the treatment of rheumatoid 
arthritis juvenile idiopathic arthritis, discoid and systemic lupus erythematosus. 
It is reported as being half as toxic as chloroquine, yet equally active against 
Plasmodium falciparum (51, 52). The in vivo studies aiming at implementation of the 
beneficial use of chloroquine in the CGD host need to focus on chloroquine as 
adjuvant therapy during invasive fungal infections in the CGD patient, as well as 
on its use as a prophylactic drug. Hydroxychloroquine shows to be of promising 
value in the treatment of granulomatous complications in chronic granulomatous 
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slightly impaired. These results shed new light on the hitherto paradigm that the 
CGD host is not able to efficiently kill Aspergillus spp.. Mechanisms responsible for 
fungicidal activity in the CGD host need to be explored in more detail, as well as 
the mechanisms leading to the observed hyperinflammation. Differential PAMPs 
on A. nidulans and A. fumigatus recognized by as yet unknown PRRs on the CGD 
phagocytes need to be assessed in association with intracellular signalling 
pathways.  
 These new findings point to a novel strategy for the prevention and treatment 
of invasive fungal infections in the CGD host. New treatment strategies need to be 
viewed in terms of targeting aberrant and inefficient consequences of the host 
response rather than the pathogen itself. In this regard, chloroquine and IL-1β 
blockade in addition to the classical antifungal drugs may prove to be potent 
additional regulators, capable of dampening the excessive inflammatory response 
in addition to the beneficial eradication of A. nidulans by NADPH-oxidase 
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be modified by chloroquine and IL-1β blockade and its influence on the pathophys-
iology are needed.
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SUMMARY
INTRODUCTION
Invasive fungal infections are a major treat for patients suffering from chronic 
granulomatous disease (CGD). Chronic granulomatous disease is a primary immuno-
deficiency characterized by the highest lifetime incidence of invasive aspergillosis 
among all immunocompromised patients. It is a genetically heterogeneous disease 
caused by a defect of the nicotinamide adenine dinucleotide phosphate-oxidase 
(NADPH-oxidase) system in which phagocytes fail to produce the microbicidal 
reactive oxidant superoxide anion and it metabolites. The NADPH-oxidase is a key 
complex in the innate immunity and plays an essential role as antimicrobial 
effector complex and as regulator of inflammation. Clinically, as a result of the 
defect in this key innate host defence pathway, CGD patients suffer from recurrent 
life-threatening bacterial and fungal infections and inflammatory sequellae 
leading to granulomata formation. The life-time incidence of invasive fungal 
infections in children with CGD varies between 25% and 40%, and is the major 
cause of premature death. 
 The basis of the fundamental research work presented in this thesis is the 
observation of the unique epidemiology of invasive fungal infections in patients 
suffering from CGD. Aspergillus fumigatus is the most commonly encountered 
species. Interestingly, Aspergillus (Emericella) nidulans is the second most isolated 
species and is seldom reported to cause disease in other immunocompromised 
patients, indicating a unique interaction between this fungus and the CGD host. 
Furthermore, A. nidulans infections in the CGD host are more virulent and 
associated with a five-to ten-fold higher mortality rate compared to invasive 
infections caused by A. fumigatus. 
 The aim of my research was to explore the unique host-pathogen interaction 
between A. nidulans and patients suffering from CGD. The studies presented in this 
thesis addresses the following research-questions:
· Is the incidence of A. nidulans infections in the CGD patient explained by the 
presence of specific defects in the innate immune system, resulting in the higher 
susceptibility for invasive infections caused by A. nidulans. 
· What are the direct and indirect consequences on anti-fungal effector mechanisms 
against A. nidulans and A. fumigatus of a deficient NADPH-oxidase complex. 
· What is the mechanism of the dysregulated inflammation and how does this 
contribute to the pathogenesis of species-specific invasive Aspergillus infections 
in the CGD host.
·	 And ultimately, it is possible to translate the improved insight in the molecular 
interaction between Aspergillus species and the CGD host into the design of new 
management strategies.
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 As the obtained results so far, shed new light on the pathogenesis of Aspergillus 
infections in CGD host, we summarized our current insights in the position paper 
entitled “Aspergillus nidulans and chronic granulomatous disease: a unique host- 
pathogen interaction” (chapter 5). This paper intends to direct further research by 
indication the gaps in current knowledge and to guide optimal treatment 
strategies. 
 In chapter 6 we evaluated the role of the individual cell-wall composition of A. 
nidulans compared to A. fumigatus and hypothesized that differences in cell-wall 
components could lead to differences in recognition and pro-inflammatory 
cytokine release.  CGD patients displayed evidence for a chronic hyperinflammatory 
state as indicated by elevated plasma IL-1β and TNF-α. Peripheral blood monocytes 
from CGD patients secreted higher levels of IL-1b and TNF-α in response to A. 
nidulans compared to A. fumigatus. The presence or absence of melanin in the cell 
wall of A. nidulans did not alter the cytokine release by healthy or CGD blood 
mononuclear cells. Purified cell wall polysaccharides of A. nidulans induced a much 
higher level of IL-1β secretion by CGD blood mononuclear cells than did cell wall 
polysaccharides isolated from A. fumigatus. Using modified A. nidulans strains 
overexpressing galactosaminogalactan, we were able to show that the increased 
secretion of inflammatory cytokines by CGD blood mononuclear cells in response 
to A. nidulans are a consequence of low levels of cell-wall associated galactosamino-
galactan. 
 Based on the above-described new insight in host-pathogen interaction of 
Aspergillus species, more precisely the interaction between A. nidulans and its 
preferred host the CGD patient, new treatment strategies for invasive aspergillosis 
in CGD should target the dysregulated inflammation in addition to fungicidal 
agents. In chapter 7, we showed that an ‘old drug’, chloroquine, might become of 
great importance in the treatment of invasive aspergillosis in patients suffering 
from CGD. The antimalarial drug chloroquine (CQ) is an acidotropic agent that 
passively diffuses and accumulates into acidic organelles.
 Beyond its known antimalarial potential, CQ has shown to have a direct 
antifungal effect (Histoplasma capsulatum, Cryptococcus neoformans) and has been 
effective in the treatment of diseases associated with increased release of pro- 
inflammatory cytokines such as rheumatoid arthritis.
 We hypothesized that the addition of CQ would enhance the antifungal 
activity of phagocytes from patients with CGD by increasing the phagolysosomal pH 
and by downregulating the exaggerated proinflammatory response. Chloroquine 
exerted a direct pH-dependent antifungal effect on A. fumigatus and A. nidulans and 
increased the antifungal activity of CGD neutrophils at a significantly lower 
concentration compared with the healthy neutrophils. In addition, CQ decreased 
the TNF-α and IL-1β release after infection with A. nidulans and A. fumigatus. 
RESULTS
In chapter 2, a general introduction is given in the form of a comprehensive review 
on the current understanding of epidemiological data, mycological characteriza-
tion and identification, clinical manifestations, diagnostic features and therapeutic 
strategies of all invasive fungal infections in patients with CGD.
 In chapter 3, we investigated the involvement of the NADPH-oxidase and the 
resulting reactive oxygen species (ROS) in antifungal host defence focussed on 
differences between A. fumigatus and A. nidulans. In contrast with current concepts, 
we showed that A. nidulans, in contrast to A. fumigatus, is not susceptible to the 
direct antimicrobial effect of ROS. Stimulation of healthy peripheral blood 
leukocytes with live A. nidulans did not result in any measurable ROS release, this 
in contrast to live A. fumigatus. Evaluating the ability of the phagocytic cells to 
inhibit fungal germination showed that human CGD leukocytes and murine CGD 
alveolar macrophages were at least equipotent at arresting conidial germination 
compared to healthy controls. Blocking of the NADPH-oxidase resulted in 
significantly reduced damage of A. fumigatus but did not affect the damage to A. 
nidulans hyphae. Furthermore, the microbicidal activity of CGD neutrophils was 
maintained toward A. nidulans but not A. fumigatus. These in-vitro studies show that 
antifungal resistance to A. nidulans is not directly ROS related and as a consequence, 
the etiology of A. nidulans infections in CGD cannot be explained by the simple 
absence of the direct microbicidal effect of ROS. 
 The results of the investigations on the role of the NADPH-oxidase complex in 
intracellular pathway signalling are described in chapter 4. In CGD mice, 
dysregulation of the L-tryptophan metabolism resulting in overproduction of 
interleukin-17 has been proposed to link ROS defects with hyperinflammation 
and susceptibility to pulmonary aspergillosis. We showed that, in contrast to CGD 
mice, A. fumigatus and A. nidulans induced interleukin-17 production by CGD blood 
mononuclear cells was strikingly low compared to healthy controls. Reactive 
oxygen species can act as co-factors for the catabolic indoleamine 2,3-dioxygenase 
enzyme (IDO). IDO is a rate-limiting enzyme of the L-tryptophan metabolism. 
Assessment of the L-tryptophan metabolism showed that the indoleamine 2,3-
dioxygenase enzyme expression was similar in blood mononuclear cells and 
neutrophils from CGD patients compared with healthy controls. Conversion of 
L-tryptophan to L-kynurenine, mediated by IDO, did not differ between CGD 
patients and healthy controls. Moreover, adding L-kynurenine to the cell cultures 
did not suppress fungal-induced interleukin-17 production. We concluded that in 
contrast to the mouse model, CGD patients do not display a defective L-tryptophan 
metabolism to explain their hyperinflammation and fungal susceptibility. 
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INTRODUCTIE
Invasieve schimmelinfecties vormen een ernstige bedreiging voor patiënten met 
chronische granulomateuze ziekte (CGD). Chronische granulomateuze ziekte is 
een genetisch heterogene ziekte veroorzaakt door een stoornis in het nicotinamide 
adenine dinucleotide fosfaat-oxidase (NADPH-oxidase) waardoor geen superoxide, 
en de hieraan gerelateerde zuurstofradicalen, geproduceerd worden. Het NADPH- 
oxidase is een sleutel-complex in de aangeboren immuniteit en speelt een centrale 
rol als antimicrobiële effector, en als regulator van de inflammatie. Klinisch zijn 
deze patiënten dan ook gekenmerkt door zowel invasieve bacteriële en schimmel-
infecties, als door gestoorde ontstekingsreacties leidend tot granulomen. De ‘lifetime’ 
incidentie van invasieve aspergillosis in patiënten met CGD varieert tussen de 
25% en de 50%, en is de belangrijkste oorzaak van vroegtijdig overlijden. 
 De aanleiding van het fundamentele onderzoek leidend tot de kern van dit 
proefschrift is de observatie van een unieke epidemiologie van invasieve schim-
melinfecties in CGD patiënten. Aspergillus fumigatus is globaal gezien de meest 
frequente verwekker van invasieve filamenteuze schimmelinfecties. Opmerkelijk 
is het feit dat in de CGD patiënt, Aspergillus (Emericella) nidulans de tweede meest 
voorkomende schimmel is, dit in tegenstelling tot het ogenschijnlijke non-virulente 
karakter in de hemato-oncologische patiënt waarbij infecties door A. nidulans slechts 
zeer sporadisch gerapporteerd zijn. Naast het uniek voorkomen van A. nidulans in 
deze gastheer, zijn deze infecties gekenmerkt door hun agressief karakter met 
uitgebreide weefseldestructie van de omliggende weefsels. De mortaliteit van 
invasive aspergillose veroorzaakt door A. nidulans is een vijf- tot tienvoud hoger 
dan invasieve infecties veroorzaakt door A. fumigatus. 
 Het doel van dit onderzoek was het ontrafelen van de unieke gastheer- 
pathogeen interactie tussen A. nidulans en patiënten met CGD. De studies beschreven 
in dit proefschrift omvatten de volgende fundamentele onderzoeksvraag-
stellingen: 
· Kan de hogere incidentie van A. nidulans infecties in CGD patiënten verklaard 
worden door het feit dat het specifieke defect in de aangeboren immuniteit meer 
consequenties heeft voor een efficiënte afweerreactie ten aanzien van A. nidulans 
in vergelijking met A. fumigatus? 
· Wat is de rol van het deficiënte NADPH-oxidase als directe en indirecte anti- 
microbiële effector in de afweer tegen A. nidulans en A. fumigatus? 
· Wat is het onderliggende mechanisme van de gedysreguleerde inflammatoire 
respons, en hoe beïnvloed dit de species-specifieke pathogenese van invasieve 
Aspergillus infecties in CGD? 
Significant inhibition of the A. nidulans-induced TNF-β and IL-1β release was 
reached in a ten-fold lower concentration of CQ compared to A. fumigatus-induced 
release. In conclusion, CQ targets both limbs of fungal pathogenesis and might be 
of great value in the clearance of invasive apsergillosis in patients with CGD.
OVERALL CONCLUSION
The studies in this thesis show that the observed clinical epidemiology of the CGD 
host is the results of a unique interaction between the pathogen and the host. The 
pathogenesis of invasive fungal infections is a continuum between infection and 
inflammation. Since the NADPH-oxidase complex acts both as an antimicrobial 
effector molecule and a regulator of inflammation, fungal pathogenesis in patients 
with CGD is the result of an imbalance of antifungal capacity and regulation of 
inflammation. 
 A. nidulans infections in the CGD host are characterized by a distinctive clinical 
phenotype and hyperinflammation. The hitherto accepted view, invasive fungal 
infections are the results of a defective antimicrobial function of the NADPH- 
oxidase, is, justified by sound of this research work, no longer appropriate. 
 This research gives us new, important insights in the host-pathogen interaction 
between filamentous fungi and the CGD host. It opens new perspectives in current 
treatment possibilities. It emphasizes the role of inflammation in infection 
diseases and the urgent need to focus on this topic if we want to make miles in the 
treatment and the survival of children with this devastating primary immuno-
deficiency.  
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stofradicalen zijn een belangrijke co-factor van het enzym indoleamine 2,3-
dioxygenase (IDO). IDO is een belangrijk enzym in het L-tryptofaan metabolisme. 
Evaluatie van het L-tryptofaan metabolisme toonde aan dat ondanks de afwezigheid 
van zuurstofradicalen, de expressie van het  enzym IDO in CGD polymorfe 
neutrofielen en mononucleaire cellen vergelijkbaar is met deze van gezonde 
controles.  De door IDO gemedieerde conversie van L-tryptofaan tot L-kynurenine, 
verschilde niet tussen CGD patiënten en gezonde controles. Opmerkelijk, 
toevoeging van L-kynurenine resulteerde niet in een onderdrukking van de 
geïnduceerde IL-17 productie. In tegenstelling tot de observaties gedaan in muizen, 
is de hyperinflammatie in CGD patiënten niet het gevolg van een gestoorde 
L-tryptofaan metabolisme. 
 Gezien het feit dat onze bevindingen nieuwe aspecten in de pathogenese van 
Aspergillus infecties in de CGD gastheer hebben laten zien, waarbij bestaande 
dogma’s werden weerlegd, bundelden we deze samen met de bestaande kennis in 
een opinie artikel getiteld “Aspergillus nidulans en Chronische Granulomateuze 
Ziekte: een unieke gastheer–pathogeen interactie” (hoofdstuk 5).
 De celwand is het belangrijkste grensvlak in de interactie tussen gastheer en 
pathogeen en een belangrijk doelwit voor behandeling. In hoofdstuk 6 
bestudeerden we de rol van de individuele celwand van A. nidulans en A. fumigatus 
en onderzochten we de hypothese dat verschillen in componenten van de 
individuele celwand, waaronder polysacchariden en melanine, resulteert in 
verschillen in herkenning en de resulterende pro-inflammatoire cytokine release. 
CGD patiënten zijn gekenmerkt door een intrinsiek pro-inflammatoir fenotype 
zoals tot uiting kwam in  verhoogde tumour necrosis factor (TNF)-α en IL-1β basale 
cytokine concentraties in het plasma van CGD patiënten. Stimulatie van 
mononucleaire cellen van CGD patiënten met A. nidulans resulteerde in hogere 
IL-1β en TNF-α cytokine release in vergelijking met A. fumigatus stimulatie. Wij 
toonden aan dat zowel de cytokine productie van gezonde mononucleaire cellen 
als die van CGD patiënten gestimuleerd door A. nidulans conidia onafhankelijk is 
van de aanwezigheid van melanine in de celwand. 
 Geïsoleerde polysacchariden uit de A. nidulans celwand stimuleren een 
opmerkelijk uitgesproken IL-β afgifte ten opzichte van polysachariden uit de A. 
fumigatus celwand. Verschillen in de compositie van de individuele polysaccha-
riden celwand van A. fumigatus en A. nidulans is duidelijk aangetoond. De meest 
opmerkelijke hierin ligt in de afwezigheid van galactosaminogalactan (GAG) in de 
celwand van A. nidulans. Door middel van gemodificeerde A. nidulans stammen, 
welke galactosaminogalactan tot overexpressie brachten, waren we in staat om 
aan te tonen dat de toegenomen secretie van IL-1β door CGD mononucleaire cellen 
in antwoord op A. nidulans stimulatie het gevolg is van de lagere hoeveelheid van 
celwand geassocieerde galactosaminogalactan. 
· Is het mogelijk om de verkregen vernieuwde moleculaire inzichten in de interactie 
tussen deze verschillende Aspergillus species en de CGD gastheer te vertalen naar 
nieuwe therapeutische strategieën?
RESULTATEN
In hoofdstuk 2 beschrijven we in een overzichtsartikel de huidige epidemiolo-
gische, klinische, diagnostische en therapeutische inzichten en gegevens met 
betrekking tot invasieve schimmelinfecties in de CGD patiënt.
 In hoofdstuk 3 onderzochten we de centrale rol van het NADPH-oxidase en de 
geproduceerde zuurstofradicalen als antimicrobiële effector in de interactie met 
A. fumigatus en A. nidulans. In tegenstelling tot alle heersende concepten, ontdekten 
we dat A. nidulans, in tegenstelling tot A. fumigatus, niet gevoelig is voor het directe 
effect van zuurstofradicalen. Het stimuleren van 2 soorten witte bloed cellen, de 
polymorfe neutrofielen en de mononucleaire cellen, van gezonde controles met A. 
nidulans leidde niet tot inductie van zuurstofradicalen, in tegenstelling tot 
stimulatie met A. fumigatus. Vervolgens bestudeerden wij het remmen van de 
ontkieming van Aspergillus conidia en zagen dat humane CGD polymorfe 
neutrofielen en mononucleaire cellen, en alveolaire macrofagen geïsoleerd uit 
CGD muizen deze ontkieming even efficiënt remmen als gezonde cellen dit 
kunnen. Het blokkeren van het NADPH-oxidase complex in gezonde polymorfe 
neutrofielen resulteerde in een significante vermindering in het vermogen tot 
aanrichten van schade aan de A. fumigatus, maar had geen enkele invloed op de 
groei van de A. nidulans hyfen. Ook de antifungale activiteit van humane CGD 
polymorfe neutrofielen tegen A. nidulans hyfen bleek vergelijkbaar met de activiteit 
van gezonde polymorfe neutrofielen. Deze in vitro resultaten gaan in tegen de 
algemeen geaccepteerde belangrijke rol van het NADPH-oxidase en de zuurstof-
radicalen in de afweer tegen schimmels, waaronder Aspergillus spp. Ook is middels 
deze experimenten duidelijk geworden dat het voorkomen van infecties door A. 
nidulans in de patiënt met CGD niet verklaard kan worden door het directe effect 
van de afwezigheid van het NAPDH-oxidase. 
 De onderzoeksresultaten met betrekking tot de rol van het NADPH-oxidase 
complex in intracellulaire signalering zijn beschreven in hoofdstuk 4. In CGD 
muizen zijn aanwijzingen gevonden dat dysregulatie van het L-tryptofaan 
metabolisme resulteert in een overproductie van interleukine(IL)-17. Deze 
overproductie zou de ontbrekende schakel vormen tussen de geobserveerde hyper-
inflammatie en de gevoeligheid voor invasieve aspergillose in CGD. Wij toonden 
aan dat in tegenstelling tot het onderzoek gedaan in CGD muizen, de IL-17 
productie bij CGD  patiënten opmerkelijk laag was na stimulatie met A. nidulans en 
A. fumigatus. Dit ondanks het pro-inflammatoire profiel van de CGD fagocyt. Zuur-
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noodzaak tot uiteenrafeling van de unieke gastheer-pathogeen interactie met 
focus op de rol van inflammatie indien men verdere vooruitgang wenst te boeken 
in de behandeling en een betere overleving van deze patiënten met een ernstige 
aangeboren afweerstoornis.
 Het ideaal therapeutisch middel voor CGD patiënten met invasieve Aspergillus 
infecties zou, gebaseerd op de resultaten van de voorgaande besproken studies, 
dus niet alleen direct antifungaal moeten werken, maar ook immunomodulatoir. 
In hoofdstuk 7 beschrijven we waarom het stokoude antimalaria middel 
chloroquine wel eens belangrijk zou kunnen worden in de behandeling van 
invasieve aspergillosis in CGD patiënten. Chloroquine dankt zijn werkzaamheid 
aan de passieve diffusie in zure organellen. Het bevat antischimmel activiteit 
zoals eerder werd aangetoond bij o.a. Histoplasma capsulatum, een zogenaamde 
dimorfe schimmel, en wordt gebruikt bij patiënten met inflammatoire 
aandoeningen zoals reumatoïde artritis op basis van haar immunomodelerende 
werking. In dit hoofdstuk onderzochten we de hypothese dat het toevoegen van 
chloroquine aan de CGD fagocyt zou resulteren in zowel een toename van 
antischimmel activiteit als een demping van de inflammatoire respons, dit door 
herstel van de alkalinisatie van het phagolysosoom. Chloroquine vertoont een 
pH-afhankelijke, directe antifungale activiteit ten aanzien van  A. fumigatus en A. 
nidulans. Bovendien versterkt chloroquine de antifungale activiteit van de CGD 
fagocyt en dit bij een twintigvoudig lagere concentratie dan in gezonde controles. 
Chloroquine remt de TNF-α en IL-1β secretie na stimulatie met  A. fumigatus en A. 
nidulans. Significante inhibitie van de A. nidulans-geïnduceerde TNF-α en IL-1β 
secretie werd geobserveerd in een tienvoudig lagere concentratie van chloroquine 
ten opzichte van A. fumigatus geïnduceerde cytokine secretie. Concluderend heeft 
chloroquine een positieve invloed op de twee effector mechanismen die gestoord 
verlopen in de afweer tegen invasieve aspergillose in CGD patiënten ten gevolge 
van het defecte NADPH-oxidase. 
CONCLUSIE EN BESCHOUWING
Samenvattend kan gezegd worden dat de geobserveerde klinische epidemiologie 
in de CGD patiënt het resultaat is van een unieke pathogenese welke het resultaat 
is van een complexe interactie tussen gastheer en pathogeen. In de CGD gastheer 
heeft de afwezigheid van een functioneel NADPH-oxidase zowel consequenties 
voor de direct antimicrobiële capaciteit als voor de functie als regulator van 
inflammatie.  
 Aspergillus nidulans infecties in de CGD patiënt zijn gekenmerkt door een zich 
onderscheidend van A. fumigatus infecties klinisch fenotype en hyperinflammatie. 
Het heersende concept dat schimmelinfecties in de CGD patiënt simpelweg het 
gevolg zijn van de afwezigheid van zuurstofradicalen is door toedoen van ons 
onderzoek niet meer staande. Ons onderzoek heeft geleid tot belangrijke nieuwe 
inzichten in de gastheer-pathogeen interactie tussen Aspergillus en de CGD gastheer. 
Het opent nieuwe perspectieven voor therapeutisch handelen en benadrukt de 
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DANKWOORD DANKWOORD
206 207
Lieve Melanie, ons pad liep samen door onderzoek en kliniek, zelfde bergen 
werden beklommen en bergmeertjes doorzwommen (letterlijk). Geen water was 
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Beste Prof. Dr. M. Netea, beste Prof. Dr. T. Kuijpers, Beste Prof. Dr. P. Verweij, tot 
mijn grote vreugde aanvaardde jullie om in de leescommissie plaatst te nemen. 
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Beste leden van de grote commissie, al bij voorbaad dank om naar Nijmegen af te 
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